
<html lang="en"     class="pb-page"  data-request-id="7da4fe85-2476-4fae-8143-a57dbf4f56f6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-18;article:article:10.1021/acs.jmedchem.0c01086;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production" /></meta><meta name="dc.Creator" content="Xiaohui  Du" /></meta><meta name="dc.Creator" content="Jared  Moore" /></meta><meta name="dc.Creator" content="Brian R.  Blank" /></meta><meta name="dc.Creator" content="John  Eksterowicz" /></meta><meta name="dc.Creator" content="Dena  Sutimantanapi" /></meta><meta name="dc.Creator" content="Natalie  Yuen" /></meta><meta name="dc.Creator" content="Todd  Metzger" /></meta><meta name="dc.Creator" content="Brenda  Chan" /></meta><meta name="dc.Creator" content="Tom  Huang" /></meta><meta name="dc.Creator" content="Xi  Chen" /></meta><meta name="dc.Creator" content="Yuping  Chen" /></meta><meta name="dc.Creator" content="Frank  Duong" /></meta><meta name="dc.Creator" content="Wayne  Kong" /></meta><meta name="dc.Creator" content="Jae H.  Chang" /></meta><meta name="dc.Creator" content="Jessica  Sun" /></meta><meta name="dc.Creator" content="Tatiana  Zavorotinskaya" /></meta><meta name="dc.Creator" content="Qiuping  Ye" /></meta><meta name="dc.Creator" content="Melissa R.  Junttila" /></meta><meta name="dc.Creator" content="Chudi  Ndubaku" /></meta><meta name="dc.Creator" content="Lori S.  Friedman" /></meta><meta name="dc.Creator" content="Valeria R.  Fantin" /></meta><meta name="dc.Creator" content="Daqing  Sun" /></meta><meta name="dc.Description" content="The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of im..." /></meta><meta name="Description" content="The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of im..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 31, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01086" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01086" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01086" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01086" /></link>
        
    
    

<title>Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01086" /></meta><meta property="og:title" content="Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0028.jpeg" /></meta><meta property="og:description" content="The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP. CD73 is overexpressed in many cancers, resulting in elevated levels of ADO that correspond to poor patient prognosis. Therefore, reducing the level of ADO via inhibition of CD73 is a potential strategy for treating cancers. Based on the binding mode of adenosine 5′-(α,β-methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small-molecule CD73 inhibitors. Among them, OP-5244 (35) proved to be a highly potent and orally bioavailable CD73 inhibitor. In preclinical studies, 35 completely inhibited ADO production in both human cancer cells and CD8+ T cells. Furthermore, 35 lowered the ratio of ADO/AMP significantly and reversed immunosuppression in mouse models, indicating its potential as an in vivo tool compound for further development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01086"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01086">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01086&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01086&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01086&amp;href=/doi/10.1021/acs.jmedchem.0c01086" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 10433-10459</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00961" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01125" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaohui Du</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohui Du</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a1d9c8c0cec9d4c88fc5d4e1ced3c8c2d1c9c0d3ccc08fc2cecc"><span class="__cf_email__" data-cfemail="92eafbf3fdfae7fbbcf6e7d2fde0fbf1e2faf3e0fff3bcf1fdff">[email protected]</span></a>. Phone: 650-388-5602.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohui++Du">Xiaohui Du</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5444-9434" title="Orcid link">http://orcid.org/0000-0001-5444-9434</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jared Moore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jared Moore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jared++Moore">Jared Moore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian R. Blank</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian R. Blank</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+R.++Blank">Brian R. Blank</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Eksterowicz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Eksterowicz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Eksterowicz">John Eksterowicz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dena Sutimantanapi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dena Sutimantanapi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dena++Sutimantanapi">Dena Sutimantanapi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalie Yuen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalie Yuen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalie++Yuen">Natalie Yuen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Todd Metzger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Todd Metzger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Todd++Metzger">Todd Metzger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brenda Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brenda Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brenda++Chan">Brenda Chan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tom Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tom Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tom++Huang">Tom Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xi Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xi Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xi++Chen">Xi Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuping Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuping Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuping++Chen">Yuping Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frank Duong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frank Duong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Duong">Frank Duong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wayne Kong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wayne Kong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wayne++Kong">Wayne Kong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jae H. Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jae H. Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jae+H.++Chang">Jae H. Chang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Sun">Jessica Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tatiana Zavorotinskaya</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatiana Zavorotinskaya</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana++Zavorotinskaya">Tatiana Zavorotinskaya</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiuping Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiuping Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiuping++Ye">Qiuping Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa R. Junttila</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa R. Junttila</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+R.++Junttila">Melissa R. Junttila</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chudi Ndubaku</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chudi Ndubaku</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chudi++Ndubaku">Chudi Ndubaku</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lori S. Friedman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lori S. Friedman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lori+S.++Friedman">Lori S. Friedman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Valeria R. Fantin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valeria R. Fantin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Valeria+R.++Fantin">Valeria R. Fantin</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Daqing Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daqing Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a5c1c4d4cccbc2d6d0cbe5dcc4cdcaca8bc6cac8"><span class="__cf_email__" data-cfemail="731712021a1d1400061d330a121b1c1c5d101c1e">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daqing++Sun">Daqing Sun</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01086&amp;href=/doi/10.1021%2Facs.jmedchem.0c01086" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 10433–10459</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 June 2020</li><li><span class="item_label"><b>Published</b> online</span>31 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01086" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01086</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10433%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaohui%2BDu%252C%2BJared%2BMoore%252C%2BBrian%2BR.%2BBlank%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D18%26contentID%3Dacs.jmedchem.0c01086%26title%3DOrally%2BBioavailable%2BSmall-Molecule%2BCD73%2BInhibitor%2B%2528OP-5244%2529%2BReverses%2BImmunosuppression%2Bthrough%2BBlockade%2Bof%2BAdenosine%2BProduction%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10459%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01086"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1922</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01086" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaohui&quot;,&quot;last_name&quot;:&quot;Du&quot;},{&quot;first_name&quot;:&quot;Jared&quot;,&quot;last_name&quot;:&quot;Moore&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;R. Blank&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Eksterowicz&quot;},{&quot;first_name&quot;:&quot;Dena&quot;,&quot;last_name&quot;:&quot;Sutimantanapi&quot;},{&quot;first_name&quot;:&quot;Natalie&quot;,&quot;last_name&quot;:&quot;Yuen&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;Metzger&quot;},{&quot;first_name&quot;:&quot;Brenda&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Tom&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Xi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yuping&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Duong&quot;},{&quot;first_name&quot;:&quot;Wayne&quot;,&quot;last_name&quot;:&quot;Kong&quot;},{&quot;first_name&quot;:&quot;Jae&quot;,&quot;last_name&quot;:&quot;H. Chang&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;Zavorotinskaya&quot;},{&quot;first_name&quot;:&quot;Qiuping&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;R. Junttila&quot;},{&quot;first_name&quot;:&quot;Chudi&quot;,&quot;last_name&quot;:&quot;Ndubaku&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;S. Friedman&quot;},{&quot;first_name&quot;:&quot;Valeria&quot;,&quot;last_name&quot;:&quot;R. Fantin&quot;},{&quot;first_name&quot;:&quot;Daqing&quot;,&quot;last_name&quot;:&quot;Sun&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10433-10459&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01086&quot;},&quot;abstract&quot;:&quot;The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP. CD73 is overexpressed in many cancers, resulting in elevated levels of ADO that correspond to poor patient prognosis. Therefore, reducing the level of ADO via inhibition of CD73 is a potential strategy for treating cancers. Based on the binding mode of adenosine 5′-(α,β-methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small-molecule CD73 inhibitors. Among them, OP-5244 (35) proved to be a highly potent and orally bioavailable CD73 inhibitor. In preclinical studies, 35 completely inhibited ADO production in both human cancer cells and CD8+ T cells. Furthermore, 35 lowered the ratio of ADO/AMP significantly and reversed immunosuppression in mouse models, indicating its potential as an in vivo tool compound for fu&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01086&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01086" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01086&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01086" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01086&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01086" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01086&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01086&amp;href=/doi/10.1021/acs.jmedchem.0c01086" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01086" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01086" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01086%26sid%3Dliteratum%253Aachs%26pmid%3D32865411%26genre%3Darticle%26aulast%3DDu%26date%3D2020%26atitle%3DOrally%2BBioavailable%2BSmall-Molecule%2BCD73%2BInhibitor%2B%2528OP-5244%2529%2BReverses%2BImmunosuppression%2Bthrough%2BBlockade%2Bof%2BAdenosine%2BProduction%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D18%26spage%3D10433%26epage%3D10459%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291157" title="Organophosphorus compounds">Organophosphorus compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/jmcmar.2020.63.issue-18/20200924/jmcmar.2020.63.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP. CD73 is overexpressed in many cancers, resulting in elevated levels of ADO that correspond to poor patient prognosis. Therefore, reducing the level of ADO via inhibition of CD73 is a potential strategy for treating cancers. Based on the binding mode of adenosine 5′-(α,β-methylene)diphosphate (AOPCP) with human CD73, we designed a series of novel monophosphonate small-molecule CD73 inhibitors. Among them, OP-5244 (<b>35</b>) proved to be a highly potent and orally bioavailable CD73 inhibitor. In preclinical studies, <b>35</b> completely inhibited ADO production in both human cancer cells and CD8<sup>+</sup> T cells. Furthermore, <b>35</b> lowered the ratio of ADO/AMP significantly and reversed immunosuppression in mouse models, indicating its potential as an <i>in vivo</i> tool compound for further development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74258" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74258" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It has become increasingly clear that adenosine (ADO) is an important immunosuppressive regulatory metabolite.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> ADO signals through G-protein-coupled adenosine receptors (A1, A2A, A2B, and A3) to regulate the function of a variety of immune cells. CD73 is a critical component of the cell-signaling machinery involved in the formation of immunosuppressive ADO. CD73 is a glycosyl phosphatidyl inositol (GPI)-anchored cell surface protein that dephosphorylates extracellular AMP to generate ADO.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> While extracellular precursors of AMP exist in the form of ATP and NAD<sup>+</sup>, both require CD73 activity as the terminal mediator of ADO production.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> CD73 expression is dynamically regulated in distinct biological contexts as a means to increase the ADO metabolite, which functions to limit immune activation and prevent excessive inflammation. The central and critical role of CD73 in ADO production places CD73 activity at the forefront of therapeutically targeting the ADO pathway.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a></div><div class="NLM_p">In the context of tumors, excessive CD73-mediated ADO generation can impair optimal antitumor immune responses. ADO signaling can skew naive T-cell development and proliferation to favor immunosuppressive fates (Tregs).<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Likewise, ADO signaling can promote polarization and activation of tumor-promoting M2 macrophages, as well as the accumulation and expansion of myeloid-derived suppressor cells (MDSCs).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Moreover, elevated concentrations of ADO in the tumor microenvironment (TME) disable the cytolytic activity of natural killer (NK) cells and diminish cytotoxic T-cell responses by interfering with CD8<sup>+</sup> T-cell activation, expansion, and cytokine secretion. In addition, ADO-mediated dysregulation of dendritic cells leads to decreased tumor antigen presentation,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> disabled T helper-1 (Th1) cell cytokine production, and further impairment of effector T-cell function.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> These events eventually lead to the repression of inflammatory responses and impaired cancer immunosurveillance, thereby promoting tumor growth.</div><div class="NLM_p">CD73 expression has been detected on various cell types within the tumor, including tumor cells, cancer-associated fibroblasts, stromal cells, endothelial cells, and tumor-infiltrating immune cells. CD73 overexpression has been reported to occur in multiple cancers such as breast cancer<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> including TNBC,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> prostate cancer,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> colorectal cancer,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> ovarian cancer,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> NSLC lung cancer,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> pancreatic cancer,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> papillary thyroid cancer,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> gastric cancer,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and melanoma.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, CD73 expression has been associated with disease progression and poor patient prognosis.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(12−22)</a> Additionally, CD73 overexpression has been found to be functionally linked to therapy resistance, including resistance to chemotherapeutic agents, anthracycline<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and vincristine,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as well as immunotherapy resistance.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> More recently, upregulation of CD73 was observed in patients treated with checkpoint inhibitors, anti-PD1/L1 or anti-CTLA-4 antibodies.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Numerous <i>in vivo</i> studies indicate that inhibition of CD73 can reverse immunosuppression and arrest tumor progression.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Mice genetically lacking CD73 cannot support the efficient subcutaneous growth of tumors and were protected against experimental lung metastasis.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The antitumor phenotypes observed in CD73-deficient mice were associated with increased antitumor immunity driven by tumor-specific CD8<sup>+</sup> T cells, consistent with the hypothesis that CD73 is immunosuppressive. Along similar lines, it was recently demonstrated that CD73 deficiency significantly improved anti-PD1 and anti-CTLA-4 checkpoint inhibitor efficacies in a glioblastoma model compared to CD73-expressing mice.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The genetic evidence has been validated in the therapeutic context as well. Several monoclonal antibodies targeting CD73 have demonstrated the antitumor efficacy in various preclinical models. For example, a TY/23 anti-CD73 monoclonal antibody delayed tumor growth and significantly inhibited lung metastasis in 4T1.2 breast-tumor-bearing mice.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Subsequent studies demonstrated that anti-CD73 antibodies significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 antibodies in several mouse tumor models.<a onclick="showRef(event, 'ref26 ref32'); return false;" href="javascript:void(0);" class="ref ref26 ref32">(26,32)</a> Therefore, preclinical work supports CD73 as a target with immunomodulatory capacity that has the potential to reverse immune suppression, which can be utilized therapeutically to enhance and prolong chemotherapy as well as immunotherapy responses.</div><div class="NLM_p">Several monoclonal antibodies targeting the activity of CD73 have entered clinical trials, including MEDI9447 (AstraZeneca, formerly Medimmune)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and BMS-986179 (Bristol-Meyer Squibb), and were reported to have hints of antitumor activity in a few patients.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">However, small-molecule inhibitors have several advantages over monoclonal antibody approaches. Antibodies may not penetrate well into solid tumors, while small molecules can easily diffuse across physiologic barriers, such as the blood–brain barrier and plasma membranes, and have greater exposures within the TME.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Small molecules may also differentiate from antibodies in their safety profile due to the flexibility of intermittent dosing and shorter circulating half-lives. Furthermore, small-molecule inhibitors can be optimized for oral administration, which can be more convenient for patients.</div><div class="NLM_p">Recently, (phosphonomethyl) phosphonic acids derived from adenosine 5′-(α,β-methylene)diphosphate (AOPCP) as CD73 inhibitors have been reported by the Müller group and others.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34−37)</a> Among them, AB680<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and PSB-12489<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> are highly potent small-molecule CD73 inhibitors although they are not orally bioavailable. Other small-molecule inhibitors include anthraquinone,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> sulfonic acid,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> sulfonamide derivatives,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and most recently hydroxamic acids.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In addition, allosteric CD73 inhibitors identified through virtual screening targeting the dimer interface have been reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Despite the high level of interests in CD73 as a novel immunotherapy target for cancer, there have been few reports of orally bioavailable small-molecule CD73 inhibitors.</div><div class="NLM_p">In this paper, we report our medicinal chemistry efforts in designing potent, orally bioavailable small-molecule inhibitors of CD73 starting from AOPCP. Structural modifications of AOPCP, focused particularly on the linker between the external phosphate and the ribose sugar, led to the discovery of novel and potent CD73 inhibitors. Within the series, OP-5244 (<b>35</b>), an α,α-disubstituted monophosphonic acid, is significantly more potent than AOPCP in biochemical and cellular assays (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). More importantly, <b>35</b> reverses immune suppression through the blocking of ADO production <i>in vivo</i>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Discovery of OP-5244 (<b>35</b>) from structural modifications of AOPCP. Potency data are reported as the average of at least two independent experiments. <sup><i>a</i></sup>IC<sub>50</sub> value in a biochemical assay; <sup><i>b</i></sup>EC<sub>50</sub> values were generated by directly measuring the inhibition of the production of ADO through inhibition of CD73 activity from AMP in H1568 (NSCLC) cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting from AOPCP, we explored compounds with different core structures such as compound <b>1</b> with a triazolopyrimidine core. Based on Müller group’s work, introducing substitution on the purine core structure of AOPCP can greatly impact the potency of the inhibitors.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Indeed, compound <b>1</b> with a 2-chlorobenzyl substitution on the amine nitrogen at the C<sub>6</sub> position and a chlorine at the C<sub>2</sub> position was found to be significantly more potent than AOPCP and comparable to PSB-12489 in a biochemical assay, where inhibition of recombinant CD73 activity was measured by quantification of free phosphate using a Malachite Green detection system (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Various amino substitutions are well tolerated at the C<sub>6</sub> position including aromatic and alkyl groups, as demonstrated in compounds <b>1–3</b>. Compound <b>2</b> with an <i>N</i>-(2,3-dihydro-1<i>H</i>-inden-1-yl)-<i>N</i>-methyl substitution at C<sub>6</sub> was more potent than compound <b>1</b>. In addition, compound <b>3</b> with a pyrazolopyrimidine core was synthesized and found to be comparable to <b>2</b> (IC<sub>50</sub> = 0.52 nM for <b>3</b> vs IC<sub>50</sub> = 1.3 nM for <b>2</b>). We also knew that triazolopyrimidine could have higher IV clearance compared to pyrazolopyrimidine (data not shown). Based on these data, we decided to further explore the SAR of the pyrazolopyrimidine analogues.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Phosphonomethyl Phosphonic Acids<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0018.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0019.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Potency data are reported as the average of at least two independent experiments.</p></div></div><div></div></div><div class="NLM_p">Even though the bisphosphonic acids are very potent CD73 inhibitors as shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, their oral exposures were generally below the limit of quantitation (BLOQ) when dosed orally in rats. We postulated that the phosphonomethyl phosphonic acid moiety was responsible for the poor oral exposure due to the high number of negative charges and the polar nature of the group. Several analogues aimed at reducing the negative charges of the bisphosphonate moiety were prepared (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Capping the internal phosphonate as a methyl ester decreased the potency significantly (IC<sub>50</sub> = 24.7 nM for <b>4</b>) compared to the single-digit nanomolar potency of bisphosphonic acids. Methylation of the terminal phosphonic acid (<b>5</b>) or methylation of both the internal and terminal phosphonic acids (<b>6</b>) led to further loss of potency. These results were consistent with the possible loss of key interactions observed in the cocrystal structure of AOPCP with CD73.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Both phosphonate groups are located in a highly positively charged environment including H38, N245, R395, R354, and zinc. The two phosphonic acids are involved in a network of extensive hydrogen-bonding interactions, and the external phosphonic acid also engages in metal-ion binding interactions with zinc. Capping the phosphonic acids could disrupt these interactions, partially explaining the loss of potency. Interestingly, compound <b>4</b> was found to have some oral exposure with an AUC<sub>inf</sub> of 0.56 μM*h at a dose of 50 mg/kg in rats. These data suggest that oral exposure could be achieved via structural modification of the internal phosphonate group.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Substitution on the Phosphonic Acids in <b>3</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0020.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center">compound</th><th class="colsep0 rowsep0" rowspan="2" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" rowspan="2" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char="±">biochemical</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">24.7 ± 14.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">130.7 ± 54.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">2874 ± 597</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Potency data are reported as the average of at least two independent experiments.</p></div></div></div><div class="NLM_p">We set out to design analogues to improve oral exposure and potency through modifications of the linker area where the internal phosphonate is located. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, replacement of the internal phosphonate with an ester, an amide, or a sulfonamide (<b>7</b>, <b>8</b>, and <b>9</b>) resulted in a significant reduction in potency compared to <b>4</b>. Changing the linker to an ether with different carbon spacers (<b>10–12</b>) was also examined. Compound <b>12</b> (IC<sub>50</sub> = 29 nM) with a one-carbon spacer between the oxygen and the external phosphonic acid and a one-carbon spacer between the same oxygen and the ribose sugar had a potency comparable to that of <b>4</b>, while <b>10</b> and <b>11</b> were less potent. These results indicate that the linker in <b>12</b> might be optimal for potency. Replacing the linker oxygen in <b>12</b> with a sulfur in <b>13</b> was not well tolerated. On the other hand, replacement of the linker oxygen in <b>12</b> with a sulfone group maintained the potency (IC<sub>50</sub> = 13 nM for <b>14</b>) compared to <b>12</b>. Both <b>12</b> and <b>14</b> showed oral exposure comparable to that of <b>4</b> at a dose of 50 mg/kg in rats. We believe that compound <b>12</b> is reasonable as a monophosphonic acid inhibitor and decided to use this compound as our next starting point for further optimization.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Modifications of the Internal Phosphonate<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0021.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0022.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Potency data are reported as the average of at least two independent experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Not available.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Terminal <i>t</i><sub>1/2</sub>.</p></div></div><div></div></div><div class="NLM_p">The cocrystal structure of <b>12</b> bound to CD73 was solved at a resolution of 2.70 Å (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Consistent with the binding mode of AOPCP, the two hydroxy groups on the sugar ring formed hydrogen bonds with D506. The pyrazolopyrimidine core moiety engaged π-stacking interactions with F417 and F500. Additionally, the 2-chlorobenzyl group on the C<sub>6</sub> amine nitrogen had extensive hydrophobic interactions with the backbone of the protein such as L184 and S185. The chloro atom at the C<sub>2</sub> position was found to displace a water molecule for a favorable entropic contribution compared to the hydrogen in AOPCP. The phosphonic acid was involved in several hydrogen-bond interactions with surrounding residues such as N117, H118, and R395 as well as metal-ion binding interactions with zinc. The oxygen of the ether linker in <b>12</b> engaged a hydrogen bond with R395. However, removal of the internal phosphonate group also eliminated the H-bond interactions of the two internal phosphonate oxygens with R354 and R395 as observed in the cocrystal structures of AOPCP with CD73. Analysis of the two cocrystal structures suggests that introducing substituents at the α-carbon to the phosphonic acid might serve as a potential means to compensate for the lost interactions resulting from removal of the internal phosphonate.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of <b>12</b> with CD73 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9">7JV9</a>). The hydrogen bonds are labeled as dashed lines. Color codes for atoms: O, red; N, dark blue; C, light blue; Cl, green; P, orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For α-substituted analogues (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), we fixed the amino group substitution as a cyclopentyl group as switching the substituent on the amine from a 2-chlorobenzyl in <b>12</b> to a cyclopentyl in <b>15</b> not only maintained the potency but also substantially improved the oral exposure in rats (IC<sub>50</sub> = 11 nM, AUC<sub>inf</sub> = 34.2 μM*h for <b>15</b> at 50 mg/kg). Several analogues of <b>15</b> with mono- and disubstitution at the α position of the phosphonic acid were synthesized to see their impact on potency. It was gratifying to observe that α-methyl substitution was tolerated (<b>16</b>), while substitution with an α-hydroxymethylene or methoxymethylene moiety resulted in significant improvement in the biochemical assay (IC<sub>50</sub> = 2.4 nM for <b>17</b>; IC<sub>50</sub> = 0.96 nM for <b>18</b>). Other monosubstitutions, such as carboxylic acid (<b>19</b>), cyano (<b>20</b>), trifluoromethyl (<b>21</b>), and methylsulfonyl (<b>22</b>), resulted in significant losses in potency. Similarly, α-tetrazole substitution (<b>23</b>, IC<sub>50</sub> = 28 nM) did not provide an increase in potency compared to the unsubstituted <b>15</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of the α-Substitution in <b>15</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0023.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0024.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Potency data are reported as the average of at least two independent experiments. Compounds <b>16–29</b> and <b>31</b> in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> are a mixture of two diastereomers generated from the α-substitution.</p></div></div><div></div></div><div class="NLM_p">Inspired by the increased potency imparted by introducing the α-hydroxymethylene group, we decided to explore disubstitution at the α-position for additional interactions with the CD73 protein (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Encouraged by the tolerance of an additional methyl group (<b>24</b>), we started to search for a better replacement of the α-hydroxymethylene moiety in <b>24</b>. Introducing an <i>N</i>,<i>N</i>-dimethylaminomethylene group (<b>25</b>) completely abolished the potency, probably due to its basicity. Changing the amine group in <b>25</b> to a less basic sulfonamide (<b>26</b>) or a sulfide (<b>27</b>) or a sulfone (<b>28</b>) partially rescued the activity compared to <b>25</b>; however, those compounds were still much less potent than <b>24</b>.</div><div class="NLM_p">These results suggest that the α-hydroxy group in the hydroxymethylene possibly interacts with CD73, leading to improved potency. Extending the hydroxy group in <b>24</b> by one more carbon (<b>29</b>) decreased the potency by 20-fold, indicating that the spacer between the hydroxy group and the α-carbon is also important for optimal interaction. To maximize interactions of the α-substituents with CD73, we maintained the favorable hydroxymethylene group and introduced another hydroxymethylene (<b>30</b>) or methoxymethylene (<b>31</b>) group. Indeed, both <b>30</b> and <b>31</b> were found to be highly potent (IC<sub>50</sub> = 0.57 and 0.53 nM for <b>30</b> and <b>31</b>, respectively).</div><div class="NLM_p">The single diastereomers of <b>24</b> and <b>31</b> were prepared and tested in the biochemical assay. Compounds <b>32</b> (IC<sub>50</sub> = 0.51 nM) and <b>35</b> (IC<sub>50</sub> = 0.25 nM) were found to be significantly more potent than their diastereomers <b>33</b> and <b>34</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In addition to tracking the activity of inhibitors in the biochemical assay using soluble CD73 and indirect detection of inorganic phosphate, we evaluated their ability to inhibit production of adenosine by cell-associated CD73. The human NSCLC H1568 cell line expresses a high level of CD73 (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf" class="ext-link">Figure S1</a> in the Supporting Information) and efficiently converts AMP into adenosine, which can be quantitated by liquid chromatography–mass spectrometry (LC-MS/MS). The inhibitory activity of <b>35</b> was significantly higher than those of <b>30</b> and <b>32</b> (EC<sub>50</sub> = 0.79 nM for <b>35</b>; EC<sub>50</sub> = 3.7 nM for <b>30</b>; EC<sub>50</sub> = 6.9 nM for <b>32</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Potency of α,α-Disubstituted Ether Phosphonic Acids in Single Stereoisomers<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0025.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0026.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Potency data are reported as the average of at least two independent experiments.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Not available.</p></div></div><div></div></div><div class="NLM_p">To prepare for <i>in vivo</i> studies in mice, we further tested the activity of compounds on murine CD73. The murine breast cancer EMT6 cell line expresses high levels of endogenous CD73 (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf" class="ext-link">Figure S1</a> in the Supporting Information) and can produce adenosine from AMP. Similarly, <b>35</b> demonstrated more potent inhibition of ADO production compared to <b>30</b> and <b>32</b>. For comparison, AB680<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was also included in the experiments. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <b>35</b> is more potent than AB680 in all three assays and comparable to one of our most potent bisphosphonic acids, compound <b>3</b>, in the biochemical assay.</div><div class="NLM_p">To understand the remarkably enhanced potency by α-substitution, the cocrystal structure of <b>35</b> with CD73 was obtained by X-ray crystallography to a resolution of 2.46 Å (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). <b>35</b> maintained all of the interactions as was seen from the interactions of <b>12</b> with CD73. Additionally, the oxygen in the methoxymethylene group formed a hydrogen bond with R354, while the oxygen in the hydroxymethylene group interacted with R395 via a hydrogen bond. It appears that the α substituents indeed mimicked the internal phosphonate group in the (phosphonomethyl) phosphonic acids as shown in the cocrystal structure of AOPCP with CD73, resulting in greatly improved binding affinity. To our knowledge, <b>35</b> is the first orally bioavailable monophosphonic acid inhibitor of CD73, which has comparable potency to the bisphosphonic acid inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of <b>35</b> with CD73 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8">7JV8</a>). The hydrogen bonds are labeled as dashed lines. Color codes for atoms: O, red; N, dark blue; C, light blue; Cl, green; P, orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Three compounds (<b>30</b>, <b>32</b>, <b>35</b>) were dosed orally in mice at a dose of 200 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Although <b>35</b> had exposure comparable to <b>32</b> and 2-fold lower than <b>30</b>, it was 3-fold more potent than <b>30</b> and <b>32</b> in the EMT6 ADO inhibition assay. Given the murine potency and oral exposure, <b>35</b> was selected for further <i>in vitro</i> characterizations and <i>in vivo</i> studies in mice to investigate its impact on the CD73 pathway.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic (PK) Data of Compounds <b>30</b>, <b>32</b>, and <b>35</b> in Mouse<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0027.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">PK parameters determined from a composite concentration-time profile (3 animals/timepoint).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Terminal <i>t</i><sub>1/2</sub>.</p></div></div><div></div></div><div class="NLM_p">To measure functional consequences of CD73 inhibition with <b>35</b>, we assessed activation of human primary, peripheral blood-derived CD8<sup>+</sup> T cells after exposure to AMP. Cytotoxic CD8<sup>+</sup> T cells express CD73 on their surface (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf" class="ext-link">Figure S1</a> in the Supporting Information) and can efficiently generate ADO in the presence of AMP. Consequently, high ADO levels result in severely suppressed T-cell proliferation and impaired production of cytokines. First, we tested whether CD73 inhibitors can block ADO production by CD8<sup>+</sup> T cells. <b>35</b> exhibited complete inhibition of AMP hydrolysis to ADO in peripheral blood-derived CD8<sup>+</sup> T cells with an EC<sub>50</sub> of 0.22 nM. To assess whether this inhibition is sufficient to rescue CD8<sup>+</sup> T-cell activation when AMP is present in the environment, we stimulated human CD8<sup>+</sup> T cells with anti-CD3/28/2 tetrameric antibodies and recombinant IL-2 for 24 h. The cells were then treated with <b>35</b>, and AMP was added 15 min later along with an ADO deaminase inhibitor, EHNA. The amount of CD8<sup>+</sup> proliferating cells and levels of secreted cytokines were measured 4 days later. As expected, AMP-treated cells were substantially impaired in proliferative capacity and produced significantly lower levels of the inflammatory cytokines IFNγ and TNFα. The number of proliferating cells was also substantially reduced by AMP treatment. Compound <b>35</b> successfully counteracted the deleterious effects of AMP and rescued T-cell activation, including proliferation and cytokine secretion, at nanomolar concentrations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Functional effects of <b>35</b> on human CD8<sup>+</sup> T cells. <b>35</b> rescued AMP-suppressed T-cell proliferation and cytokine production. Human PBMC-derived CD8<sup>+</sup> T cells were activated for 24 h with tetrameric anti-CD3/CD28/CD2 antibodies in serum-free media, labeled with CellTrace Violet and plated onto 96-well plates. Compounds and AMP were added at indicated concentrations, and cells were incubated for 96 h. Proliferating cells were quantified by flow cytometry. Cytokines in cell supernatants were measured by MSD ELISA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also investigated the efficiency of blocking ADO production by an anti-CD73 antibody, MEDI9447, which is currently undergoing testing in clinical trials (NCT02503774). We found that this antibody could only partially inhibit ADO production in H1568 cells, while <b>35</b> completely blocked ADO generation in human and murine cancer cell lines and in human CD8<sup>+</sup> T cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Not surprisingly, when tested in CD8<sup>+</sup> T cells, the anti-CD73 antibody did not rescue AMP-suppressed proliferation or cytokine production (data not shown), suggesting that complete, rather than partial, inhibition of ADO production is required to impact activation of cytotoxic cells.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>35</b> inhibited ADO production completely in human and murine cancer cell lines (H1568 and EMT6, respectively) as well as in human CD8<sup>+</sup> T cells. A CD73-targeted antibody (MEDI9447) showed incomplete inhibition in H1568. ADO concentrations were quantitated using mass spectrometry. Here, 100% corresponds to dimethyl sulfoxide (DMSO)-treated cells, 0% corresponds to a very small amount of adenosine produced in the absence of cells. Single data point was collected for each compound concentration in one experiment. Each compound was tested at least 3 times. Shown is a representative experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next examined the inhibitory effects of <b>35</b> on CD73 activity <i>ex vivo</i> using an <i>in situ</i> ecto-5′-nucleotidase activity assay, also called the modified Wachstein–Meisel lead phosphate method.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Consecutive fresh frozen sections of E.G7-OVA murine T-cell lymphoma syngeneic tumor were fixed and treated with AOPCP or <b>35</b> at different concentrations in the presence of 1 mM AMP. This approach allows the distribution and localization of CD73 activity to be identified. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> demonstrated that <b>35</b> inhibited CD73 enzymatic activity in a dose-dependent manner. Significant inhibition was observed when <b>35</b> was at concentrations of 10–100 nM, and <b>35</b> exhibits significantly higher potency compared to AOPCP.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0007.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative staining images of CD73 enzymatic activities post <b>35</b> treatment in E.G7-OVA consecutive tumor sections. CD73 activity was assessed by incubating tissue cryosections with the indicated concentrations of <b>35</b> in the presence of 1 mM AMP, followed by microscopic detection of the nucleotide-derived Pi as a brown precipitate. The first two boxes are negative and positive controls in which AMP was absent and present in E.G7-OVA tumor sections, respectively, in the absence of the CD73 inhibitor. AOPCP was used for comparison in this experiment. Bar is 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also evaluated whether <b>35</b> could block ADO production in the murine EMT6 breast cancer model. EMT6 cells exhibit a high level of CD73 expression. To ensure continuous coverage, <b>35</b> was administered via an osmotic minipump at a dose of 15 mg/kg/day in the EMT6 model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). <b>35</b> exhibits antitumor effects as a single agent as shown by the tumor growth inhibition in the <b>35</b>-treated group on day 13. Moreover, the <b>35</b>-treated group showed a 95% lower ADO/AMP ratio compared to that of the vehicle group, indicating almost complete blocking of the ADO production through AMP by <b>35</b>. Consistent with the observed PD response, the unbound exposures in plasma on Day 9 and the exposures in tumor on Day 13 were determined to be well above the unbound concentration of the cellular EC<sub>90</sub> obtained from the EMT6 assay.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0008.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> pharmacodynamics of <b>35</b> in the murine EMT6 model. BALB/c mice were subcutaneously implanted with minipumps with either <b>35</b> at a dose of 15 mg/kg/day or vehicle. (A) Tumor growth inhibition. (B) Significant ADO modulation. (C) Unbound plasma and tumor concentration on Day 9 and Day 13, respectively. *, <i>p</i> < 0.05 vs the vehicle group by Student’s <i>t</i>-test. ****, <i>p</i> < 0.0001 vs the vehicle group by Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, <b>35</b> was examined in the E.G7-OVA T-cell lymphoma model.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> E.G7-OVA cells are mouse T-cell lymphoma EL4 cells stably transfected with the cDNA of chicken ovalbumin (OVA) and thus express intracellular OVA protein and present OVA peptides on cell surface MHC class I molecules, resulting in enhanced immunogenicity. <b>35</b> was orally dosed at 150 mg/kg, BID for 16 days. The increase in the CD8<sup>+</sup>/Treg ratio and the percentage of CD8<sup>+</sup> T cells over the total CD45<sup>+</sup> cells on Day 16 were observed with the group treated with <b>35</b> by TIL analysis (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). These data indicate that treatment with <b>35</b> increases CD8<sup>+</sup> T-cell infiltration and reverses immunosuppression.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0009.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> TIL pharmacodynamics of <b>35</b> in the E.G7-OVA model. C57BL6 mice were treated with <b>35</b> at 150 mg/kg, BID for 16 days, PO. (A) CD8<sup>+</sup>/Treg ratio in the tumor; (B) percentage of CD8<sup>+</sup> T cells in total CD45<sup>+</sup> leukocytes. *, <i>p</i> < 0.05 vs the vehicle group by the Mann–Whitney test. **, <i>p</i> < 0.01 vs the vehicle group by the Mann–Whitney test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assess oral bioavailability of compound <b>35</b> in other species, we evaluated the pharmacokinetic properties of <b>35</b> in rats, dogs, and cynomolgus monkeys (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). We found that <b>35</b> had oral exposure in all three species, with a low clearance in rats and cynomolgus monkeys, a moderate clearance in dogs, and a high oral exposure in cynomolgus monkeys. <b>35</b> was also evaluated in the CYP inhibition assay and was found to have a low potential for CYP3A4, 2C8, and 2C9 inhibition (IC<sub>50</sub> > 20 μM).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters of <b>35</b> in Rats, Dogs, and Cynomolgus Monkeys<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">iv (0.2 mg/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">po (10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="±">CL (L/kg/h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC (μM*h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2,term</sub> (hr)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">AUC (μM*h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">2.11 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">1.96 ± 0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="±">1.22 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.29 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.40</td><td class="colsep0 rowsep0" align="char" char="±">1.25 ± 0.45</td><td class="colsep0 rowsep0" align="char" char="±">1.75 ± 0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyno</td><td class="colsep0 rowsep0" align="char" char="±">0.05 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">7.72 ± 1.55</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.72 ± 1.21</td><td class="colsep0 rowsep0" align="char" char="±">14.2 ± 3.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Data represents mean ± SD. All PK studies were run as <i>N</i> = 3.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Terminal <i>t</i><sub>1/2</sub>.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of compounds <b>1</b>–<b>3</b> followed the synthetic routes reported in the literature for making bisphosphonic acids with a purine core structure.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> describes the synthesis of compounds <b>4</b>–<b>6</b>. Commercially available 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine and β-<span class="smallcaps smallerCapital">d</span>-ribofuranose 1,2,3,5-tetraacetate were coupled to form intermediate <b>36</b>, followed by displacement of the chlorine at C<sub>6</sub> with 2-chlorobenzylamine to afford intermediate <b>37</b> and deprotection of the acetate groups to provide intermediate <b>38</b>. Protection of the C3, C4-diol on the ribose ring in <b>38</b> resulted in acetonide <b>39</b>. Compounds <b>4</b>–<b>6</b> were obtained from a 2-step process of coupling <b>39</b> with phosphoramidites <b>40</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>41</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and <b>42</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> respectively, followed by oxidation with <i>t</i>BuOOH to bisphosphonates and then removal of the <i>tert</i>-butyl protecting groups under acidic conditions.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>4</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SnCl<sub>4</sub>, 130 °C, 68%; (b) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 50 °C, 58%; (c) SnO(<i>n</i>-Bu)<sub>2</sub>, MeOH, 65 °C, 77%; (d) 2,2-dimethoxypropane, TsOH, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 70 °C, 85%; (e) (i) <b>40</b> for <b>4</b>, <b>41</b> for <b>5</b>, <b>42</b> for <b>6</b>, 1<i>H</i>-imidazole-4,5-dicarbonitrile, <i>t</i>BuOOH, ACN; (ii) HCl in dioxane, water, (CF<sub>3</sub>)<sub>2</sub>CHOH, 56% over two steps for <b>4</b>; 41% over two steps for <b>5</b>; 13% over two steps for <b>6</b>.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> describes the syntheses of compounds <b>7</b>–<b>9</b>. Compound <b>7</b> was synthesized through coupling of intermediate <b>39</b> with diethoxyphosphorylacetic acid, followed by deprotection of the phosphonate ester and acetonide groups in the resulting intermediate <b>43</b>. To synthesize compound <b>8</b>, <b>39</b> was converted to amine <b>44</b> through oxidation and reductive amination. Subsequently, the same sequence to prepare <b>7</b> was used for the synthesis of <b>8</b>. Synthesis of compound <b>9</b> started from the Mitsunobu reaction of <b>39</b> with diphenylphosphoryl azide to provide intermediate <b>45</b>. Reduction of the azide group in <b>45</b> afforded amine <b>46</b>, which reacted with methanesulfonyl chloride to form sulfonamide <b>47</b>. Alkylation of <b>47</b> with diethyl chlorophosphate followed by deprotection of the resulting intermediate <b>48</b> led to compound <b>9</b>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>7</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diethoxyphosphorylacetic acid, <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC), dichloromethane (DCM), 4-dimethylaminopyridine (DMAP), 61–85%; (b) (i) TMSBr, DCM; (ii) (CF<sub>3</sub>)<sub>2</sub>CHOH, 2 N HCl in dioxane, water, 24–35% over 2 steps; (c) (i) DCC, DMSO, trifluoroacetic acid (TFA), pyridine; (ii) NaBH(OAc)<sub>3</sub>, methylamine, HOAc, 1,2-dichloroethane (DCE), 16% over 2 steps; (d) PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), (PhO)<sub>2</sub>P(O)N<sub>3</sub>, THF, 60%; (e) PPh<sub>3</sub>, pyridine, NH<sub>4</sub>OH, 95%; (f) MsCl, Et<sub>3</sub>N, DMAP, DCM, 83%; (g) LDA, −78 °C, 30 min and then diethyl chlorophosphate, 24%.</p></p></figure><div class="NLM_p">Synthesis of compound <b>10</b> is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Starting from commercially available ribofuranoside <b>49</b>, Michael addition of <b>49</b> to diethyl vinylphosphonate resulted in intermediate <b>50</b>, which was deprotected to form triol <b>51</b> and globally protected as triacetate <b>52</b>. Glycosylation of <b>52</b> with 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine catalyzed by TMSOTf led to intermediate <b>53</b>. Displacement of the chlorine at C<sub>6</sub> in <b>53</b> by 2-chlorobenzylamine followed by deprotection of the acetate and the phosphonate ester groups afforded compound <b>10</b>.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, diethyl vinylphosphonate, 50 °C, 49%; (b) 80% HOAc, 85 °C; (c) Ac<sub>2</sub>O, DMAP, pyridine, 78% over 2 steps; (d) 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, TMSOTf, 62%; (e) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 55 °C, 63%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH; (g) TMSBr, Et<sub>3</sub>N, 26% over 2 steps.</p></p></figure><div class="NLM_p">Synthesis of compound <b>11</b> is shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Literature-known alcohol <b>56</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> was deprotected and then globally protected as tetraacetate <b>57</b>. Glycosylation of <b>57</b> with 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine and displacement of the chlorine at C<sub>6</sub> by 2-chlorobenzylamine provided triacetate <b>59</b>, which was deprotected to generate triol <b>60</b>. After protecting the C3, C4-diol on the ribose ring as an acetonide, the primary hydroxy group in <b>61</b> was alkylated with (di<i>-tert</i>-butoxyphosphoryl) methyl trifluoromethanesulfonate to provide <b>62</b>. Finally, deprotection of the terminal <i>tert</i>-butyl groups and the acetonide group provided compound <b>11</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) HOAc, 85 °C; (ii) Ac<sub>2</sub>O, DMAP, pyridine, 57% over 2 steps; (b) SnCl<sub>4</sub>, ACN, room temperature (rt), 72%; (c) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 50 °C, 77%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH; (e) 2,2-dimethoxypropane, TsOH, 78% over 2 steps; (f) (di<i>-tert</i>-butoxyphosphoryl) methyl trifluoromethanesulfonate, NaH; (g) 50% TFA, 11% over 2 steps.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> describes the syntheses of compounds <b>12</b>–<b>14</b>. Alkylation of the primary alcohol in <b>39</b> with (di-<i>tert</i>-butoxyphosphoryl)methyl trifluoromethanesulfonate in the presence of NaH followed by deprotection of the <i>tert</i>-butyl and the acetonide groups provided phosphonic acid <b>12</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0014.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of Compounds <b>12</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, −78 °C, (<i>t</i>-BuO)<sub>2</sub>P(O)CH<sub>2</sub>OTf, 49%; (b) HCl, (CF<sub>3</sub>)<sub>2</sub>CHOH, 26%; (c) DIAD, PPh<sub>3</sub>, AcSH, THF, 0 °C to rt; (d) DL-dithiothreitol, TEA, MeOH, rt, 98%; (e) NaH, (<i>t</i>-BuO)<sub>2</sub>P(O)CH<sub>2</sub>OTf, DMF, −10 °C to rt, 69%; (f) HCl, water, dioxane, (CF<sub>3</sub>)<sub>2</sub>CHOH, rt, 53%; (g) (i) oxone, MeOH, H<sub>2</sub>O, THF, rt; (ii) HCl, water, dioxane, (CF<sub>3</sub>)<sub>2</sub>CHOH, rt, 65%.</p></p></figure><div class="NLM_p">Syntheses of <b>13</b> and <b>14</b> started from the same intermediate <b>39</b>. Mitsunobu reaction of <b>39</b> with thioacetic acid, followed by deprotection of the thiol acetate group, provided thiol <b>63</b>. Alkylation of <b>63</b> with (di-<i>tert</i>-butoxyphosphoryl)methyl trifluoromethanesulfonate, followed by deprotection of the <i>tert</i>-butyl and the acetonide group in <b>64</b> under acidic conditions, resulted in sulfide <b>13</b>. The sulfone <b>14</b> was synthesized from <b>64</b> through oxone-mediated oxidation followed by deprotection. Compound <b>15</b> was prepared from the appropriate starting materials according to the similar procedures described for the synthesis of <b>12</b>.</div><div class="NLM_p">The synthesis of α-monosubstituted analogues <b>16</b>–<b>19</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) started with the intermediate <b>65</b>, which was prepared according to similar procedures described for the synthesis of <b>37</b>. Boc protection of the amino cyclopentyl group in <b>65</b>, followed by deprotection of the acetate groups in <b>66</b> and acetonide protection of the C3, C4-diol on the ribose ring, afforded alcohol <b>68</b>. Rhodium-catalyzed coupling reaction of <b>68</b> with ethyl 2-diazo-2-(diethoxyphosphoryl)acetate afforded ester <b>69</b>, which was reduced to alcohol <b>70</b> by lithium borohydride. Conversion of <b>70</b> into the 1<i>H</i>-imidazole-1-carbothioate with di(1<i>H</i>-imidazol-1-yl)methanethione, followed by radical deoxygenation with tributytin hydride, provided α-methyl substituted phosphonate <b>71</b>. Lastly, global deprotection of the diethyl phosphonate, the Boc-protected amine, and the acetonide groups in <b>71</b> with TMSBr and 50% TFA in water provided the α-methyl substituted compound <b>16</b>.</div><figure id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0015.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Syntheses of Compounds <b>16</b>–<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, DMAP, ACN, 70%; (b) NH<sub>3</sub> in MeOH, 89%; (c) 2,2-dimethoxypropane, TsOH, DMF, 68%; (d) Rh<sub>2</sub>(OAc)<sub>4</sub>, ethyl 2-diazo-2-(diethoxyphosphoryl)acetate, toluene, 100 °C, 76%; (e) LiBH<sub>4</sub>, THF, 0 °C to rt, 62%; (f) (Im)<sub>2</sub>CS, Et<sub>3</sub>N, DCM, rt, 56%; (g) Bu<sub>3</sub>SnH, toluene, reflux, 31%; (h) TMSBr, Et<sub>3</sub>N, ACN, rt, and then 50% TFA, rt, 14–34%; (i) trimethyloxonium tetrafluoroborate, DCM, 1 h, 66%; (j) LiOH, THF.</p></p></figure><div class="NLM_p">In a similar manner, compounds <b>17</b>–<b>19</b> were synthesized from either intermediate <b>69</b> or <b>70</b>. Global deprotection of <b>70</b> led to <b>17</b>, while methylation of <b>70</b> on the hydroxymethylene group, followed by global deprotection, led to <b>18</b>. Hydrolysis of <b>69</b> followed by global deprotection generated <b>19</b>. Compounds <b>20</b>–<b>23</b> were prepared by similar procedures described for the synthesis of <b>19</b>.</div><div class="NLM_p">Syntheses of compounds <b>24</b>–<b>29</b> started from intermediate <b>69</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Alkylation of <b>69</b> with methyl iodide, followed by reduction of the ester with Ca(BH<sub>4</sub>)<sub>2</sub> formed <i>in situ</i> with NaBH<sub>4</sub> and CaCl<sub>2,</sub> provided α-disubstituted diethyl phosphonate <b>73</b>, which served as a common intermediate for the syntheses of <b>24</b>–<b>28</b>. Global deprotection of the diethyl phosphonate, the Boc-protected amine, and the acetonide groups in <b>73</b> with TMSBr and then water provided compound <b>24</b>.</div><figure id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0016.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Compounds <b>24</b>–<b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, MeI, THF, 0 °C, 49%; (b) CaCl<sub>2</sub>, NaBH<sub>4</sub>, EtOH, rt, 81%; (c) TMSBr, ACN;, and then H<sub>2</sub>O, overnight, 19–40%; (d) DMP, DCM, rt, 62%; (e) dimethylamine, NaBH(OAc)<sub>3</sub>, DCE, rt, 53%; (f) methylamine, NaBH(OAc)<sub>3</sub>, DCE, rt, 61%; (g) TEA, MsCl, DCM, rt, 26%; (h) DIAD, PPh<sub>3</sub>, HSAc, THF, 0 °C to RT, 73%; (i) DL-dithiothreitol, TEA, MeOH, rt, 23%; (j) K<sub>2</sub>CO<sub>3</sub>, MeI, acetone, rt, 65%; (k) <i>m</i>CPBA, DCM, rt, 68%; (l) LiOH, THF, H<sub>2</sub>O, 93%; (m) (i) oxalyl chloride; (ii) TMSCHN<sub>2</sub>, silver benzoate, 50 °C; (iii) NaBH<sub>4</sub>, CaCl<sub>2</sub>.</p></p></figure><div class="NLM_p">Oxidation of the primary alcohol <b>73</b> to an aldehyde <b>74</b> with Dess–Martin periodinane (DMP), followed by reductive amination with <i>N</i>,<i>N</i>-dimethylamine and global deprotection, resulted in compound <b>25</b>. Similarly, compound <b>26</b> was obtained by a reductive amination of <b>74</b> with methylamine, followed by <i>N</i>-sulfonylation of the amine and global deprotection.</div><div class="NLM_p">Compounds <b>27</b> and <b>28</b> were synthesized from the methyl sulfide <b>80</b> by simple global deprotection or by oxidation of the sulfide followed by deprotection. The methyl sulfide <b>80</b> was obtained by methylation of the thiol <b>79</b>, which was prepared from <b>73</b> according to the procedures described for the synthesis of <b>63</b>.</div><div class="NLM_p">Compound <b>29</b> was prepared from <b>72</b>. Hydrolysis of the ester group in <b>72</b> provided acid <b>81</b>, which went through the Arndt–Eistert reaction to form the homologated ethyl ester, and the ester was further reduced to the homologated alcohol <b>82</b>. Global deprotection of <b>82</b> provided <b>29</b>.</div><div class="NLM_p"><a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a> describes the syntheses of compounds <b>34</b> and <b>35</b>. Alkylation of <b>69</b> with MOMCl in the presence of NaHMDS, followed by reduction of the ester <b>83</b>, resulted in α-disubstituted <b>84</b>. Separation of the diastereomers of <b>84</b> was achieved by preparative chiral high-performance liquid chromatography (HPLC, Chiralpak AD-H) to afford optically pure <b>85a</b> and <b>85b</b>, which were globally deprotected with TMSBr and TFA to provide compounds <b>34</b> and <b>35</b>, respectively.</div><figure id="sch8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0017.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Syntheses of Compounds <b>34</b> and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MOMCl, NaHMDS, TBAI, THF, −15 °C, 91%; (b) NaBH<sub>4</sub>, CaCl<sub>2</sub>, EtOH, 0 °C to rt, 80%; (c) CHIRALPAK AD-H, 5% isopropyl alcohol (IPA)/hex isocratic, 41% isolated for <b>55a</b> and 41% for <b>55b</b>; (d) TMSBr, CH<sub>3</sub>CN, rt, H<sub>2</sub>O, ACN, rt, 39%; (e) (i) TMSBr, Et<sub>3</sub>N, ACN, rt; (ii) TFA/H<sub>2</sub>O (1:1), 65%.</p></p></figure><div class="NLM_p last">Finally, compound <b>30</b> was prepared in an analogous fashion to the route shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>, replacing MOMCl with SEMCl in Step a. The same synthetic route without chiral separation was used for the synthesis of compound <b>31</b>. Compounds <b>32</b> and <b>33</b>, the diastereomers of <b>24</b>, were synthesized through chiral separation of intermediate <b>73</b> in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. The stereochemistry of <b>32</b> was confirmed by its cocrystal structure with CD73 (data not shown).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, structural modifications of AOPCP, focused on the linker between the external phosphonic acid and the sugar ring, led to the discovery of novel monophosphonic acid CD73 inhibitors. Introducing hydroxymethylene or methoxymethylene groups at the α position of the phosphonic acid resulted in highly potent, orally bioavailable inhibitors. The enhanced potency by the α-substituents can be rationalized by the favorable interactions between the hydroxymethylene or methoxymethylene moieties and the protein, which was observed in the cocrystal structure of <b>35</b> with CD73. In preclinical studies, <b>35</b> demonstrated complete inhibition of ADO production in human cancer cells and CD8<sup>+</sup> T cells and rescue of the AMP-suppression effects toward T cells, as well as dose-dependent inhibitory effects on CD73 activity in tumors <i>ex vivo</i>. Furthermore, <b>35</b> modulated the AMP-ADO pathway and reversed immunosuppression <i>in vivo</i>. Compound <b>35</b> is a promising prototype CD73 inhibitor that paves the way for further optimization toward the identification of a clinical candidate.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Chemistry</h3><div class="NLM_p">Reactions were usually carried out under an argon or nitrogen atmosphere. Anhydrous solvents and reagents purchased from commercial sources were used without further purification. For compounds that were purified by silica gel chromatography, we use prepacked Teledyne RediSep Rf Flash silica gel columns. Solvents were removed through a rotary evaporator under reduced pressure, and residual solvents were removed further from the final compounds under a high vacuum at approximately 1 Torr. All yields are reported as isolated yields. Reverse-phase HPLC purification was performed using an Agilent 1100 Series HPLC and a Phenomenex Gemini C18 column (5 μm, 100 mm × 21.2 mm i.d.), using solvent systems A (H<sub>2</sub>O with 0.1% trifluoroacetic acid) and B (CH<sub>3</sub>CN with 0.1% trifluoroacetic acid) with UV detection at 220 nm. Final compounds were purified to ≥95% purity. Purity of compounds was analyzed on an Agilent 1100 Series analytical HPLC instrument (UV detection at 220 nm) using the following method: Phenomenex Gemini 5μ C18 110A column (3.5 μm, 150 mm × 4.6 mm i.d.); flow rate, 1.5 mL/min; mobile phase: same solvent system A and B as in the reverse-phase HPLC above and with gradient elution (5–95% B) in 15 min. Mass spectral (MS) data were analyzed on an Agilent 1100 Series LCMS (UV detection at 254 nm) and in the electrospray mode (ESI). <sup>1</sup>H NMR spectra were collected on a Bruker 400 (400 MHz) instrument. Chemical shifts (δ) are reported in parts per million (ppm) relative to the reference solvents used. The following abbreviations were used to report the multiplicities of the peaks: br, broad; m, multiplet; s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; sep, septet.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(5-Chloro-7-{[(2-chlorophenyl)methyl]amino}-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl]methyl}phosphonic Acid (<b>1</b>)</h4><div class="NLM_p last">Compound <b>1</b> was prepared from 5,7-dichloro-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine according to similar procedures described in the literature.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ ppm 7.35–7.47 (m, 2H), 7.20–7.32 (m, 2H), 6.18 (d, <i>J</i> = 4.09 Hz, 1H), 5.04 (t, <i>J</i> = 4.01 Hz, 1H), 4.79–4.86 (m, 2H), 4.63–4.68 (m, 1H), 4.33 (q, <i>J</i> = 4.63 Hz, 1H), 3.93–4.08 (m, 2H), 2.04 (t, <i>J</i> = 19.88 Hz, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 585.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(5-Chloro-7-{[(1<i>S</i>)-2,3-dihydro-1<i>H</i>-inden-1-yl](methyl)amino}-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl]methyl}phosphonic Acid (<b>2</b>)</h4><div class="NLM_p last">Compound <b>2</b> was prepared from 5,7-dichloro-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine according to similar procedures described in the literature.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.14–7.42 (m, 4H), 6.63 (t, <i>J</i> = 7.8 Hz, 1H), 6.12 (t, <i>J</i> = 4.09 Hz, 1H), 4.71–4.81 (m, 1H), 4.40 (dt, <i>J</i> = 7.24, 5.01 Hz, 1H), 4.06–4.24 (m, 2H), 3.87–4.01 (m, 1H), 3.39/2.91 (s, 3H total), 3.05–3.20 (m, 1H), 2.94–3.03 (m, 1H), 2.41–2.65 (m, 1H), 2.05–2.25 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) 591.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(1<i>S</i>)-2,3-dihydro-1<i>H</i>-inden-1-yl](methyl)amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl]methyl}phosphonic Acid (<b>3</b>)</h4><div class="NLM_p last">Compound <b>3</b> was prepared from 5,7-dichloro-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine according to similar procedures described in the literature.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ ppm 8.23–8.33 (m, 1H), 7.01–7.38 (m, 4H), 6.55 (br t, <i>J</i> = 8.19 Hz, 1H), 6.10–6.19 (m, 1H), 4.82–4.93 (m, 1H), 4.54 (br t, <i>J</i> = 4.77 Hz, 1H), 4.25 (q, <i>J</i> = 3.91 Hz, 1H), 3.90–4.09 (m, 2H), 2.83–3.18 (m, 5H), 2.39–2.56 (m, 1H), 1.91–2.20 (m, 3H). <i>m</i>/<i>z</i> (ESI, −ve ion) = 588.2 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(methoxy)phosphoryl]methyl}phosphonic Acid (<b>4</b>)</h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Step a: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(Acetoxymethyl)-5-(4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl Diacetate (<b>36</b>)</h5><div class="NLM_p last">β-<span class="smallcaps smallerCapital">d</span>-Ribofuranose 1,2,3,5-tetraacetate (5.73 g, 17.99 mmol) was heated at 90 °C for 10 min. 4,6-Dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (1.5 g, 17.99 mmol) and SnCl<sub>4</sub> (60 mg, 0.23 mmol) were added successively. After the mixture was heated at 130 °C for 15 min under reduced pressure, it was cooled to rt, diluted with water, and extracted with DCM. The combined organics were washed with water and brine, dried with MgSO<sub>4</sub>, and concentrated. The residue was purified by column chromatography on silica gel (gradient elution, petroleum ether/ethyl acetate: from 10:1 to 5:1) to provide <b>36</b> (2.4 g, 68%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.23 (d, <i>J</i> = 0.73 Hz, 1H), 6.58 (d, <i>J</i> = 3.65 Hz, 1H), 5.96 (dd, <i>J</i> = 5.34, 3.73 Hz, 1H), 5.75 (t, <i>J</i> = 5.41 Hz, 1H), 4.40–4.49 (m, 2H), 4.15–4.23 (m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 447.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Step b: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(Acetoxymethyl)-5-(6-chloro-4-(2-chlorobenzylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl Diacetate (<b>37</b>)</h5><div class="NLM_p last">A mixture of <b>36</b> (2.4 g, 5.37 mmol), 2-chlorobenzylamine (912 mg, 6.44 mmol), triethylamine (1.13 mL, 8.03 mmol), and EtOH (40 mL) was heated at 50 °C for 1 h. The mixture was cooled to room temperature (RT) and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate: 5:1) to afford <b>37</b> (1.7 g, 58%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.60–7.80 (m, 1H), 7.38–7.53 (m, 2H), 7.27–7.31 (m, 2H), 6.51 (d, <i>J</i> = 3.65 Hz, 1H), 6.07 (br s, 1H), 5.93 (br s, 1H), 5.71–5.80 (m, 1H), 4.92 (br d, <i>J</i> = 5.14 Hz, 2H), 4.34–4.46 (m, 2H), 4.13–4.21 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.07 (br s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 552.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step c: (2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>R</i>)-2-(6-Chloro-4-(2-chlorobenzylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (<b>38</b>)</h5><div class="NLM_p last">A mixture of <b>37</b> (240 mg, 3.8 mmol), SnO(<i>n</i>-Bu)<sub>2</sub> (3.07 g, 12.3 mmol), and methanol (40 ml) was heated at 65 °C overnight. The mixture was cooled to RT and concentrated. The residue was purified by silica gel column chromatography (gradient elution, DCM/MeOH: from 50:1 to 20:1) to provide <b>38</b> (1.0 g, 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.27–9.37 (m, 1H), 8.29 (s, 1H), 7.40–7.54 (m, 2H), 7.28–7.39 (m, 2H), 6.02 (d, <i>J</i> = 4.65 Hz, 1H), 5.42 (d, <i>J</i> = 5.87 Hz, 1H), 5.19 (d, <i>J</i> = 5.62 Hz, 1H), 4.69–4.85 (m, 3H), 4.57 (q, <i>J</i> = 5.05 Hz, 1H), 4.19 (q, <i>J</i> = 4.97 Hz, 1H), 3.91 (q, <i>J</i> = 4.65 Hz, 1H), 3.50–3.61 (m, 1H), 3.38–3.48 (m, 1H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 426.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step d: ((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methanol (<b>39</b>)</h5><div class="NLM_p last">To a solution of <b>38</b> (3.00 g, 7.04 mmol) in DMF (32 mL) was added 2,2-dimethoxypropane (2.59 mL, 21.1 mmol) followed by addition of <i>p</i>-toluenesulfonic acid monohydrate (268 mg, 1.41 mmol). After the mixture was heated to 70 °C for 1 h, it was cooled to RT and concentrated. The residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes) to provide <b>39</b> (2.79 g, 85%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.34 (br t, <i>J</i> = 5.50 Hz, 1H), 8.31 (s, 1H), 7.50 (d, <i>J</i> = 6.32 Hz, 1H), 7.45 (t, <i>J</i> = 5.08 Hz, 1H), 7.35 (t, <i>J</i> = 4.78 Hz, 2H), 6.20–6.25 (m, 1H), 5.31 (dd, <i>J</i> = 6.11, 1.47 Hz, 1H), 4.85–4.99 (m, 2H), 4.77 (d, <i>J</i> = 5.62 Hz, 2H), 4.10–4.18 (m, 1H), 3.43–3.52 (m, 1H), 1.52 (s, 3H), 1.33 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 466.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Step e: {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(methoxy)phosphoryl]methyl}phosphonic Acid (<b>4</b>)</h5><div class="NLM_p last">To an oven-dried flask were added <b>39</b> (188 mg, 0.40 mmol), <b>40</b><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (223 mg, 0.60 mmol), and ACN (5 mL). To this suspension was added 1<i>H</i>-imidazole-4,5-dicarbonitrile (71 mg, 0.60 mmol). After stirring at RT for 2 h, <i>tert</i>-butyl hydroperoxide (0.22 mL, 1.2 mmol) was added. After 1 h, the mixture was poured into saturated NaHCO<sub>3</sub>, extracted with EtOAc (2×), and washed with brine. The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was dissolved in hexafluoroisopropanol (4.4 mL), and water (0.21 mL) and hydrochloric acid (0.21 mL, 4 N HCl in dioxane) were added. After the solution was stirred for 1 h, it was quenched with 28% aqueous NH<sub>4</sub>OH (0.3 mL) and concentrated. The solution was purified by reverse-phase HPLC (gradient elution, 0–65% ACN/H<sub>2</sub>O with 0.1% TFA modifier) to afford <b>4</b> (158 mg, 56%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.24–9.36 (m, 1H), 8.30 (t, <i>J</i> = 0.73 Hz, 1H), 7.47–7.55 (m, 1H), 7.40–7.47 (m, 1H), 7.29–7.38 (m, 2H), 6.05 (d, <i>J</i> = 3.95 Hz, 1H), 4.71–4.82 (m, 2H), 4.48–4.56 (m, 1H), 4.29–4.34 (m, 1H), 4.11–4.21 (m, 1H), 4.04–4.11 (m, 1H), 3.92–4.04 (m, 1H), 3.58 (dd, <i>J</i> = 11.25, 4.38 Hz, 3H), 2.35 (dt, <i>J</i> = 19.88, 3.20 Hz, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 598.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> [(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl Methyl Methylenebis[hydrogen (phosphonate)] (<b>5</b>)</h4><div class="NLM_p last">Compound <b>5</b> was prepared from <b>39</b> and <b>41</b><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> according to similar procedures described for the synthesis of <b>4</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.27–9.37 (m, 1H), 8.26–8.35 (m, 1H), 7.47–7.56 (m, 1H), 7.40–7.47 (m, 1H), 7.30–7.38 (m, 2H), 6.04 (d, <i>J</i> = 4.24 Hz, 1H), 4.70–4.83 (m, 2H), 4.50–4.57 (m, 1H), 4.28 (t, <i>J</i> = 4.75 Hz, 1H), 4.00–4.15 (m, 2H), 3.83–3.94 (m, 1H), 3.53 (d, <i>J</i> = 11.25 Hz, 3H), 2.15–2.39 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 597.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Methyl Hydrogen {[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(methoxy)phosphoryl]methyl}phosphonate (<b>6</b>)</h4><div class="NLM_p last">Compound <b>6</b> was prepared from <b>39</b> and <b>42</b><a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> according to similar procedures described for the synthesis of <b>4</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.29–9.37 (br s, 1H), 8.30 (t, <i>J</i> = 0.8 Hz, 1H), 7.48–7.52 (m, 1H), 7.41–7.46 (m, 1H), 7.31–7.38 (m, 2H), 6.03–6.07 (m, 1H), 4.73–4.80 (m, 2H), 4.48–4.55 (m, 1H), 4.29–4.37 (m, 1H), 4.13–4.23 (m, 1H), 4.05–4.10 (m, 1H), 3.95–4.05 (m, 1H), 3.56–3.61 (m, 3H), 3.48–3.56 (m, 3H), 2.41–2.59 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 612.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (2-{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}-2-oxoethyl)phosphonic Acid (<b>7</b>)</h4><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step a: ((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methyl 2-(Diethoxyphosphoryl)acetate (<b>43</b>)</h5><div class="NLM_p last">To a slurry of <b>39</b> (100 mg, 0.21 mmol) and diethoxyphosphorylacetic acid (0.070 mL, 0.43 mmol) in DCM (2 mL) were added DCC (88 mg, 0.43 mmol) and 4-dimethylaminopyridine (1.3 mg, 0.010 mmol). After stirring at RT overnight, the reaction mixture was filtered over celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (gradient elution 0–100% EtOAc in hexanes) to provide <b>43</b> (118 mg, 85%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.80–7.93 (m, 1H), 7.36–7.54 (m, 2H), 7.28–7.33 (m, 2H), 6.58 (d, <i>J</i> = 1.61 Hz, 1H), 4.87–5.01 (m, 3H), 4.40–4.50 (m, 1H), 4.28–4.37 (m, 1H), 4.05–4.23 (m, 6H), 2.91–3.00 (m, 2H), 1.59 (s, 3H), 1.38 (s, 3H), 1.29–1.34 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 644.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step b: (2-{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}-2-oxoethyl)phosphonic Acid (<b>7</b>)</h5><div class="NLM_p last">To a solution of <b>43</b> (118 mg, 0.18 mmol) in DCM (6.5 mL) was added bromo(trimethyl)silane (0.14 mL, 1.1 mmol) at rt. After stirring overnight, the mixture was concentrated and dissolved in MeOH (5.0 mL). The mixture was stirred for 30 min and was concentrated again. The residue was dissolved in hexafluoroisopropanol (2.3 mL) and water (0.11 mL), and hydrochloric acid (0.11 mL, 0.44 mmol, 2 N in dioxane) was added dropwise. One hour later, the mixture was quenched with 28% aqueous NH<sub>4</sub>OH (0.3 mL) and concentrated. The residue was purified by reverse-phase HPLC (0–65% gradient elution with ACN and water with 0.1% TFA modifier) to provide <b>7</b> (43 mg, 35%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.32 (t, <i>J</i> = 5.55 Hz, 1H) 8.23–8.30 (s, 1H), 7.47–7.56 (m, 1H), 7.41–7.47 (m, 1H), 7.31–7.38 (m, 2H), 6.05 (d, <i>J</i> = 3.51 Hz, 1H), 4.77 (d, <i>J</i> = 5.55 Hz, 2H), 4.46–4.55 (m, 1H), 4.26–4.37 (m, 2H), 4.05–4.13 (m, 1H), 3.97 (dd, <i>J</i> = 11,55, 6.72 Hz,1 H), 2.72–2.85 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) 548.0 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> {2-[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)amino]-2-oxoethyl}phosphonic Acid (<b>8</b>)</h4><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step c: 6-Chloro-<i>N</i>-(2-chlorobenzyl)-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-2,2-dimethyl-6-((methylamino)methyl)tetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>44</b>)</h5><div class="NLM_p last">To an oven-dried flask were added <b>39</b> (900 mg, 1.93 mmol) and DCC (1590 mg, 7.72 mmol) followed by DMSO (8.1 mL). To this mixture was added a DMSO (0.6 mL) solution of trifluoroacetic acid (0.12 mL, 1.54 mmol) and pyridine (0.23 mL, 2.9 mmol). After stirring overnight, the resulting cloudy suspension was poured into H<sub>2</sub>O (30 mL) and extracted with EtOAc (3×). The organic layer was washed with water and brine, dried with MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography (gradient elution, 0–10% MeOH in DCM), which resulted in an impure aldehyde intermediate that was taken to the next step without further purification. To a vial containing the above impure residue were added DCE (12 mL), methylamine (2.18 mL, 5.79 mmol), and acetic acid (0.33 mL, 5.79 mmol). This mixture was stirred for 5 min before sodium triacetoxyborohydride (1230 mg, 5.79 mmol) was added. After stirring for 30 min, the reaction mixture was quenched with saturated NaHCO<sub>3</sub> and extracted with EtOAc (3×). The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 0–10% MeOH in DCM with 0.1% TEA modifier) to afford <b>44</b> (153 mg, 16%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.14–8.22 (m, 1H), 7.34–7.65 (m, 3H), 7.23–7.26 (m, 1H), 6.51 (s, 1H), 5.03–5.17 (m, 2H), 4.85–4.97 (m, 2H), 4.66–4.75 (m, 1H), 3.40–3.54 (m, 1H), 3.11–3.17 (m, 1H), 2.62 (br s, 3H), 1.35 (br s, 3H) 1.26 (br s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) 479.0 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> {2-[{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}(methyl)amino]-2-oxoethyl}phosphonic Acid (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared from <b>44</b> according to the procedures described for Steps a and b in the synthesis of <b>7</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.28–9.40 (m, 1H), 8.29–8.36 (m, 1H), 7.48–7.54 (m, 1H), 7.42–7.47 (m, 1H), 7.30–7.38 (m, 2H), 6.00–6.09 (m, 1H), 4.74–4.81 (m, 2H), 4.34–4.63 (m, 1H), 4.16–4.30 (m, 1H), 4.03–4.12 (m, 1H), 3.71–3.97 (m, 1H), 3.58–3.67 (m, 1H), 2.69–3.12 (m, 5H). <i>m</i>/<i>z</i> (ESI, +ve ion) 561.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> [({[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfamoyl)methyl]phosphonic Acid (<b>9</b>)</h4><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step d: 1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(Azidomethyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-6-chloro-<i>N</i>-(2-chlorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>45</b>)</h5><div class="NLM_p last">To a solution of <b>39</b> (228 mg, 0.49 mmol) in THF (2.3 mL) were added triphenylphosphine (154 mg, 0.590 mmol) and DIAD (0.12 mL, 0.59 mmol) dropwise. After stirring for 10 min at 0 °C, diphenyl phosphorazidate (0.13 mL, 0.59 mmol) was added. The mixture was warmed to RT and allowed to stir overnight. The mixture was concentrated, and the resulting residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes) to provide <b>45</b> (144 mg, 60%) as a foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.27–7.92 (m, 4H), 6.59 (d, <i>J</i> = 1.17 Hz, 1H), 5.28–5.38 (m, 1H), 4.85–4.98 (m, 3H), 4.30–4.41 (m, 1H), 3.48–3.57 (m, 1H), 3.33–3.44 (m, 1H), 1.60 (s, 3H), 1.38 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) 491.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step e: 1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(Aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-6-chloro-<i>N</i>-(2-chlorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>46</b>)</h5><div class="NLM_p last">To a solution of <b>45</b> (144 mg, 0.29 mmol) dissolved in pyridine (3 mL) was added triphenylphosphine (115 mg, 0.440 mmol). After 2 h, 28% aqueous NH<sub>4</sub>OH (7 mL) was added and the mixture was allowed to stir overnight. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (gradient elution, 0–10% methanol in DCM with 0.1% TEA) to provide <b>46</b> (130 mg, 95%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.29–7.95 (m, 4H), 6.53 (d, <i>J</i> = 2.19 Hz, 1H), 5.33–5.39 (m, 1H), 4.86–4.97 (m, 3H), 4.23 (dt, <i>J</i> = 5.74, 3.05 Hz, 1H), 2.89–2.96 (m, 2H), 1.62 (s, 3H), 1.39 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) 465.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step f: <i>N</i>-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methyl)methanesulfonamide (<b>47</b>)</h5><div class="NLM_p last">To a solution of <b>46</b> (250 mg, 0.54 mmol) dissolved in DCM (2.5 mL) was added triethylamine (0.22 mL, 1.6 mmol) followed by methanesulfonyl chloride (0.050 mL, 0.64 mmol) and 4-dimethylaminopyridine (13 mg, 0.11 mmol). After stirring overnight, the reaction mixture was concentrated and the residue was purified by silica gel column chromatography (gradient elution, 0–6% MeOH in DCM) to provide <b>47</b> (242 mg, 83% yield) as a white sold. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.70–7.98 (m, 1H), 7.49–7.55 (m, 1H), 7.40–7.46 (m, 1H), 7.27–7.33 (m, 2H), 6.49 (d, <i>J</i> = 2.63 Hz, 1H), 5.94–6.22 (m, 1H), 5.20 (dd, <i>J</i> = 5.99, 2.63 Hz, 1H), 4.96–5.01 (m, 1H), 4.88–4.96 (m, 2H), 4.45–4.53 (m, 1H), 3.35–3.55 (m, 2H), 2.90 (s, 3H), 1.61 (s, 3H), 1.37 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) 543.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step g: Diethyl ((<i>N</i>-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methyl)sulfamoyl)methyl)phosphonate (<b>48</b>)</h5><div class="NLM_p last">To a solution of anhydrous diisopropylamine (0.11 mL, 0.79 mmol) dissolved in THF (3 mL) at −78 °C was added <i>n</i>-butyllithium (1.6 M in hexanes, 0.46 mL, 0.73 mmol) over 5 min. The solution was slowly warmed to 0 °C over 30 min, and the mixture was cooled back to −78 °C. To the reaction mixture was added a solution of <b>47</b> (120 mg, 0.220 mmol) in THF (2 mL) dropwise over 5 min. After stirring for 30 min at −78 °C, diethyl chlorophosphate (0.040 mL, 0.24 mmol) was added dropwise and the mixture was allowed to stir for 15 min. The solution was slowly warmed to 0 °C over 1 h. The reaction mixture was quenched with saturated NH<sub>4</sub>Cl (1.0 mL) and was partitioned between EtOAc (25 mL) and water (25 mL). The aqueous layer was extracted with EtOAc (×2), and the combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 20–100% EtOAc in hexanes) to provide <b>48</b> (36 mg, 24%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.90–7.99 (m, 1H), 7.48–7.58 (m, 1H), 7.37–7.48 (m, 1H), 7.27–7.32 (m, 2H), 6.52 (d, <i>J</i> = 2.19 Hz, 1H), 5.26 (dd, <i>J</i> = 6.14, 2.05 Hz, 1H), 4.98 (dd, <i>J</i> = 4.97, 1.02 Hz, 1H), 4.88–4.95 (m, 2H), 4.46–4.53 (m, 1H), 4.07–4.24 (m, 4H), 3.61–3.71 (m, 1H), 3.47–3.56 (m, 2H), 3.40–3.46 (m, 1H), 1.60 (s, 3H), 1.37 (s, 3H), 1.27–1.37 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) 679.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> [({[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfamoyl)methyl]phosphonic Acid (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared from <b>48</b> according to the procedures described for Step b in the synthesis of <b>7</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.32 (t, <i>J</i> = 5.55 Hz, 1H), 8.31 (s, 1H), 7.47–7.54 (m, 1H), 7.44 (t, <i>J</i> = 5.09 Hz, 1H), 7.34 (t, <i>J</i> = 4.78 Hz, 2H), 6.99 (br s, 1H), 6.03 (d, <i>J</i> = 4.86 Hz, 1H), 4.77 (br d, <i>J</i> = 5.26 Hz, 2H), 4.46–4.61 (m, 1H), 4.23 (t, <i>J</i> = 4.46 Hz, 1H), 3.89–4.02 (m, 1H), 3.45–3.54 (m, 2H), 3.22–3.31 (m, 1H), 3.08–3.17 (m, 1H). <i>m</i>/<i>z</i> (ESI, +ve ion) 583.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (2-{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}ethyl)phosphonic Acid (<b>10</b>)</h4><div id="sec5_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Step a: Diethyl (2-(((3<i>aR</i>,4<i>R</i>,6<i>aR</i>)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3] Dioxol-4-yl)methoxy)ethyl)phosphonate (<b>50</b>)</h5><div class="NLM_p last">To a solution of ribofuranoside <b>49</b> (1 g, 4.9 mmol) in diethyl vinylphosphonate (1 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (0.32 g, 0.1 mmol). The reaction was stirred at 50 °C overnight. Then, the mixture was cooled down, diluted with EtOAc (10 mL), and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 5:1 to 3:1) to afford <b>50</b> (880 mg, 49% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 4.95 (s, 1H), 4.65 (d, <i>J</i> = 6.11 Hz, 1H), 4.56 (d, <i>J</i> = 6.11 Hz, 1H), 4.28 (ddd, <i>J</i> = 8.31, 6.36, 0.73 Hz, 1H), 4.04–4.15 (m, 4H), 3.64–3.78 (m, 2H), 3.49 (dd, <i>J</i> = 9.54, 6.11 Hz, 1H), 3.42 (dd, <i>J</i> = 9.29, 8.56 Hz, 1H), 3.31 (s, 3H), 2.05–2.18 (m, 2H), 1.47 (s, 3H), 1.29–1.35 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 391.3 [M + Na]<sup>+</sup>.</div></div><div id="sec5_1_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Step b: Diethyl (2-(((2<i>R</i>,3<i>S</i>,4<i>R</i>)-3,4,5-Trihydroxytetrahydrofuran-2-yl)methoxy)ethyl) Phosphonate (<b>51</b>)</h5><div class="NLM_p last">A solution of <b>50</b> (880 mg, 2.39 mmol) in 80% aqueous HOAc (20 mL) was heated at 85 °C for 5 h. The reaction mixture was cooled to RT and concentrated under reduced pressure to afford the crude compound <b>51</b> (750 mg), which was used in the next step without further purification.</div></div><div id="sec5_1_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Step c: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-5-((2-(Diethoxyphosphoryl)ethoxy)methyl)tetrahydrofuran-2,3,4- triyl Triacetate (<b>52</b>)</h5><div class="NLM_p last">Crude <b>51</b> (750 mg, 2.39 mmol) was dissolved in dry pyridine (15 mL), and the solution was cooled to 0 °C. Acetic anhydride (1.2 g, 11.94 mmol) and DMAP (290 mg, 2.38 mmol) were added. The reaction mixture was stirred at RT overnight. The mixture was concentrated, and the residue was treated with EtOAc (30 mL) and 10% aqueous citric acid (20 mL). The organic layer was washed with saturated NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 5:1 to 2:1) to afford <b>52</b> (1 g, 78% yield over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 6.14–6.43 (m, 1H), 5.23–5.39 (m, 2H), 4.26–4.37 (m, 1H), 4.03–4.19 (m, 4H), 3.56–3.78 (m, 4H), 2.04–2.18 (m, 11 H), 1.23–1.35 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 463.2 [M + Na]<sup>+</sup>.</div></div><div id="sec5_1_12_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step d: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(4,6-Dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-5-((2-(diethoxyphosphoryl)ethoxy)methyl)tetrahydrofuran-3,4-diyl Diacetate (<b>53</b>)</h5><div class="NLM_p last">To a solution of 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (430 mg, 2.27 mmol) and <b>52</b> (1 g, 2.27 mmol) in ACN (20 mL) were added TMSOTf (2.02 g, 9.10 mmol) and DBU (1.04 g, 6.82 mmol). The reaction was stirred at RT for 2 h. The mixture was diluted with EtOAc (40 mL) and then washed with water (20 mL). The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 2:1 to 2:3) to afford <b>53</b> (800 mg, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.24 (s, 1H), 6.56 (d, <i>J</i> = 4.16 Hz, 1H), 5.93–6.01 (m, 1H), 5.69 (t, <i>J</i> = 5.14 Hz, 1H), 4.38 (q, <i>J</i> = 4.89 Hz, 1H), 4.06–4.17 (m, 4H), 3.65–3.78 (m, 4H), 2.07–2.18 (m, 8H), 1.19–1.38 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 569.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Step e: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidin-1-yl)-5-((2-(diethoxyphosphoryl)ethoxy)methyl)tetrahydrofuran-3,4-diyl Diacetate (<b>54</b>)</h5><div class="NLM_p last">To a solution of <b>53</b> (500 mg, 0.88 mmol) and 2-chlorobenzylamine (150 mg, 1.05 mmol) in EtOH (10 mL) was added Et<sub>3</sub>N (0.15 mL, 1.09 mmol). The reaction mixture was stirred at 55 °C for 1 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 2:1 to 1:3) to afford <b>54</b> (370 mg, 63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.41 (br t, <i>J</i> = 5.88 Hz, 1H), 8.36 (s, 1H), 7.49–7.53 (m, 1H) 7.42–7.47 (m, 1H), 7.31–7.39 (m, 2H), 6.28 (d, <i>J</i> = 3.91 Hz, 1H), 5.81 (dd, <i>J</i> = 5.38, 3.91 Hz, 1H), 5.53 (t, <i>J</i> = 5.50 Hz, 1H), 4.77 (d, <i>J</i> = 5.38 Hz, 2H), 4.24–4.32 (m, 1H), 3.86–3.98 (m, 4H), 3.49–3.63 (m, 4H), 2.10 (s, 3H), 2.06 (s, 3H), 1.95–2.05 (m, 2H), 1.16 (t, <i>J</i> = 7.09 Hz, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 674.5 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Step f: Diethyl (2-(((2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo [3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)ethyl) Phosphonate (<b>55</b>)</h5><div class="NLM_p last">To a solution of crude <b>54</b> (370 mg, 0.55 mmol) in methanol (6 mL) was added K<sub>2</sub>CO<sub>3</sub> (152 mg, 1.1 mmol). The reaction was stirred at RT for 2 h. The mixture was diluted with EtOAc and then washed with water. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The resulting crude <b>55</b> (250 mg) was used in the next step without further purification. <i>m</i>/<i>z</i> (ESI, +ve ion) = 590.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step g: (2-{[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}ethyl)phosphonic Acid (<b>10</b>)</h5><div class="NLM_p last">To a solution of <b>55</b> (250 mg, 0.43 mmol) in ACN (20 mL) were added Et<sub>3</sub>N (2.4 mL, 16.95 mmol) and TMSBr (1.94 g, 12.71 mmol). The reaction mixture was stirred at RT for 3 h. The mixture was concentrated, and the residue was purified by reverse-phase HPLC to afford <b>10</b> (94.9 mg, 26% over two steps). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.13 (s, 1H), 7.46 (dd, <i>J</i> = 5.70, 3.65 Hz, 1H), 7.41–7.45 (m, 1H), 7.25–7.33 (m, 2H), 6.21 (d, <i>J</i> = 3.51 Hz, 1H), 4.85 (s, 2H), 4.68 (dd, <i>J</i> = 5.12, 3.65 Hz, 1H), 4.47 (t, <i>J</i> = 5.41 Hz, 1H), 4.13–4.19 (m, 1H), 3.59–3.76 (m, 4H), 1.97–2.10 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 534.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> ({2-[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]ethoxy}methyl)phosphonic Acid (<b>11</b>)</h4><div id="sec5_1_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Step a: (3<i>R</i>,4<i>R</i>,5<i>R</i>)-5-(2-Acetoxyethyl)tetrahydrofuran-2,3,4-triyl Triacetate (<b>57</b>)</h5><div class="NLM_p last">A mixture of <b>56</b> (3.18 g, 14.6 mmol) in 70% aqueous HOAc (30 mL) was heated at 85 °C overnight. The mixture was concentrated to afford a crude residue. To the flask with the crude residue (2.4 g, 14.6 mmol) was added DMAP (1.78 g, 14.6 mmol) followed by pyridine (24 mL). The reaction was cooled to 0 °C, and acetic anhydride (11.9 g, 117 mmol) was added dropwise. The reaction mixture was stirred overnight at RT and quenched with saturated NaHCO<sub>3</sub> solution (40 mL). The resulting mixture was stirred for 10 min and then extracted with ethyl acetate (2×). The combined extracts were washed with water (50 mL) and brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 100:1 to 50:1) to afford <b>57</b> (2.7 g, 57% yield over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.13–6.39 (m, 1H), 5.29–5.35 (m, 1H), 5.22–5.27 (m, 1H), 4.19–4.31 (m, 2H), 4.08–4.17 (m, 1H), 2.12–2.13 (m, 3H), 2.09–2.10 (m, 3H), 2.07–2.08 (m, 3H), 2.05–2.06 (m, 3H), 1.91–2.04 (m, 2H).</div></div><div id="sec5_1_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Step b: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(2-Acetoxyethyl)-5-(4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl Diacetate (<b>58</b>)</h5><div class="NLM_p last">A mixture of <b>57</b> (1.5 g, 4.52 mmol) and SnCl<sub>4</sub> (853 mg, 4.52 mmol) in ACN (15 mL) was stirred at RT for 2 h. The mixture was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 50:1 to 30:1) to afford <b>58</b> (1.5 g, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.24 (s, 1H), 6.55 (d, <i>J</i> = 3.91 Hz, 1H), 5.95 (dd, <i>J</i> = 5.14, 3.91 Hz, 1H), 5.62 (t, <i>J</i> = 5.26 Hz, 1H), 4.32–4.39 (m, 1H), 4.21 (dt, <i>J</i> = 11.31, 5.72 Hz, 1H), 4.08 (dt, <i>J</i> = 11.31, 6.82 Hz, 1H), 2.16 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 2.04–2.15 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 483.0 [M + Na]<sup>+</sup>.</div></div><div id="sec5_1_13_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step c: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(2-Acetoxyethyl)-5-(6-Chloro-4-(2-chlorobenzylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl Diacetate (<b>59</b>)</h5><div class="NLM_p last">To a solution of <b>58</b> (900 mg, 1.95 mmol) in EtOH (9 mL) were added 2-chlorobenzylamine (415 mg, 2.93 mmol) and Et<sub>3</sub>N (0.41 mL, 2.93 mmol), and the resulting mixture was stirred at 50 °C for 30 min. The mixture was concentrated, and the residue was diluted with EtOAc and then washed with water. The organic layer was washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude was purified by silica gel column chromatography (petroleum ether/EtOAc = 10:1 to 5:1) to afford <b>59</b> (848 mg, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.93 (br s, 1H), 7.37–7.56 (m, 2H), 7.27–7.31 (m, 2H), 6.48 (d, <i>J</i> = 3.91 Hz, 1H), 5.87–5.96 (m, 1H), 5.62 (br s, 1H), 4.93 (br d, <i>J</i> = 5.62 Hz, 2H), 4.30 (q, <i>J</i> = 6.11 Hz, 1H), 4.20 (dt, <i>J</i> = 11.19, 5.78 Hz, 1H), 4.06 (dt, <i>J</i> = 11.25, 6.72 Hz, 1H), 2.12 (s, 3H), 2.08 (s, 3H), 2.05–2.10 (m, 2H), 2.04 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 566.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step d: (2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>R</i>)-2-(6-Chloro-4-(2-chlorobenzylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidin-1-yl)-5-(2-hydroxyethyl)tetrahydrofuran-3,4-diol (<b>60</b>)</h5><div class="NLM_p last">A solution of <b>59</b> (550 mg, 0.97 mmol) in methanol (5 mL) was cooled to 0 °C and stirred for 10 min. Potassium carbonate (403 mg, 2.92 mmol) was added in one portion. The reaction mixture was stirred for 30 min, quenched with saturated aqueous NH<sub>4</sub>Cl, and diluted with EtOAc and water. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford crude <b>60</b> (500 mg), which was used in the next step without further purification. <i>m</i>/<i>z</i> (ESI, +ve ion) = 440.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Step e: 2-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-(2-chlorobenzylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)ethanol (<b>61</b>)</h5><div class="NLM_p last">To a solution of crude <b>60</b> (500 mg, 1.14 mmol) and 2,2-dimethoxypropane (354 mg, 3.4 mmol) in acetone (10 mL) was added TsOH-H<sub>2</sub>O (43 mg, 0.23 mmol). After the mixture was stirred at RT for 20 min, saturated aqueous NaHCO<sub>3</sub> (10 mL) was added. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 10:1 to 2:1) to afford <b>61</b> (450 mg, 78% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.54–7.88 (m, 1H), 7.35–7.51 (m, 2H), 7.28–7.34 (m, 2H), 6.50 (d, <i>J</i> = 1.96 Hz, 1H), 5.98 (br s, 1H), 5.33–5.39 (m, 1H), 4.92 (br d, <i>J</i> = 5.87 Hz, 3H), 4.39 (ddd, <i>J</i> = 8.31, 5.14, 3.18 Hz, 1H), 3.59–3.74 (m, 2H), 1.94–2.04 (m, 1H), 1.84–1.92 (m, 1H), 1.60 (s, 3H), 1.37 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 480.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step f: Di-<i>tert</i>-butyl (2-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-(2-chlorobenzylamino)-1<i>H</i>- pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4- yl)ethoxy)methylphosphonate (<b>62</b>)</h5><div class="NLM_p last">A solution of <b>61</b> (200 mg, 0.21 mmol) and (di<i>-tert</i>-butoxyphosphoryl) methyl trifluoromethanesulfonate (222 mg, 0.62 mmol) in dry THF (10 mL) was cooled in an ice-water bath. Then, NaH (60% in mineral oil, 21 mg, 3.0 mmol) was added and the reaction mixture was stirred at RT for 2 h. The mixture was quenched with saturated NH<sub>4</sub>Cl and then extracted with EtOAc. The organic layer was concentrated to afford crude <b>61</b> (200 mg), which was used directly in the next step without further purification. <i>m</i>/<i>z</i> (ESI, +ve ion) = 686.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step g: ({2-[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]ethoxy}methyl)phosphonic Acid (<b>11</b>)</h5><div class="NLM_p last">The crude <b>62</b> (200 mg) was treated with 50% aqueous TFA (10 mL) and then stirred at RT for 3 h. The mixture was diluted with water and then purified by reverse-phase HPLC to afford <b>11</b> (26 mg, 11% over 2 steps) as a white solid. <sup>1</sup>H NMR (400 MHz, CH<sub>3</sub>OD) δ ppm 8.12 (s, 1H), 7.40–7.50 (m, 2H), 7.23–7.34 (m, 2H), 6.17 (d, <i>J</i> = 3.51 Hz, 1H), 4.85 (s, 2H), 4.68 (dd, <i>J</i> = 5.19, 3.73 Hz, 1H), 4.39 (t, <i>J</i> = 5.34 Hz, 1H), 4.09–4.19 (m, 1H), 3.59–3.74 (m, 4H), 2.00–2.10 (m, 1H), 1.87–1.98 (m, 1H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 534.1 [M + H]<sup>+</sup>. <i>m</i>/<i>z</i> (ESI, +ve ion) = 534.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> ({[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}methyl)phosphonic Acid (<b>12</b>)</h4><div id="sec5_1_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Step a: Di-<i>tert</i>-butyl ((((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)methyl)phosphonate</h5><div class="NLM_p last">To a solution of <b>39</b> (300 mg, 0.64 mmol) in dry THF (8 mL) was added NaH (60% in mineral oil, 129 mg, 3.22 mmol) at −78 °C, and the mixture was stirred for 30 min at the same temperature. A solution of (di-<i>tert</i>-butoxyphosphoryl)methyl trifluoromethanesulfonate (573 mg, 1.61 mmol) in dry THF (2 mL) was added dropwise. After the mixture was allowed to warm to RT and stirred for 1 h, it was quenched with saturated NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was washed with saturated NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by reverse-phase HPLC (gradient elution, 30–90% ACN with 0.1% TFA in water with 0.1% TFA) to provide the title intermediate di-<i>tert</i>-butyl ((((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)methyl)phosphonate (210 mg, 49%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.63–7.92 (m, 1H), 7.36–7.52 (m, 2H), 7.24–7.32 (m, 2H), 6.53 (d, <i>J</i> = 1.71 Hz, 1H), 5.32–5.44 (m, 1H), 4.85–5.02 (m, 3H), 4.40 (td, <i>J</i> = 6.54, 2.57 Hz, 1H), 3.77 (dd, <i>J</i> = 10.27, 6.85 Hz, 1H), 3.53–3.65 (m, 3H), 1.59 (s, 3H), 1.48 (s, 9H), 1.44 (br s, 9H), 1.36 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 672.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Step b: ({[(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}methyl)phosphonic Acid (<b>12</b>)</h5><div class="NLM_p last">To a solution of the above intermediate (210 mg, 0.31 mmol) in hexafluoro-2-propanol (8 mL) was added 6 N HCl (0.35 mL), and the resulting mixture was stirred at RT for 1 h. The reaction mixture was adjusted to a pH of 7 with ammonium hydroxide and concentrated. The residue was purified by reverse-phase HPLC (gradient elution, 10–40% ACN with 0.1% TFA in water with 0.1% TFA) to afford <b>12</b> (55 mg, 26%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13 (s, 1H), 7.40–7.49 (m, 2H), 7.26–7.32 (m, 2H), 6.22 (d, <i>J</i> = 3.65 Hz, 1H), 4.85 (s, 2H), 4.70 (dd, <i>J</i> = 4.90, 4.02 Hz, 1H), 4.48 (t, <i>J</i> = 5.19 Hz, 1H), 4.15–4.23 (m, 1H), 3.78–3.84 (m, 1H), 3.71–3.75 (m, 1H), 3.69 (d, <i>J</i> = 8.77 Hz, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 520.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> [({[(2<i>S</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfanyl)methyl]phosphonic Acid (<b>13</b>)</h4><div id="sec5_1_15_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Steps c and d: ((3a<i>S</i>,4<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methanethiol (<b>63</b>)</h5><div class="NLM_p last">To an oven-dried flask were added (<i>E</i>)-diisopropyl azodicarboxylate (0.46 mL, 2.4 mmol) and THF (12 mL) followed by triphenylphosphine (620 mg, 2.4 mmol) at 0 °C. After the mixture was stirred for 5 min, <b>39</b> (500 mg, 1.07 mmol) and thioacetic acid (0.17 mL, 2.4 mmol) were added. After the mixture was stirred overnight and allowed to warm to rt, it was quenched with 100 μL of TEA and concentrated. The residue was partitioned between EtOAc and water, and the aqueous layer was extracted with EtOAc (2×). Organic layers were combined, dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was dissolved in methanol (24 mL) and triethylamine (1.69 mL, 12.1 mmol). To this mixture was added DL-dithiothreitol (165 mg, 1.07 mmol), and the resulting mixture was stirred for 3 h. The mixture was concentrated, and the residue was purified by silica gel column chromatography (gradient elution, 0–50% EtOAc in hexanes) to afford <b>63</b> (505 mg, 98%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.85–8.19 (m, 1H), 7.29–7.62 (m, 2H), 7.16–7.26 (m, 2H), 6.46 (s, 1H), 5.20–5.35 (m, 1H), 4.79–5.01 (m, 3H), 4.18–4.27 (m, 1H), 2.69 (br t, <i>J</i> = 7.31 Hz, 2H), 1.55 (s, 3H), 1.46 (t, <i>J</i> = 8.48 Hz, 1H), 1.35 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 482.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Step e: Di-<i>tert-</i>butyl (((((3a<i>S</i>,4<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-((2-chlorobenzyl)amino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methyl)thio)methyl)phosphonate (<b>64</b>)</h5><div class="NLM_p last">To an oven-dried flask was added sodium hydride (42 mg, 1.05 mmol) and DMF (4 mL). This solution was cooled to −10 °C, and a solution of <b>63</b> (505 mg, 1.05 mmol) in DMF (6 mL) was added. After 30 min, a solution of di-<i>tert</i>-butoxyphosphorylmethyl trifluoromethanesulfonate (410 mg, 1.15 mmol) in DMF (1 mL) was added at the same temperature. After the mixture was allowed to warm to RT and stirred for 1 h, it was quenched with saturated NH<sub>4</sub>Cl and extracted with EtOAc (3×). The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 30–100% EtOAc in hexanes) to give product <b>64</b> (500 mg, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.90 (br s, 1H), 7.39–7.57 (m, 2H), 7.27–7.32 (m, 2H), 6.54 (d, <i>J</i> = 1.46 Hz, 1H), 5.32 (br s, 1H), 4.87–5.01 (m, 3H), 4.38 (td, <i>J</i> = 7.20, 2.63 Hz, 1H), 2.89 (d, <i>J</i> = 7.60 Hz, 2H), 2.51–2.69 (m, 2H), 1.60 (s, 3H), 1.47 (s, 9H), 1.45 (br s, 9H), 1.38 (s, 3H). <i>m</i>/<i>z</i> (ESI, −ve ion) = 686.2 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_15_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Step f: [({[(2<i>S</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfanyl)methyl]phosphonic Acid (<b>13</b>)</h5><div class="NLM_p last">To an oven-dried flask were added <b>64</b> (82 mg, 0.12 mmol) and hexafluoro-2-propanol (1.48 mL), followed by addition of water (0.07 mL, 4 mmol) and hydrochloric acid (4 M in dioxane, 0.07 mL, 0.29 mmol). After the mixture was stirred at RT for 25 min, it was quenched with saturated ammonium hydroxide and concentrated. The residue was purified by reverse-phase HPLC (gradient elution, 0–65% ACN with 0.1% TFA in water with 0.1% TFA) to afford <b>13</b> (41 mg, 53%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.31 (t, <i>J</i> = 5.55 Hz, 1H), 8.30 (s, 1H), 7.47–7.53 (m, 1H), 7.41–7.47 (m, 1H), 7.30–7.37 (m, 2H), 6.02 (d, <i>J</i> = 4.39 Hz, 1H), 4.77 (d, <i>J</i> = 5.55 Hz, 2H), 4.57 (br t, <i>J</i> = 4.75 Hz, 1H), 4.21 (br t, <i>J</i> = 4.82 Hz, 1H), 4.01–4.07 (m, 1H), 2.97 (dd, <i>J</i> = 13.52, 5.34 Hz, 1H), 2.81 (dd, <i>J</i> = 13.59, 7.31 Hz, 1H), 2.54–2.65 (m, 2H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 536.0 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> ({[(2<i>S</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-(6-Chloro-4-{[(2-chlorophenyl)methyl]amino}-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methanesulfonyl}methyl)phosphonic Acid (<b>14</b>)</h4><div class="NLM_p last">To an oven-dried flask was added <b>64</b> (235 mg, 0.34 mmol) followed by addition of MeOH (2 mL), water (2 mL), and THF (4 mL). To this mixture was added potassium peroxymonosulfate (519 mg, 3.41 mmol) at rt. After the mixture was stirred at RT for 24 h, it was quenched with saturated NaHCO<sub>3</sub> and extracted with EtOAc (3×). The combined organic layers were dried with brine and MgSO<sub>4</sub>, filtered, and concentrated. The crude sulfone was taken forward to the next step without further purification. To the flask containing the crude material (246 mg, 0.34 mmol) was added hexafluoro-2-propanol (4.3 mL), followed by addition of water (0.2 mL) and hydrochloric acid (0.2 mL, 0.82 mmol, 4 M in dioxane). After 25 min, the mixture was quenched with saturated NH<sub>4</sub>OH (0.2 mL). The solution was concentrated, and the residue was dissolved in DMF (6 ml). The solution was purified by reverse-phase HPLC (gradient elution, 0–65% ACN with 0.1% TFA in water with 0.1% TFA,) to afford <b>14</b> (127 mg, 65%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.34 (t, <i>J</i> = 5.63 Hz, 1H), 8.32 (d, <i>J</i> = 0.58 Hz, 1H), 7.47–7.53 (m, 1H), 7.41–7.47 (m, 1H), 7.31–7.37 (m, 2H), 6.06 (d, <i>J</i> = 3.51 Hz, 1H), 5.55–5.69 (m, 1H), 4.77 (d, <i>J</i> = 5.85 Hz, 2H), 4.45–4.50 (m, 1H), 4.30–4.39 (m, 2H), 3.57–3.72 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 568.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> [({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)methyl]phosphonic Acid (<b>15</b>)</h4><div class="NLM_p last">Compound <b>15</b> was prepared by similar procedures described for the synthesis of <b>12</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13 (s, 1H), 6.20 (d, <i>J</i> = 3.51 Hz, 1H), 4.63–4.70 (m, 1H), 4.54 (t, <i>J</i> = 6.87 Hz, 1H), 4.46 (t, <i>J</i> = 5.41 Hz, 1H), 4.14–4.22 (m, 1H), 3.79–3.86 (m, 1H), 3.68–3.77 (m, 3H), 2.03–2.18 (m, 2H), 1.76–1.88 (m, 2H), 1.52–1.75 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 464.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> [1-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)ethyl]phosphonic Acid (<b>16</b>)</h4><div id="sec5_1_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step a: (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-2-(Acetoxymethyl)-5-(4-(<i>tert</i>-butoxycarbonyl(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)tetrahydrofuran-3,4-diyl Diacetate (<b>66</b>)</h5><div class="NLM_p last">To a solution of <b>65</b> (12.6 g, 25.44 mmol) in ACN (120 mL) was added triethylamine (7.1 mL, 50.88 mmol) followed by di-<i>tert</i>-butyl dicarbonate (44.35 g, 203.52 mmol) and 4-dimethylaminopyridine (0.31 g, 2.544 mmol). The reaction mixture was stirred at RT overnight. The mixture was concentrated, and the residue was partitioned between EtOAc (50 mL) and saturated aqueous NaHCO<sub>3</sub>. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 8:1) to provide <b>66</b> (10.56 g, 70%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.03 (s, 1H), 6.58 (d, <i>J</i> = 3.91 Hz, 1H), 5.96 (dd, <i>J</i> = 5.14, 3.91 Hz, 1H), 5.77 (t, <i>J</i> = 5.26 Hz, 1H), 5.03 (quin, <i>J</i> = 8.74 Hz, 1H), 4.36–4.48 (m, 2H), 4.15–4.20 (m, 1H), 2.13 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.07–2.14 (m, 2H), 1.86–2.03 (m, 6H), 1.56 (s, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 596.7 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step b: <i>tert</i>-Butyl 6-Chloro-1-((2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>R</i>)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl(cyclopentyl)carbamate (<b>67</b>)</h5><div class="NLM_p last">An oven-dried flask was charged with <b>66</b> (10.56 g, 17.74 mmol). Ammonia solution (5.0 M in methanol, 140 mL) was added. The reaction mixture was stirred at RT overnight and then concentrated. The resulting crude oil was purified by silica gel column chromatography (2% MeOH in DCM) to provide <b>67</b> (7.39 g, 89%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.02 (s, 1H), 6.40 (d, <i>J</i> = 5.38 Hz, 1H), 5.04 (quin, <i>J</i> = 8.80 Hz, 1H), 4.91 (t, <i>J</i> = 5.14 Hz, 1H), 4.61 (dd, <i>J</i> = 4.77, 2.81 Hz, 1H), 4.30 (d, <i>J</i> = 2.20 Hz, 1H), 3.96 (dd, <i>J</i> = 12.72, 2.20 Hz, 1H), 3.67–3.81 (m, 1H), 2.68–2.90 (br s, 3H), 1.79–2.05 (m, 6H), 1.59–1.68 (m, 2H), 1.57 (s, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 470.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Step c: <i>tert</i>-Butyl 6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(hydroxymethyl)-2,2-dimethyl Tetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl (Cyclopentyl)carbamate (<b>68</b>)</h5><div class="NLM_p last">To a solution of <b>67</b> (7.39 g, 15.75 mmol) and 2,2-dimethoxypropane (4.92 g, 47.25 mmol) in DMF (75 mL) was added TsOH (0.6 g, 3.15 mmol, monohydrate). The reaction mixture was stirred at 70 °C for 1 h, and then saturated NaHCO<sub>3</sub> (100 mL) was added. The resulting mixture was extracted with EtOAc (3×). The combined extracts were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 8:1) to provide <b>68</b> (5.5 g, 68%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (s, 1H), 6.57 (d, <i>J</i> = 2.93 Hz, 1H), 5.20 (dd, <i>J</i> = 5.87, 2.93 Hz, 1H), 4.98–5.14 (m, 2H), 4.54 (s, 1H), 3.91 (dd, <i>J</i> = 12.72, 1.96 Hz, 1H), 3.76 (dd, <i>J</i> = 12.72, 2.93 Hz, 1H), 1.84–2.05 (m, 6H), 1.65 (s, 3H), 1.58–1.64 (m, 2H), 1.57 (s, 9H), 1.38 (s, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 510.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step d: Ethyl 2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-(<i>tert</i>-Butoxycarbonyl(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)acetate (<b>69</b>)</h5><div class="NLM_p last">A solution of ethyl 2-diazo-2-(diethoxyphosphoryl)acetate (13.5 g, 54.0 mmol) and <b>68</b> (5.5 g, 10.8 mmol) in toluene (80 mL) was degassed with argon. Then, Rh<sub>2</sub>(OAc)<sub>4</sub> (0.96 g, 2.16 mmol) was added and the mixture was degassed again with argon. After the mixture was stirred at 95 °C overnight, it was concentrated and the residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 5:1) to provide <b>69</b> (6.0 g, 76%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.97 (d, <i>J</i> = 9.29 Hz, 1H), 6.60 (d, <i>J</i> = 8.47 Hz, 1H), 5.32 (td, <i>J</i> = 6.11, 1.47 Hz, 1H), 4.99–5.09 (m, 2H), 4.48 (tdd, <i>J</i> = 6.69, 6.69, 4.10, 2.57 Hz, 1H), 4.10–4.33 (m, 7H), 3.54–3.93 (m, 2H), 1.83–2.02 (m, 8H), 1.60 (s, 3H), 1.56 (s, 9H), 1.38 (s, 3H), 1.25–1.35 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 732.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step e: <i>tert</i>-Butyl 6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-((1-(diethoxyphosphoryl)-2-hydroxy ethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo [3,4-<i>d</i>]pyrimidin-4-yl(cyclopentyl)carbamate (<b>70</b>)</h5><div class="NLM_p last">To a solution of <b>69</b> (3.0 g, 4.10 mmol) in THF (40 mL) was added LiBH<sub>4</sub> (0.36 g, 16.4 mmol) at 0 °C. The reaction mixture was stirred at RT for 30 min, and saturated aqueous NH<sub>4</sub>Cl (10 mL) was added. The resulting mixture was extracted with EtOAc (3×). The combined extracts were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 2:1) to provide <b>70</b>, a 45:55 mixture of diastereomers (1.75 g, 62%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 8.00–8.05 (m, 1H), 6.54–6.68 (m, 1H), 5.25–5.39 (m, 1H), 4.96–5.08 (m, 2H), 4.42–4.48 (m, 1H), 4.12–4.21 (m, 4H), 4.02–4.11 (m, 1H) 3.80–3.87 (m, 1H), 3.59–3.78 (m, 3H), 2.19–2.46 (m, 2H), 1.86–2.08 (m, 6H), 1.61–1.64 (m, 3H), 1.56–1.57 (m, 9H), 1.39 (br s, 3H), 1.29–1.36 (m, 6H); <i>m</i>/<i>z</i> (ESI, +ve ion) = 690.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Steps f and g: <i>tert</i>-Butyl 6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-((1-(diethoxyphosphoryl)ethoxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>] Pyrimidin-4-yl(cyclopentyl)carbamate (<b>71</b>)</h5><div class="NLM_p last"><b>Step f:</b> To a solution of <b>70</b> (450 mg, 0.65 mmol) and TEA (0.09 mL, 0.65 mmol) in DCM (10 mL) was added (Im)<sub>2</sub>CS (0.17 g, 6.5 mmol). The reaction mixture was stirred at RT overnight, and saturated aqueous NH<sub>4</sub>Cl (10 mL) was added. The resulting mixture was extracted with DCM. The combined extracts were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 2:1) to provide the intermediate <i>O</i>-(2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-((<i>tert</i>-butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)ethyl) 1<i>H</i>-imidazole-1-carbothioate (260 mg, 56%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.51 (d, <i>J</i> = 8.80 Hz, 1H), 7.95–8.00 (m, 1H), 7.68–7.74 (m, 1H), 7.07 (s, 1H), 6.60 (m, 1H), 5.20–5.33 (m, 1H), 4.88–5.11 (m, 3H), 4.69 (dddd, <i>J</i> = 16.57, 11.98, 7.40, 5.14 Hz, 1H), 4.41 (td, <i>J</i> = 6.42, 2.08 Hz, 1H), 4.14–4.25 (m, 4H), 3.98–4.09 (m, 1H), 3.77–3.96 (m, 2H), 1.84–2.05 (m, 6H), 1.59–1.64 (m, 2H), 1.54–1.59 (m, 12 H), 1.29–1.37 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 800.7 [M + H]<sup>+</sup>. <b>Step g:</b> To a solution of the intermediate above (260 mg, 0.33 mmol) in toluene (10 mL) was added Bu<sub>3</sub>SnH (110 mg, 0.38 mmol). After the reaction mixture was stirred under reflux for 2 h, it was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 4:1) to provide <b>71</b> (68 mg, 31%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.98–8.01 (m, 1H), 6.57–6.63 (m, 1H), 5.31–5.39 (m, 1H), 4.96–5.08 (m, 2H), 4.36–4.44 (m, 1H), 4.06–4.22 (m, 4H), 3.59–3.90 (m, 3H), 1.85–2.08 (m, 6H) 1.59–1.65 (m, 5H), 1.56 (s, 9H), 1.24–1.41 (m, 12 H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 674.6 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step h: [1-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)ethyl]phosphonic Acid (<b>16</b>)</h5><div class="NLM_p last">To a solution of <b>71</b> (68 mg, 0.10 mmol) and TEA (404 mg, 4.0 mmol) in MeCN (6 mL) was added TMSBr (460 mg, 3.0 mmol) at rt. After the reaction mixture was stirred at RT for 2 h, it was concentrated under reduced pressure to provide crude phosphonic acid as a yellow oil. The crude material was treated with 4 mL of 50% TFA, and the resulting mixture was stirred at RT for 1 h. The mixture was then concentrated and purified by reverse-phase HPLC to provide <b>16</b> (7 mg, 14%) as a pink solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13 (d, <i>J</i> = 7.16 Hz, 1H), 6.15–6.26 (m, 1H), 4.67–4.74 (m, 1H), 4.50–4.59 (m, 1H), 4.39–4.49 (m, 1H), 4.12–4.21 (m, 1H), 3.63–3.91 (m, 3H), 2.01–2.17 (m, 2H), 1.55–1.85 (m, 6H), 1.28–1.41 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 478.0 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> [1-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-2-hydroxyethyl]phosphonic Acid (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was prepared from intermediate <b>70</b> using the same condition as Step h in the synthesis of compound <b>16</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.14 (s, 1H), 6.18–6.26 (m, 1H), 4.65–4.78 (m, 1H), 4.44–4.58 (m, 2H), 4.18–4.27 (m, 1H), 4.03–4.12 (m, 1H), 3.65–3.89 (m, 4H), 2.03–2.16 (m, 2H), 1.77–1.86 (m, 2H), 1.53–1.75 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 494.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> [1-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-2-methoxyethyl]phosphonic Acid (<b>18</b>)</h4><div class="NLM_p last"><b>Step i:</b> To a solution of <b>70</b> (500 mg, 0.72 mmol) and <i>N</i>1<i>,N</i>1<i>,N</i>8<i>,N</i>8-tetra methylnaphthalene-1,8-diamine (620 mg, 2.88 mmol) in DCM (15 mL) were added trimethyloxonium tetrafluoroborate (320 mg, 2.16 mmol) and 4 Å molecular sieve (1.5 g). The reaction mixture was stirred at RT for 1 h and then filtered. The filtrate was washed with 5% aqueous citric acid, saturated aqueous NaHCO<sub>3</sub>, and brine, sequentially. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/EtOAc = 1:1) to provide the α-methoxymethyl intermediate (340 mg, 66%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.96–7.99 (m, 1H) 6.57–6.62 (m, 1H), 5.34–5.38 (m, 1H), 4.94–5.10 (m, 2H), 4.37–4.49 (m, 1H), 4.03–4.23 (m, 4H), 3.58–3.86 (m, 5H), 3.28–3.38 (m, 3H), 1.84–2.06 (m, 6H), 1.58–1.63 (m, 5H), 1.56 (s, 9H), 1.37–1.39 (m, 3H), 1.26–1.36 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 704.0 [M + H]<sup>+</sup>. Compound <b>18</b> was synthesized from the intermediate above using the same condition as Step h in the synthesis of <b>16</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.12–8.14 (m, 1H), 6.18–6.22 (m, 1H), 4.68–4.74 (m, 1H), 4.51–4.59 (m, 1H), 4.46 (dt, <i>J</i> = 13.96, 5.15 Hz, 1H), 4.16–4.24 (m, 1H), 3.85–3.98 (m, 2H), 3.69–3.85 (m, 2H), 3.56–3.65 (m, 1H), 3.32–3.34 (m, 3H), 2.05–2.15 (m, 2H), 1.75–1.85 (m, 2H), 1.53–1.75 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 508.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> ({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)(phosphono)acetic Acid (<b>19</b>)</h4><div class="NLM_p last"><b>Step j:</b> To a flask charged with intermediate <b>69</b> (125 mg, 0.17 mmol) and THF (1.6 mL) was added a lithium hydroxide monohydrate (14.3 mg, 0.34 mmol) solution in water (0.15 mL). After the reaction was stirred for 1 h at rt, it was cooled down in an ice-bath and pH of the solution was adjusted to 6 with 1 N HCl. The resulting mixture was diluted with water and extracted with EtOAc, washed with brine, dried, and concentrated to provide a crude product (90 mg). <i>m</i>/<i>z</i> (ESI, +ve ion) = 704.2 [M + H]<sup>+</sup>. The crude product was directly used in the next step without further purification. Compound <b>19</b> (27 mg, 34%) was prepared from the crude product above using the same condition as Step h in the synthesis of compound <b>16</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.12–8.16 (m, 1H), 6.22 (d, <i>J</i> = 4.09 Hz, 1H), 4.67–4.77 (m, 1H), 4.46–4.59 (m, 2H), 4.31–4.41 (m, 1H), 4.20–4.31 (m, 1H), 3.85–3.99 (m, 1H), 3.68–3.84 (m, 1H), 2.04–2.16 (m, 2H), 1.76–1.87 (m, 2H), 1.54–1.76 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 508.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> [({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)(cyano)methyl]phosphonic Acid (<b>20</b>)</h4><div class="NLM_p last">Compound <b>20</b> was prepared from intermediate <b>68</b> by procedures similar to those described for Steps d and h in the synthesis of <b>19</b>, replacing ethyl 2-diazo-2-(diethoxyphosphoryl)acetate with diethyl (cyano(diazo)methyl)phosphonate in Step a. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.12–8.19 (m, 1H), 6.20–6.24 (m, 1H), 4.60–4.77 (m, 2H), 4.45–4.59 (m, 2H), 4.18–4.28 (m, 1H), 3.78–4.09 (m, 2H), 2.04–2.16 (m, 2H), 1.75–1.86 (m, 2H), 1.54–1.74 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 489.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> [1-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-2,2,2-trifluoroethyl]phosphonic Acid (<b>21</b>)</h4><div class="NLM_p last">Compound <b>21</b> was prepared from intermediate <b>68</b> by procedures similar to those described for Steps d and h in the synthesis of <b>19</b>, replacing ethyl 2-diazo-2-(diethoxyphosphoryl)acetate with diethyl (1-diazo-2,2,2-trifluoroethyl)phosphonate in Step a. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ ppm 7.99–8.25 (m, 1H), 6.01–6.25 (m, 1H), 4.78–4.86 (m, 1H), 4.40–4.53 (m, 1H), 4.19–4.34 (m, 2H), 3.84–4.04 (m, 3H), 1.90–2.07 (m, 2H), 1.45–1.73 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 532.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> [({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)(methanesulfonyl)methyl]phosphonic Acid (<b>22</b>)</h4><div class="NLM_p last">Compound <b>22</b> was prepared from intermediate <b>68</b> by procedures similar to those described for Steps d and h in the synthesis of <b>19</b>, replacing ethyl 2-diazo-2-(diethoxyphosphoryl)acetate with diethyl (diazo(methylsulfonyl)methyl)phosphonate in Step a. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.11–8.14 (m, 1H), 6.18–6.28 (m, 1H), 4.58–4.72 (m, 2H), 4.48–4.58 (m, 2H), 4.19–4.32 (m, 2H), 3.99–4.13 (m, 1H), 3.00–3.02 (2 s, 3H), 2.03–2.18 (m, 2H), 1.75–1.87 (m, 2H), 1.54–1.74 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 542.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> [({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)(2H-tetrazol-5-yl)methyl]phosphonic Acid (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was prepared from intermediate <b>68</b> by procedures similar to those described for Steps d and h in the synthesis of <b>19</b>, replacing ethyl 2-diazo-2-(diethoxyphosphoryl)acetate with diethyl (diazo(2-((2-(trimethylsilyl)ethoxy)methyl)-2<i>H</i>-tetrazol-5-yl)methyl)phosphonate in Step a. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.05–8.15 (m, 1H), 6.22 (d, <i>J</i> = 3.95 Hz, 1H), 5.22–5.26 (m, 1H), 4.64 (t, <i>J</i> = 4.60 Hz, 1H), 4.50–4.59 (m, 1H), 4.44–4.50 (m, 1H), 4.24 (dt, <i>J</i> = 5.08, 2.50 Hz, 1H), 3.90–3.97 (m, 1H), 3.80–3.87 (m, 1H), 2.05–2.18 (m, 2H), 1.77–1.90 (m, 2H), 1.55–1.77 (m, 4H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 532.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxypropan-2-yl]phosphonic Acid (<b>24</b>)</h4><div id="sec5_1_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Step a: Ethyl 2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-((<i>tert</i>-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propanoate (<b>72</b>)</h5><div class="NLM_p last">To an oven-dried flask was added sodium hydride (328 mg, 8.19 mmol), followed by addition of THF (13 mL). The mixture was cooled to 0 °C, and a solution of intermediate <b>69</b> (3.0 g, 4.1 mmol) in THF (12 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 30 min, and methyl iodide (1.75 mL, 12.3 mmol) was added dropwise. After the mixture was stirred for 1 h, it was quenched with saturated NH<sub>4</sub>Cl and extracted with EtOAc (3×). The combined organic layer was dried, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 20–100% EtOAc in hexanes) to afford the methylated intermediate <b>72</b> (1.50 g, 49%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.94 (d, <i>J</i> = 5.62 Hz, 1H), 6.58 (d, <i>J</i> = 5.59 Hz, 1H), 5.30–5.38 (m, 1H) 5.08–5.22 (m, 1H), 5.00 (quin, <i>J</i> = 8.74 Hz, 1H), 4.38–4.49 (m, 1H), 4.07–4.32 (m, 6H), 3.63–3.82 (m, 1H), 3.57 (ddd, <i>J</i> = 8.80, 5.87, 2.69 Hz, 1H), 1.80–2.09 (m, 8H), 1.57–1.67 (m, 6H), 1.54 (s, 9H), 1.37 (s, 3H), 1.24–1.35 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 746.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Step b: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-hydroxypropan-2-yl)oy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>73</b>)</h5><div class="NLM_p last">To a flask containing <b>72</b> (4.30 g, 5.76 mmol) was added ethanol (87 mL). The mixture was cooled to 0 °C, and calcium dichloride (1.98 g, 17.3 mmol) was added, followed by addition of sodium borohydride (654 mg, 17.3 mmol). The mixture was warmed to RT and stirred for 1.5 h and then cooled to 0 °C. 1 N HCl was slowly added until the mixture became acidic. EtOAc (100 mL) was added, and the mixture was stirred for 5 min. The aqueous layer was diluted with water and extracted with EtOAc (2×). The combined organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 60–100% EtOAc in hexanes) to afford product <b>73</b> (3.30 g, 81%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.97–8.07 (m, 1H), 6.59 (dd, <i>J</i> = 11.25, 2.45 Hz, 1H), 5.32–5.42 (m, 1H), 4.93–5.07 (m, 2H), 4.36–4.48 (m, 1H), 4.08–4.24 (m, 4H), 3.68–3.90 (m, 3H), 3.47–3.64 (m, 1H), 1.81–2.11 (m, 6H), 1.60–1.66 (m, 5H), 1.53–1.58 (m, 9H), 1.26–1.41 (m, 12 H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 704.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Step c: [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxypropan-2-yl]phosphonic Acid (<b>24</b>)</h5><div class="NLM_p last">To a vial was added compound <b>73</b> (64 mg, 0.09 mmol), followed by addition of ACN (1.5 mL). To this solution was added bromo(trimethyl)silane (0.08 mL, 0.63 mmol), and the resulting mixture was allowed to stir for 4 h at rt. Water (0.30 mL) was added, and the mixture was allowed to stir overnight. The mixture was quenched with 28% NH<sub>4</sub>OH solution (0.30 mL) and concentrated. The resulting residue was purified by reverse-phase HPLC (gradient elution, 0–50% ACN with 0.1% TFA in water with 0.1% TFA) to afford product <b>24</b> (11 mg, 19%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.69–8.78 (m, 1H), 8.23–8.27 (m, 1H), 5.96–6.05 (m, 1H), 4.54–4.65 (m, 1H), 4.37–4.46 (m, 1H), 4.18–4.23 (m, 1H), 3.93–4.02 (m, 1H), 3.58–3.79 (m, 3H), 3.40–3.47 (m, 1H), 1.94–2.07 (m, 2H), 1.67–1.79 (m, 2H), 1.48–1.67 (m, 4H), 1.19–1.29 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 508.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(dimethylamino)propan-2-yl]phosphonic Acid (<b>25</b>)</h4><div id="sec5_1_27_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> Step d: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-oxopropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>74</b>)</h5><div class="NLM_p last">Dess–Martin periodinane (451 mg, 1.06 mmol) was added to a solution of <b>73</b> (555 mg, 0.79 mmol) in DCM (15 mL) at rt. After the mixture was allowed to stir for 50 min, it was diluted with DCM, quenched with saturated NaHCO<sub>3</sub>, and extracted with DCM (3×). The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The residue (<b>74</b>) was taken forward to the next step without further purification. <i>m</i>/<i>z</i> (ESI, +ve ion) = 702.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Step e: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-(dimethylamino)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>75</b>)</h5><div class="NLM_p last">To a flask containing <b>46</b> (334 mg, 0.48 mmol) was added DCE (5 mL) and dimethylamine (0.71 mL, 1.43 mmol), followed by addition of sodium triacetoxyborohydride (303 mg, 1.43 mmol). After the reaction was stirred for 2 h at rt, it was quenched with saturated NaHCO<sub>3</sub> and extracted with DCM and EtOAc. The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes followed by 0–10% MeOH in DCM) to afford <b>75</b> (185 mg, 53%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.97–8.01 (m, 1H), 6.59 (dd, <i>J</i> = 8.04, 1.46 Hz, 1H), 5.37 (dt, <i>J</i> = 6.18, 1.95 Hz, 1H), 4.96–5.06 (m, 2H), 4.33–4.38 (m, 1H), 3.99–4.22 (m, 4H), 3.57–3.94 (m, 2H), 2.60–2.72 (m, 2H), 2.39 (s, 3H), 2.27 (s, 3H), 1.83–2.09 (m, 8H), 1.60 (s, 3H), 1.56 (s, 9H), 1.40–1.54 (m, 3H), 1.38 (s, 3H), 1.21–1.36 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 731.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(dimethylamino)propan-2-yl]phosphonic Acid (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was prepared as a mixture of diastereomers from intermediate <b>75</b> using the same procedure as Step c in the synthesis of <b>24</b>. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ ppm 7.98– 8.19 (m, 1H), 6.03–6.15 (m, 1H), 4.79–4.84 (m, 1H), 4.41–4.53 (m, 1H), 4.25–4.34 (m, 1H), 4.16–4.25 (m, 1H), 3.59–3.94 (m, 2H), 3.23–3.36 (m, 2H), 2.81–2.85 (m, 3H), 2.72–2.81 (m, 3H), 1.88–2.06 (m, 2H), 1.44–1.73 (m, 6H), 1.24–1.34 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 535.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> {2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-[(methanesulfonyl)(methyl)amino]propan-2-yl}phosphonic Acid (<b>26</b>)</h4><div id="sec5_1_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Step f: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-(methylamino)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>76</b>)</h5><div class="NLM_p last">To a flask containing <b>74</b> (546 mg, 0.78 mmol) in DCE (5 mL) was added methylamine (1.17 mL, 2.33 mmol), followed by addition of sodium triacetoxyborohydride (495 mg, 2.33 mmol). The mixture was stirred for 2 h. Then, the reaction mixture was quenched with saturated NaHCO<sub>3</sub> and extracted with DCM and EtOAc. The mixture was dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes followed by 0–10% MeOH in DCM) to afford <b>76</b> (340 mg, 61%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.03 (d, <i>J</i> = 5.26 Hz, 1H), 6.59 (dd, <i>J</i> = 7.09, 1.97 Hz, 1H), 5.28–5.33 (m, 1H), 4.97–5.06 (m, 2H), 4.35–4.41 (m, 1H), 4.05–4.21 (m, 4H), 3.67–3.89 (m, 2H), 2.77–3.01 (m, 2H), 2.36–2.51 (m, 3H), 1.84–2.25 (m, 8H), 1.60–1.63 (m, 3H), 1.56 (s, 9H), 1.40–1.48 (m, 3H), 1.39 (s, 3H), 1.26–1.35 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 717.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Step g: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-(N-methylmethylsulfonamido)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>77</b>)</h5><div class="NLM_p last">To a flask was added <b>76</b> (170 mg, 0.240 mmol), followed by addition of DCM (2.4 mL). To this solution was added triethylamine (0.07 mL, 0.47 mmol) followed by methanesulfonyl chloride (0.02 mL, 0.3 mmol). The mixture was stirred overnight at RT and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 0–10% MeOH in DCM) to afford <b>77</b> (49 mg, 26%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ ppm 7.98–8.00 (m, 1H), 6.58–6.63 (m, 1H), 5.32–5.38 (m, 1H), 4.92–5.06 (m, 2H), 4.29–4.40 (m, 1H), 3.97–4.22 (m, 4H), 3.55–3.91 (m, 3H), 3.02–3.18 (m, 1H), 2.68–2.99 (m, 6H), 1.69–2.06 (m, 8H), 1.60 (s, 3H), 1.56 (s, 9H), 1.39 (s, 3H), 1.30–1.36 (m, 3H), 1.20–1.31 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 795.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> {2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-[(methanesulfonyl)(methyl)amino]propan-2-yl}phosphonic Acid (<b>26</b>)</h4><div class="NLM_p last">Compound <b>26</b> was prepared as a mixture of diastereomers from <b>77</b> using the same procedure as Step c in the synthesis of <b>24</b> in 40% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.64–8.78 (m, 1H), 8.18 −8.31 (m, 1H), 5.98 (dd, <i>J</i> = 9.35, 4.82 Hz, 1H), 4.51–4.58 (m, 1H), 4.42 (m, 1H), 4.16–4.24 (m, 1H), 3.92–4.00 (m, 1H), 3.67–3.92 (m, 2H), 3.47–3.61 (m, 1H), 2.97–3.09 (m, 1H), 2.69–2.84 (m, 6H), 1.94–2.05 (m, 2H), 1.66–1.79 (m, 2H), 1.47–1.65 (m, 4H), 1.23–1.33 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 599.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(methylsulfanyl)propan-2-yl]phosphonic Acid (<b>27</b>)</h4><div id="sec5_1_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Step h: <i>S</i>-(2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-((<i>tert</i>-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propyl) Ethanethioate (<b>78</b>)</h5><div class="NLM_p last">A dried flask charged with triphenylphosphine (277 mg, 1.06 mmol) was flushed with Ar. THF (5 mL) was added, and the mixture was cooled to 0 °C. To this mixture was added DIAD (0.21 mL, 1.06 mmol) dropwise, and the resulting mixture was stirred for 5 min at 0 °C. Then, a solution of intermediate <b>73</b> (323 mg, 0.460 mmol) THF (1 mL) was added, followed by thioacetic acid (0.08 mL, 1.1 mmol). The mixture was slowly allowed to warm to RT overnight and then quenched with TEA (0.1 mL). The mixture was concentrated, and the residue was partitioned between EtOAc and water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography (gradient elution, 0–70% EtOAc in hexanes) to afford <b>78</b> (255 mg, 73%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.97 (dd, <i>J</i> = 3.87, 0.66 Hz, 1H), 6.58 (dd, <i>J</i> = 3.51, 1.32 Hz, 1H), 5.31–5.41 (m, 1H), 4.91–5.07 (m, 2H), 4.33 (td, <i>J</i> = 6.47, 3.00 Hz, 1H), 3.98–4.24 (m, 4H), 3.58–3.80 (m, 2H), 3.22–3.49 (m, 2H), 2.30–2.34 (m, 3H), 1.99–2.06 (m, 2H), 1.82–1.99 (m, 6H), 1.57–1.60 (m, 3H), 1.54 (s, 9H), 1.38–1.40 (m, 3H), 1.32–1.37 (m, 3H), 1.23–1.32 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 762.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Step i: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-mercaptopropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>79</b>)</h5><div class="NLM_p last">To a flask containing intermediate <b>78</b> (260 mg, 0.33 mmol) was added methanol (4 mL), followed by addition of triethylamine (0.66 mL, 4.8 mmol). To this mixture was added DL-dithiothreitol (64 mg, 0.42 mmol). After the mixture was stirred for 2 h, it was concentrated and purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes). This impure material was further purified by reverse-phase HPLC (gradient elution, 50–90% ACN with 0.1% TFA in water with 0.1% TFA) to afford <b>79</b> (55 mg, 23%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.99 (dd, <i>J</i> = 2.19, 0.58 Hz, 1H), 6.60–6.63 (m, 1H), 5.31–5.39 (m, 1H), 4.96–5.07 (m, 2H), 4.36–4.41 (m, 1H), 4.04–4.22 (m, 4H), 3.61–3.84 (m, 2H), 3.02–3.14 (m, 1H), 2.52–2.66 (m, 1H), 1.82–2.12 (m, 8H), 1.61 (s, 3H), 1.56 (s, 9H), 1.42–1.51 (m, 3H), 1.39 (s, 3H), 1.23–1.35 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 720.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step j: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-(methylthio)propan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>80</b>)</h5><div class="NLM_p last">To an oven-dried vial was added K<sub>2</sub>CO<sub>3</sub> (141 mg, 1.02 mmol), followed by a solution of intermediate <b>79</b> (245 mg, 0.340 mmol) in acetone (5 mL). To this mixture was added methyl iodide (0.06 mL, 1.02 mmol). The mixture was stirred at RT for 30 min and then partitioned between saturated NaHCO<sub>3</sub> and EtOAc. The aqueous layer was further extracted with EtOAc. The combined organic layer was washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 20–100% EtOAc in hexanes) to afford <b>80</b> (218 mg, 87%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.97–7.99 (m, 1H), 6.59 (dd, <i>J</i> = 5.12, 1.46 Hz, 1H), 5.36–5.43 (m, 1H), 4.95–5.11 (m, 2H), 4.37 (td, <i>J</i> = 6.83, 2.12 Hz, 1H), 4.00–4.20 (m, 4H), 3.63–3.90 (m, 2H), 2.98–3.09 (m, 1H), 2.68–2.79 (m, 1H), 2.07–2.17 (m, 3H), 1.80–2.07 (m, 8H), 1.59 (s, 3H), 1.55 (s, 9H), 1.41–1.53 (m, 3H), 1.38 (s, 3H), 1.21–1.34 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 734.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(methylsulfanyl)propan-2-yl]phosphonic Acid (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was prepared as a mixture of diastereomers from intermediate <b>80</b> using the same procedure as Step c in the synthesis of <b>24</b> in 28% yield. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13 (d, <i>J</i> = 5.85 Hz 1 H), 6.16–6.21 (m, 1H), 4.75–4.85 (m, 1H), 4.47–4.58 (m, 2H), 4.13–4.19 (m, 1H), 3.89–3.97 (m, 1H), 3.78–3.85 (m, 1H) 3.09–3.18 (m, 1H), 2.77–2.84 (m, 1H), 2.05–2.15 (m, 5H), 1.55–1.86 (m, 6H), 1.45–1.53 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 538.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(methanesulfonyl)propan-2-yl]phosphonic Acid (<b>28</b>)</h4><div id="sec5_1_33_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step k: Diethyl (2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-1-(methylsulfonyl)propan-2-yl)phosphonate</h5><div class="NLM_p last">To an oven-dried flask was added intermediate <b>80</b> (218 mg, 0.30 mmol) followed by DCM (10 mL). <i>m</i>CPBA (137 mg, 0.590 mmol) was added, and the mixture was stirred at RT for 3 h. The mixture was quenched with saturated NaHCO<sub>3</sub>, and the reaction mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (gradient elution, 20–100% EtOAc in hexanes). The impure material was further purified by reverse-phase HPLC (gradient elution, 60–95% ACN with 0.1% TFA in water with 0.1% TFA) to afford the title sulfone (154 mg, 68%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.99 (d, <i>J</i> = 1.75 Hz, 1H), 6.55–6.67 (m, 1H), 5.32–5.44 (m, 1H), 4.87–5.07 (m, 2H), 4.31–4.43 (m, 1H), 3.98–4.26 (m, 4H), 3.86–3.97 (m, 1H), 3.47–3.75 (m, 2H), 2.77–3.21 (m, 4H), 2.04–2.14 (m, 2H), 1.86–2.03 (m, 6H), 1.59 (s, 3H), 1.55–1.58 (m, 9H), 1.47–1.55 (m, 3H), 1.37–1.40 (m, 3H), 1.19–1.36 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 766.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-(methanesulfonyl)propan-2-yl]phosphonic Acid (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was prepared as a mixture of diastereomers from the sulfone intermediate above using the same procedure as Step c in the synthesis of <b>24</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.07–8.20 (m, 1H), 6.18 (dd, <i>J</i> = 9.94, 3.65 Hz, 1H), 4.65–4.79 (m, 1H), 4.42–4.61 (m, 2H), 4.12–4.24 (m, 1H), 3.65–4.10 (m, 3H), 3.08–3.24 (m, 1H), 2.86–3.01 (m, 3H), 2.01–2.18 (m, 2H), 1.55–1.85 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 570.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-4-hydroxybutan-2-yl]phosphonic Acid (<b>29</b>)</h4><div id="sec5_1_35_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Step l: 2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-((<i>tert</i>-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)propanoic Acid (<b>81</b>)</h5><div class="NLM_p last">A flask was charged with the α-disubstituted ester <b>72</b> (642 mg, 0.86 mmol) and dissolved in THF (10 mL). A solution of lithium hydroxide monohydrate (72.2 mg, 1.72 mmol) in water (0.9 mL) was added. After stirring overnight at rt, the reaction was cooled down in an ice-bath and neutralized with 1 N HCl (1.0 mL). The resulting mixture was diluted with water, extracted with EtOAc, washed with brine, dried with MgSO<sub>4</sub>, and concentrated to provide <b>81</b> (572 mg, 93%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.05–8.07 (m, 1H), 6.48 (br s, 1H), 5.38–5.47 (m, 1H), 5.11–5.19 (m, 1H), 4.97–5.09 (m, 1H), 4.39–4.47 (m, 1H), 4.08–4.20 (m, 4H), 3.83 (t, <i>J</i> = 8.11 Hz, 1H), 3.56–3.70 (m, 1H), 1.82–2.08 (m, 8H), 1.59 (s, 3H), 1.58 (s, 9H), 1.39 (s, 3H), 1.43–1.55 (m, 3H), 1.20–1.31 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 718.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Step m: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-4-hydroxybutan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>82</b>)</h5><div class="NLM_p last">To an oven-dried flask was added <b>81</b> (413 mg, 0.58 mmol) followed by DCM (4.1 mL) under N<sub>2</sub>. The solution was cooled in an ice-bath, and two drops of DMF were added, followed by oxalyl chloride (0.29 mL, 0.58 mmol, 2 N in DCM). The reaction was warmed to RT and stirred for 1 h. The reaction mixture was concentrated, and the crude acid chloride was redissolved in THF (4 mL) and ACN (4 mL). After the mixture was cooled in an ice-bath, trimethylsilyldiazomethane (0.43 mL, 0.86 mmol) was added dropwise and the reaction was stirred at RT for 1 h. The mixture was quenched with saturated NaHCO<sub>3</sub> and extracted with EtOAc. The organic layer was dried with MgSO<sub>4</sub>, filtered, concentrated, and azeotroped from toluene. This crude residue was dissolved in EtOH (4 mL), and the resulting solution was cooled to 0 °C. Silver benzoate (131.7 mg, 0.58 mmol) was added. After stirring overnight at rt, the reaction mixture was filtered and extracted with EtOAc (3×). The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude was purified by silica gel column chromatography (gradient elution, 35–70% EtOAc/hexanes) to provide an impure compound ethyl 3-[[(3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-4-[4-[tert-butoxycarbonyl(cyclopentyl)amino]-6-chloro-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-6-yl]methoxy]-3-diethoxyphosphoryl-butanoate (62 mg). To the flask containing this impure ester (62 mg, 0.08 mmol) was added ethanol (1 mL). The solution was cooled to 0 °C, followed by addition of calcium dichloride (18.7 mg, 0.16 mmol) and sodium borohydride (6.2 mg, 0.16 mmol). After stirring at RT overnight, the reaction was quenched with saturated NH<sub>4</sub>Cl, extracted with EtOAc (3×), dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes followed by 0–10% MeOH in DCM) to provide an impure <b>82</b> (11 mg), which was carried to the next step without further purification. <i>m</i>/<i>z</i> (ESI, +ve ion) = 718.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-4-hydroxybutan-2-yl]phosphonic Acid (<b>29</b>)</h4><div class="NLM_p last">To a vial with the impure <b>82</b> (11 mg, 0.02 mmol) was added ACN (0.25 mL), followed by bromo(trimethyl)silane (0.01 mL, 0.11 mmol). After the mixture was stirred at RT for 4 h, water (0.05 mL) was added and the mixture was stirred for 5 h. The reaction was quenched with 28% aqueous NH<sub>4</sub>OH (0.3 mL) and concentrated. The crude residue was purified by reverse-phase HPLC (0–65% ACN with 0.1% TFA in water with 0.1% TFA) to provide <b>29</b> (3.3 mg, 34%) as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ ppm 8.01–8.18 (m, 1H), 6.03–6.13 (m, 1H), 4.82–4.88 (m, 1H), 4.42–4.52 (m, 1H), 4.25–4.35 (m, 1H), 4.11–4.21 (m, 1H), 3.70–3.77 (m, 1H), 3.44–3.66 (m, 3H), 1.87–2.06 (m, 3H), 1.74–1.87 (m, 1H), 1.45–1.73 (m, 6H), 1.23–1.27 (m, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 522.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1,3-dihydroxypropan-2-yl]phosphonic Acid (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was prepared from intermediate <b>69</b> by procedures similar to those described for Steps a, b, and e in the synthesis of <b>35</b>, replacing MOMCl in Step a with SEMCl. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13–8.19 (m, 1H), 6.21–6.29 (m, 1H), 4.79 (t, <i>J</i> = 5.0 Hz, 1H), 4.48–4.59 (m, 2H), 4.22 (dd, <i>J</i> = 8.1, 4.1 Hz, 1H), 4.05 (dd, <i>J</i> = 10.3, 3.4 Hz, 1H), 3.99 (dd, <i>J</i> = 10.2, 5.0 Hz, 1H), 3.86–3.97 (m, 4H), 2.05–2.17 (m, 2H), 1.52–1.88 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 524.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> [2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> is the diastereomer mixture of <b>34</b> and <b>35</b> and was prepared from intermediate <b>69</b> by procedures similar to those described for Steps a, b, and d in the synthesis of compound <b>34</b>. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.08–8.19 (m, 1H), 6.17–6.30 (m, 1H), 4.72–4.85 (m, 1H), 4.45–4.59 (m, 2H), 4.15–4.23 (m, 1H), 3.83–4.10 (m, 4H), 3.70–3.80 (m, 2H), 3.31–3.34 (m, 3H), 2.03–2.16 (m, 2H), 1.53–1.88 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 538.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> [(2<i>R</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxypropan-2-yl]phosphonic Acid (<b>32</b>) and [(2<i>S</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxypropan-2-yl]phosphonic Acid (<b>33</b>)</h4><div class="NLM_p last">The diastereomers of intermediate <b>73</b> were separated by chiral column (CHIRALPAK AD, 50 mm × 500 mm, 20 μm, 17% IPA with 0.1% DEA/hexanes, an isocratic elution, a flow rate of 75 mL/min, 50 min run) and converted to <b>32</b> and <b>33</b>, respectively, using the same procedure as Step c in the synthesis of <b>24</b>. Compound <b>32</b> was derived from the first eluting isomer off the chiral column. The stereochemistry of <b>32</b> is confirmed by its cocrystal structure with CD73. Compound <b>33</b> was derived from the second eluting isomer off the chiral column. <b>32</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.12–8.20 (m, 1H), 6.22 (d, <i>J</i> = 4.24 Hz, 1H), 4.74 (t, <i>J</i> = 4.75 Hz, 1H), 4.45–4.58 (m, 2H), 4.15–4.23 (m, 1H), 3.91–4.00 (m, 1H), 3.77–3.90 (m, 2H), 3.61 (dd, <i>J</i> = 12.13, 8.48 Hz, 1H), 2.04–2.18 (m, 2H), 1.75–1.88 (m, 2H), 1.56–1.75 (m, 4H), 1.41 (d, <i>J</i> = 15.06 Hz, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 508.0 [M + H]<sup>+</sup>. <b>33</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.14–8.15 (m, 1H), 6.22 (d, <i>J</i> = 5.12 Hz, 1H), 4.82 (t, <i>J</i> = 5.60 Hz,1 H), 4.51–4.61 (m, 1H), 4.46 (dd, <i>J</i> = 4.90, 3.87 Hz, 1H), 4.19 (q, <i>J</i> = 3.75 Hz, 1H), 3.80–3.96 (m, 3H), 3.63 (dd, <i>J</i> = 11.99, 7.45 Hz, 1H), 2.07–2.19 (m, 2H), 1.57–1.87 (m, 6H), 1.43 (d, <i>J</i> = 15.16 Hz, 3H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 508.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> [(2<i>S</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid (<b>34</b>) and [(2<i>R</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid (<b>35</b>)</h4><div id="sec5_1_40_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> Step a. Ethyl 2-(((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(4-((<i>tert</i>-Butoxycarbonyl)(cyclopentyl)amino)-6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)methoxy)-2-(diethoxyphosphoryl)-3-methoxypropanoate (<b>83</b>)</h5><div class="NLM_p last">To a solution of intermediate <b>69</b> (2.9 g, 3.96 mmol) in THF (75 mL) was added sodium bis(trimethylsilyl)amide (5.15 mL, 5.15 mmol) dropwise at −15 °C. After stirring at −15 °C for 25 min, tetra-<i>n</i>-butylammonium iodide (732 mg, 1.98 mmol) was added, which was immediately followed by the dropwise addition of chloromethyl methyl ether (1.12 mL, 13.86 mmol). After the reaction was stirred at −15 °C for 65 min, it was quenched with saturated aqueous NH<sub>4</sub>Cl. The reaction mixture was extracted with EtOAc (3×), and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (gradient elution, 0–75% EtOAc in hexanes) to afford <b>83</b> (2.79 g, 91%) as a yellow gummy syrup. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.90–7.98 (m, 1H), 6.59 (dd, <i>J</i> = 5.6, 1.7 Hz, 1H), 5.39 (dt, <i>J</i> = 6.2, 2.1 Hz, 1H), 5.21 (td, <i>J</i> = 6.6, 2.2 Hz, 1H), 4.95–5.06 (m, 1H), 4.44–4.53 (m, 1H), 4.09–4.36 (m, 6H), 3.76–4.06 (m, 4H), 3.28–3.41 (m, 3H), 1.66–2.10 (m, 8H), 1.60 (s, 3H), 1.55 (s, 9H), 1.38 (s, 3H), 1.24–1.35 (m, 9H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 776.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> Step b. <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(((2-(diethoxyphosphoryl)-1-hydroxy-3-methoxypropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>84</b>)</h5><div class="NLM_p last">To a solution of <b>83</b> (1.61 g, 2.07 mmol) in ethanol (34 mL) was added calcium dichloride (712 mg, 6.22 mmol) at 0 °C, followed by the addition of sodium borohydride (235.4 mg, 6.22 mmol). The reaction was warmed to rt, where it was stirred for 5 h. The reaction was cooled back down to 0 °C and then quenched with saturated aqueous NH<sub>4</sub>Cl. The solution was extracted with EtOAc (3×), and the combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (gradient elution, 0–100% EtOAc in hexanes followed by 0–10% MeOH in DCM) to yield <b>84</b> (1.22 g, 80%) as a white foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.98–8.05 (m, 1H), 6.59 (d, <i>J</i> = 2.3 Hz, 1H), 5.33–5.42 (m, 1H), 4.93–5.10 (m, 2H), 4.37–4.50 (m, 1H), 4.07–4.24 (m, 4H), 3.93–4.03 (m, 1H), 3.78–3.93 (m, 3H), 3.67–3.78 (m, 2H), 3.28–3.41 (m, 3H), 1.85–2.09 (m, 6H), 1.59–1.67 (m, 5H), 1.56 (s, 9H), 1.39 (s, 3H), 1.27–1.35 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 734.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> Step c: <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-((((<i>S</i>)-2-(diethoxyphosphoryl)-1-hydroxy-3-methoxypropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>85a</b>) and <i>tert</i>-Butyl (6-Chloro-1-((3a<i>R</i>,4<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-((((<i>R</i>)-2-(diethoxyphosphoryl)-1-hydroxy-3-methoxypropan-2-yl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-<i>d</i>][1,3]dioxol-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)(cyclopentyl)carbamate (<b>85b</b>)</h5><div class="NLM_p last">The diastereomers of <b>84</b> were separated by chiral chromatography (CHIRALPAK AD-H, 21 mm × 250 mm, 5 μm, 5% IPA/hexanes, an isocratic elution, a flow rate of 20 mL/min, 30 min run) to provide <b>85a</b> (the first eluting isomer, 41%) and <b>85b</b> (the second eluting isomer, 41%), respectively. The assignment of stereochemistry was confirmed by the cocrystal structure of <b>35</b> with CD73. <b>85a</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.01 (s, 1H), 6.59 (d, <i>J</i> = 2.2 Hz, 1H), 5.36 (dd, <i>J</i> = 6.1, 2.3 Hz, 1H), 5.06 (dd, <i>J</i> = 6.2, 2.5 Hz, 1H), 5.00 (dd, <i>J</i> = 17.5, 8.8 Hz, 1H), 4.41 (td, <i>J</i> = 5.4, 2.5 Hz, 1H), 4.06–4.20 (m, 4H), 3.97 (dd, <i>J</i> = 10.1, 5.7 Hz, 1H), 3.81–3.89 (m, 3H), 3.73 (d, <i>J</i> = 2.9 Hz, 1H), 3.71 (d, <i>J</i> = 3.4 Hz, 1H), 3.36 (s, 3H), 1.84–2.10 (m, 6H), 1.58–1.66 (m, 5H), 1.55 (s, 9H), 1.39 (s, 3H), 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H). <b>85b</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.02 (d, <i>J</i> = 0.7 Hz, 1H), 6.59 (d, <i>J</i> = 2.8 Hz, 1H), 5.38 (dd, <i>J</i> = 6.0, 2.8 Hz, 1H), 5.05 (dd, <i>J</i> = 6.1, 2.0 Hz, 1H), 5.00 (dd, <i>J</i> = 17.5, 8.8 Hz, 1H), 4.46 (td, <i>J</i> = 4.8, 2.1 Hz, 1H), 4.10–4.23 (m, 4H), 3.96 (ddd, <i>J</i> = 10.0, 4.9, 1.4 Hz, 1H), 3.89 (ddd, <i>J</i> = 10.0, 4.8, 1.1 Hz, 1H), 3.81–3.84 (m, 1H), 3.80 (d, <i>J</i> = 3.4 Hz, 1H), 3.72 (d, <i>J</i> = 3.1 Hz, 1H), 3.70 (d, <i>J</i> = 2.3 Hz, 1H), 3.33 (s, 3H), 1.84–2.11 (m, 6H), 1.57–1.66 (m, 5H), 1.55 (s, 9H), 1.39 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_1_40_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> Step d: [(2<i>S</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid (<b>34</b>)</h5><div class="NLM_p last">To a solution of <b>85a (</b>the first eluting isomer) (265 mg, 0.361 mmol) in ACN (18 mL) was added bromo(trimethyl)silane (0.54 mL, 3.97 mmol) dropwise. After stirring at RT for 5.5 h, DI H<sub>2</sub>O (6 mL) was added to the reaction. After stirring at RT for another 16.5 h, the solution was concentrated under reduced pressure and the resulting residue was purified by reverse-phase HPLC (gradient elution, 20–50% ACN with 0.1% TFA in water with 0.1% TFA) to afford <b>34</b> (92.6 mg, 39%) as a white powder. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.11–8.20 (m, 1H), 6.15–6.30 (m, 1H), 4.76 (t, <i>J</i> = 4.8 Hz, 1H), 4.45–4.60 (m, 2H), 4.19 (dd, <i>J</i> = 8.3, 4.3 Hz, 1H), 4.01–4.10 (m, 1H), 3.81–3.97 (m, 3H), 3.68–3.81 (m, 2H), 3.34 (s, 3H), 2.03–2.16 (m, 2H), 1.53–1.89 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 538.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> Step e: [(2<i>R</i>)-2-({(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-5-[6-Chloro-4-(cyclopentylamino)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl}methoxy)-1-hydroxy-3-methoxypropan-2-yl]phosphonic Acid (<b>35</b>)</h5><div class="NLM_p last">To a solution of <b>85b</b> (the second eluting isomer) (520 mg, 0.71 mmol) in ACN (36 mL) was added triethylamine (1.98 mL, 14.17 mmol), followed by the dropwise addition of bromo(trimethyl)silane (1.45 mL, 10.62 mmol). After stirring at RT for 2.5 h, the reaction was concentrated under reduced pressure, and the resulting residue was dissolved in a 1:1 mixture of deionized water and TFA (20 mL). The mixture was stirred for 2 h at RT and concentrated under reduced pressure. The resulting residue was purified via reverse-phase HPLC (gradient elution, 20–40% ACN with 0.1% TFA in water with 0.1% TFA) to provide <b>35</b> (300 mg, 65%) as a white powder. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.12–8.20 (m, 1H), 6.19–6.29 (m, 1H), 4.82 (t, <i>J</i> = 5.0 Hz, 1H), 4.54 (p, <i>J</i> = 6.9 Hz, 1H), 4.48 (t, <i>J</i> = 4.4 Hz, 1H), 4.19 (dd, <i>J</i> = 8.2, 4.1 Hz, 1H), 3.81–4.05 (m, 4H), 3.70–3.81 (m, 2H), 3.34 (s, 3H), 2.04–2.16 (m, 2H), 1.53–1.88 (m, 6H). <i>m</i>/<i>z</i> (ESI, +ve ion) = 538.1 [M + H]<sup>+</sup>.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Biochemical CD73 Assay</h3><div class="NLM_p last">Activity of recombinant CD73 was measured by quantification of free phosphate using the Malachite Green detection system (R&D Systems #DY996). Test compounds were solubilized in DMSO and dispensed into 384-well polystyrene plates using an Echo 555 dispenser (Labcyte Inc.) in a 10-point half-log titration in duplicates. Then, 25 μL of 0.64 nM human CD73 enzyme (R&D Systems #5795EN) in assay buffer (25 mM Tris-HCl, pH 7.4, 0.01% Brij-35, 0.01% bovine serum albumin (BSA), 5 mM MgCl<sub>2</sub>) was added to the plates. The compound and enzyme were incubated for 15 min at rt. Then, 25 μL of 30 μM AMP in an assay buffer was added and the reaction mixture was incubated for 10 min at rt. The final concentrations of CD73 and AMP in the reaction are 320 pM and 15 μM, respectively. The reaction was stopped by adding 10 μL of Malachite Green reagent A and incubating for 10 min at rt, followed by addition of Malachite Green reagent B and incubation for 45 min at rt. Absorbance was then read at 620 nM on an EnVision plate reader (PerkinElmer). Reactions lacking CD73 were used as the 100% inhibition control. The IC<sub>50</sub> values were determined using a four-parameter nonlinear regression curve fit.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Cellular CD73 Assays</h3><div class="NLM_p">Activity of cell-bound CD73 was assessed by direct measurement of adenosine produced from AMP using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Human NSCLC H1568 cells expressing endogenous CD73 on their surface were obtained from ATCC (CRL-5876) and cultured in a growth medium (RPMI, 10% fetal bovine serum (FBS), 1 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 100 μL of penicillin-streptomycin). Cells were seeded onto 96-well tissue culture plates at 10 000 cells/well and allowed to adhere for 20–24 h. Then, 500× serial compound dilutions were prepared in DMSO in a 12-point 3-fold titration and diluted 1:50 into RPMI supplemented with 10% human plasma (BioIVT, cat#HMPLEDTA5), generating 10× compound dilutions. The growth medium was removed from the cells and replaced with 80 μL of RPMI/10% human plasma. Then, 10 μL of 10× compound dilutions was added to the cells and incubated for 15 min at 37 °C, 5% CO<sub>2</sub>. Next, 10 μL of 100 μM AMP/50 μM EHNA (Sigma-Aldrich, A1752 and E114) was added to a final concentration of 10 μM AMP/5 μM EHNA. After 1 h of incubation at 37 °C, 5% CO<sub>2</sub>, 80 μL of supernatant was removed from the cells and transferred to a deep-well polypropylene 96-well plate (Costar #3961) prefilled with 240 μL of organic solvent composed of methanol:acetonitrile (1:1, v/v) with 0.1% formic acid, plus 150 ng/mL of Adenosine-<sup>15</sup>N and AMP-<sup>13</sup>C as internal standards. The amounts of unlabeled adenosine and AMP in each well were measured on AB Sciex API 4000 QTrap with a Shimadzu LC-30AD UPLC system. The ranges of adenosine and AMP detection were 10–10 000 and 20–10 000 nM, respectively. The IC<sub>50</sub> values were determined based on the amount of adenosine in the supernatant using a four-parameter nonlinear regression curve fit. DMSO-treated cells produced 3000–4000 nM adenosine under these conditions with negligible variability on the same-day assays. A small amount of adenosine generated from AMP in the absence of cells (less than 100 nM) was used as the 100% inhibition control.</div><div class="NLM_p">To determine the inhibitory activity of the anti-CD73 antibody, H1568 cells were preincubated with the antibody for 2 h at 37 °C, 5% CO<sub>2</sub> before adding AMP/EHNA, thus allowing CD73 internalization, which was described as one of the antibody’s mechanism of action.</div><div class="NLM_p">Primary human peripheral blood CD8<sup>+</sup> T-cells cells were obtained from StemCell Technologies (cat#70027). Cells were thawed and cultured for 24 h in a complete growth medium (Stemline T-cell expansion medium (Sigma, S1694) supplemented with 1 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 50 IU/mL IL-2, and 25 μL/mL human CD3/CD28/CD2 T-Cell Activator (StemCell Technologies cat# 10970)) at density 10<sup>6</sup> cells/mL. Then, cells were gently pelleted and resuspended in the Stemline T-cell expansion medium without the T-cell activator. Cells were seeded onto U-bottom 96-well plates at 80 000 viable cells/90 μL/well. Compound dilutions were made in the Stemline T-cell expansion medium. The assay and adenosine measurements were performed as described above. DMSO-treated cells produced 4000–4500 nM adenosine under these conditions with negligible variability on the same-day assays.</div><div class="NLM_p last">To determine the activity of compounds on mouse CD73, we used mouse EMT6 breast cancer cells, which express endogenous CD73 on their surface (ATCC, CRL-2755). Cells were grown in Waymouth’s MB752/1 medium with 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine and 15% FBS. They were seeded onto 96-well tissue culture plates at 5000 cells/well and allowed to adhere for 20–24 h. Then, the growth medium was replaced with phosphate-buffered saline (PBS)/3% BSA, and the assay and adenosine measurement were performed as described above. DMSO-treated cells produced 1000–1500 nM adenosine under these conditions with negligible variability on the same-day assays.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Rescue of AMP-Mediated Suppression of Human CD8<sup>+</sup> T-Cells</h3><div class="NLM_p">Primary human peripheral blood CD8<sup>+</sup> T-cells obtained from StemCell Technologies (cat# 70027) were thawed and cultured for 24 h in a complete growth medium (Stemline T-cell expansion medium (Sigma, S1694) supplemented with 1 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 50 IU/mL IL-2 and 25 μL/mL of human CD3/CD28/CD2 T-Cell Activator (StemCell Technologies cat# 10970)) at a density of 10<sup>6</sup> cells/mL. Then, cells were labeled with 1.25 μM Cell Trace Violet (ThermoFisher cat# C34557) according to the manufacturer’s instructions. Labeled cells were resuspended in a warm complete growth medium and plated onto U-bottom 96-well plates at 25 000 cells/90 μL/well. Next, 500× serial compound dilutions were prepared in DMSO in a 10-point 3-fold titration and then diluted 1:25 into a complete growth medium, generating 20× compound dilutions. Then, 5 μL of 20× compound dilutions was added to the cells and incubated for 15 min at 37 °C. After this, 5 μL of 20× AMP/EHNA was added to a final concentration of 25 μM AMP/5 μM EHNA. Treated cells were cultured for 4 days at 37 °C, 5% CO<sub>2</sub>. Thereafter, cells were gently pelleted by centrifugation, and supernatants were collected and frozen at −80 °C for subsequent cytokine analysis. Cell pellets were resuspended in 100 μL of PBS/2% FBS and gently pipetted up and down to produce a single cell suspension. Then, 3 μL of 7-AAD (BD Biosciences #559925) was added to each well and plates were incubated on ice for 5 min. Cells were then washed and resuspended in 150 μL of PBS/2% FBS. Divided and nondivided live cells were quantified by flow on a Sony SA3800 spectral analyzer. Cell Trace Violet-labeled cells cultured without a T-cell activator were used as the nondividing control.</div><div class="NLM_p last">For cytokine analysis, supernatants were thawed on ice, diluted 1:10 in the buffer (Meso Scale Discovery cat# R50AG). The concentration of cytokines was determined using MesoScale electroluminescent ELISA according to the manufacturer’s instructions (Meso Scale Discovery cat# K15067L).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01086" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01086?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01086</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><i>In vivo</i> and <i>ex vivo</i> study protocols; HPLC profiles of compounds <b>12</b>, <b>30</b>, <b>32</b>, and <b>35</b>; determination of the cocrystal structures of <b>12</b> and <b>35</b> CD73 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf">jm0c01086_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_002.csv">jm0c01086_si_002.csv (2.9 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB files of the cocrystal structures of <b>12</b> and <b>35</b> with CD73 have been deposited with the PDB data bank (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9">7JV9</a> for <b>12</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8">7JV8</a> for <b>35</b>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01086" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohui Du</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5444-9434" title="Orcid link">http://orcid.org/0000-0001-5444-9434</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#601809010f0815094e0415200f120903100801120d014e030f0d"><span class="__cf_email__" data-cfemail="abd3c2cac4c3dec285cfdeebc4d9c2c8dbc3cad9c6ca85c8c4c6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daqing Sun</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8aeeebfbe3e4edf9ffe4caf3ebe2e5e5a4e9e5e7"><span class="__cf_email__" data-cfemail="b4d0d5c5dddad3c7c1daf4cdd5dcdbdb9ad7dbd9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jared Moore</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian R. Blank</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Eksterowicz</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dena Sutimantanapi</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalie Yuen</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd Metzger</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brenda Chan</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tom Huang</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xi Chen</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuping Chen</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Duong</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wayne Kong</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jae H. Chang</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Sun</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana Zavorotinskaya</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuping Ye</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa R. Junttila</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chudi Ndubaku</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori S. Friedman</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valeria R. Fantin</span> - <span class="hlFld-Affiliation affiliation">ORIC Pharmaceuticals, 240 E. Grand Avenue, Floor 2, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8624-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i124">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Stephan Krapp, Dr. Klaus Maskos, and Dr. Alfred Lammens from Proteros Biostructures GmbH for protein production, crystallography, and structure determination and Dr. Tim Craig and Paul Gibbons for the deposit of structures to the PDB data bank.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">ADO</td><td class="NLM_def"><p class="first last">adenosine</p></td></tr><tr><td class="NLM_term">AOPCP</td><td class="NLM_def"><p class="first last">adenosine 5′-(α,β-methylene)diphosphate</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">BLOQ</td><td class="NLM_def"><p class="first last">below the limit of quantitation</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">cytochrome P450 3A4</p></td></tr><tr><td class="NLM_term">CYP2C8</td><td class="NLM_def"><p class="first last">cytochrome P450 2C8</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">FaSSGF</td><td class="NLM_def"><p class="first last">fasted-state simulated gastric fluids</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted-state intestinal fluids</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall-cell lung cancer</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once-a-day dosing</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SS</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TIL</td><td class="NLM_def"><p class="first last">tumor-infiltrating lymphocytes</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrobak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the CD73-adenosine axis in immuno-oncology</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.imlet.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.imlet.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29758241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2019&pages=31-39&author=D.+Allardauthor=P.+Chrobakauthor=B.+Allardauthor=N.+Messaoudiauthor=J.+Stagg&title=Targeting+the+CD73-adenosine+axis+in+immuno-oncology&doi=10.1016%2Fj.imlet.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the CD73-adenosine axis in immuno-oncology</span></div><div class="casAuthors">Allard, David; Chrobak, Pavel; Allard, Bertrand; Messaoudi, Nouredin; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine.  As such, they constitute crit. components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis.  With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses.  With early-phase clin. trials showing promising results, it is becoming increasingly important to decipher the distinct mechanisms-of-action of adenosine-targeting agents, identify patients that will benefit from these agents and rationally develop novel synergistic combinations.  Given the broad expression of ectonucleotidases and adenosine receptors, a better understanding of cell-specific roles will also be key for successful implementation of this new generation of immuno-oncol. therapeutics.  We here review the latest studies on the roles of CD73 and adenosine in cancer with a focus on cell-specific function.  We also discuss ongoing clin. trials and future avenues for adenosine-targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzg498nnmnLVg90H21EOLACvtfcHk0ljIGQtq1WhoFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSku7fJ&md5=31694428ae1cf4c69448bc6ba310f31e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.imlet.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.imlet.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DChrobak%26aufirst%3DP.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DMessaoudi%26aufirst%3DN.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520CD73-adenosine%2520axis%2520in%2520immuno-oncology%26jtitle%3DImmunol.%2520Lett.%26date%3D2019%26volume%3D205%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.imlet.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer-derived adenosine: new therapeutic approaches</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F2159-8290.CD-14-0341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=25035124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=879-888&author=A.+Youngauthor=D.+Mittalauthor=J.+Staggauthor=M.+J.+Smyth&title=Targeting+cancer-derived+adenosine%3A+new+therapeutic+approaches&doi=10.1158%2F2159-8290.CD-14-0341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cancer-Derived Adenosine:New Therapeutic Approaches</span></div><div class="casAuthors">Young, Arabella; Mittal, Deepak; Stagg, John; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">879-888</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes.  Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development.  In contrast, A2A adenosine receptor antagonists have progressed to late-stage clin. trials in Parkinson disease, yet evidence of their role in oncol. is limited.  This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic.  Significance: High concns. of immunosuppressive adenosine have been reported in cancers, and adenosine is implicated in the growth of tumors.  This brief review delineates the current treatment strategies and tumor subtypes that will benefit from targeting adenosinergic pathways, alone or in combination with contemporary approaches to cancer treatment.  Cancer Discov; 4(8); 879-88. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfrzk2Na9ZJbVg90H21EOLACvtfcHk0ljIGQtq1WhoFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzO&md5=3a0c66b7081f996c52c7686034bf5797</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0341%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520cancer-derived%2520adenosine%253A%2520new%2520therapeutic%2520approaches%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D879%26epage%3D888%26doi%3D10.1158%2F2159-8290.CD-14-0341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2161</span>– <span class="NLM_lpage">2173</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.str.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23142347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2161-2173&author=K.+Knappauthor=M.+Zebischauthor=J.+Pippelauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCllerauthor=N.+Str%C3%A4ter&title=Crystal+structure+of+the+human+ecto-5%E2%80%B2-nucleotidase+%28CD73%29%3A+insights+into+the+regulation+of+purinergic+signaling&doi=10.1016%2Fj.str.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling</span></div><div class="casAuthors">Knapp, Karen; Zebisch, Matthias; Pippel, Jan; El-Tayeb, Ali; Mueller, Christa E.; Straeter, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2161-2173</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In vertebrates ecto-5'-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.  Due to its pivotal role for activation of P1 adenosine receptors, e5NT has emerged as an appealing drug target for treatment of inflammation, chronic pain, hypoxia, and cancer.  Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme.  The dimerization interface is formed by the C-terminal domains and exhibits interchain motions of up to 13°.  Complex structures with adenosine and AMPCP indicate that structural control of the domain movement dets. the selectivity for monophosphate nucleotides.  Binding modes of nucleotide-derived and flavonoid-based compds. complexed to the C-terminal domain in the open form reveal an addnl. binding pocket of ∼210 Å3 that might be explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MOj4dwx2J7Vg90H21EOLACvtfcHk0lgAZRoBrFuJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK&md5=e108171e8079cca4dd11483dfacb909e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DK.%26aulast%3DZebisch%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%253A%2520insights%2520into%2520the%2520regulation%2520of%2520purinergic%2520signaling%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D2161%26epage%3D2173%26doi%3D10.1016%2Fj.str.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C.</span></span> <span> </span><span class="NLM_article-title">5′-Nucleotidases and their new roles in NAD<sup>+</sup> and phosphate metabolism</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">845</span>– <span class="NLM_lpage">853</span>, <span class="refDoi"> DOI: 10.1039/b9nj00758j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1039%2Fb9nj00758j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12jtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=845-853&author=K.+L.+Boganauthor=C.+Brenner&title=5%E2%80%B2-Nucleotidases+and+their+new+roles+in+NAD%2B+and+phosphate+metabolism&doi=10.1039%2Fb9nj00758j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">5'-Nucleotidases and their new roles in NAD+ and phosphate metabolism</span></div><div class="casAuthors">Bogan, Katrina L.; Brenner, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">845-853</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  5'-Nucleotidase (EC 3.1.3.5) designates a set of enzymes, which catalyze the hydrolysis of ribonucleoside and deoxyribonucleoside monophosphates into the corresponding nucleosides plus orthophosphate.  5'-Nucleotidases are classified according to subcellular localization, nucleobase specificity, and their ability to hydrolyze deoxynucleoside monophosphate substrates.  Membrane-bound 5'-nucleotidases are ectoenzymes principally involved in salvage of extracellular nucleosides, and often display a preference toward adenosine monophosphate, thereby modulating signal transduction cascades involving purinergic receptors.  Cytosolic 5'-nucleotidases are members of the haloacid dehalogenase superfamily of enzymes, which are 2-domain proteins contg. a modified Rossman fold as the core and a variable cap structure.  Extracellular and intracellular 5'-nucleotidase activities participate in purine and pyrimidine salvage to support balanced synthesis of nucleotides, which is crit. for maintaining high-fidelity DNA replication.  While the prodn. of ribonucleosides from ribonucleotides by 5'-nucleotidases remains the most well studied function, it appears that the physiol. functions of these activities are more broad.  Indeed, Sdt1, previously termed a pyrimidine-specific 5'-nucleotidase, and Isn1, previously termed an IMP-specific 5'-nucleotidase, have recently been implicated in catabolic processes in NAD metab., and are regulated by the NAD precursor vitamin, nicotinic acid, glucose, and phosphate availability in the medium.  In addn., Usha, Pho5, Sdt1, and Phm8 are phosphate starvation-induced 5'-nucleotidases with diverse substrate specificities that liberate phosphate under phosphate starvation conditions.  Here, the authors review 5'-nucleotidase structure, catalytic mechanism, and substrate specificity, and focus on new biol. roles for these enzymes in nucleotide, NAD, and phosphate metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFsNps9U1JkLVg90H21EOLACvtfcHk0lgAZRoBrFuJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12jtbg%253D&md5=3c1920b322d1a06881f6619b9af2894b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2Fb9nj00758j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb9nj00758j%26sid%3Dliteratum%253Aachs%26aulast%3DBogan%26aufirst%3DK.%2BL.%26aulast%3DBrenner%26aufirst%3DC.%26atitle%3D5%25E2%2580%25B2-Nucleotidases%2520and%2520their%2520new%2520roles%2520in%2520NAD%252B%2520and%2520phosphate%2520metabolism%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2010%26volume%3D34%26spage%3D845%26epage%3D853%26doi%3D10.1039%2Fb9nj00758j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghalamfarsa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazemi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojjat-Farsangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadidi-Niaragh, F.</span></span> <span> </span><span class="NLM_article-title">CD73 as a potential opportunity for cancer immunotherapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1080/14728222.2019.1559829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1080%2F14728222.2019.1559829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30556751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=127-142&author=G.+Ghalamfarsaauthor=M.+H.+Kazemiauthor=S.+R.+Mohseniauthor=A.+Masjediauthor=M.+Hojjat-Farsangiauthor=G.+Aziziauthor=M.+Yousefiauthor=F.+Jadidi-Niaragh&title=CD73+as+a+potential+opportunity+for+cancer+immunotherapy&doi=10.1080%2F14728222.2019.1559829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 as a potential opportunity for cancer immunotherapy</span></div><div class="casAuthors">Ghalamfarsa, Ghasem; Kazemi, Mohammad Hossein; Raoofi Mohseni, Sahar; Masjedi, Ali; Hojjat-Farsangi, Mohammad; Azizi, Gholamreza; Yousefi, Mehdi; Jadidi-Niaragh, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer cells apply various mechanisms to induce and enhance immune escape.  The complex network of immune-response modulating factors in the tumor microenvironment is a reason for the difficulties encountered when attempting to treat many cancers.  Adenosine is a potent immune-modulating factor that can be generated through the degrdn. of ATP by cooperative action of NTPDase1 (CD39) and ecto-5'-nucleotidase (CD73) mols.  Overexpression of CD73 on tumor and immune cells leads to the presence of a high concn. of this factor in the tumor region.  Upregulation of CD73 is assocd. with the overprodn. of adenosine; it suppresses antitumor immune responses and helps proliferation, angiogenesis, and metastasis.: We attempt to clarify the immunobiol. of CD73 in assocn. with its role in cancer development, angiogenesis, and metastasis.  Moreover, we have reviewed CD73-targeting studies and highlighted CD73 as a potent target for cancer immunotherapy.: It seems that blockade of CD73, in combination with immune checkpoint inhibitors such as anti-PD-L1 and anti-CTLA-4, can be a novel promising therapeutic strategy that can be evaluated in the future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vOmOMwkrsbVg90H21EOLACvtfcHk0lhY5yWf87oCiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whsr7P&md5=582913bc842ed86cdec07f5aefa3461b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F14728222.2019.1559829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2019.1559829%26sid%3Dliteratum%253Aachs%26aulast%3DGhalamfarsa%26aufirst%3DG.%26aulast%3DKazemi%26aufirst%3DM.%2BH.%26aulast%3DMohseni%26aufirst%3DS.%2BR.%26aulast%3DMasjedi%26aufirst%3DA.%26aulast%3DHojjat-Farsangi%26aufirst%3DM.%26aulast%3DAzizi%26aufirst%3DG.%26aulast%3DYousefi%26aufirst%3DM.%26aulast%3DJadidi-Niaragh%26aufirst%3DF.%26atitle%3DCD73%2520as%2520a%2520potential%2520opportunity%2520for%2520cancer%2520immunotherapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2019%26volume%3D23%26spage%3D127%26epage%3D142%26doi%3D10.1080%2F14728222.2019.1559829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.trecan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27014745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=95-109&author=L.+Antonioliauthor=G.+G.+Yegutkinauthor=P.+Pacherauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Anti-CD73+in+cancer+immunotherapy%3A+awakening+new+opportunities&doi=10.1016%2Fj.trecan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span></div><div class="casAuthors">Antonioli Luca; Yegutkin Gennady G; Pacher Pal; Blandizzi Corrado; Hasko Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-109</span>
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    </div><div class="casAbstract">In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology.  In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.  Targeting CD73 results in favorable antitumor effects in pre-clinical models and combined treatments of CD73 blockade with other immune-modulating agents (i.e. anti-CTLA-4 mAb or anti-PD1 mAb) is particularly attractive.  Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 monoclonal antibodies, can potentially constitute a new biologic therapy for cancer patients.  In this review, we discuss the link between CD73 and the onset, development and spread of tumors, highlighting the potential value of this molecule as a target and as a novel biomarker in the context of personalized cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJjr-hcquXE36CEoQgWY10fW6udTcc2eZmvG6U7yhYPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D&md5=c67d1d1472d80ac9b0f3f0753dc37196</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAnti-CD73%2520in%2520cancer%2520immunotherapy%253A%2520awakening%2520new%2520opportunities%26jtitle%3DTrends%2520Cancer%26date%3D2016%26volume%3D2%26spage%3D95%26epage%3D109%26doi%3D10.1016%2Fj.trecan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor may allow expansion of T Cells lacking effector functions in extracellular adenosine-rich microenvironments</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">5487</span>– <span class="NLM_lpage">5493</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.4049%2Fjimmunol.0901247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=19843934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ymtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=5487-5493&author=A.+Ohtaauthor=A.+Ohtaauthor=M.+Madasuauthor=R.+Kiniauthor=M.+Subramanianauthor=N.+Goelauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+may+allow+expansion+of+T+Cells+lacking+effector+functions+in+extracellular+adenosine-rich+microenvironments&doi=10.4049%2Fjimmunol.0901247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments</span></div><div class="casAuthors">Ohta, Akio; Ohta, Akiko; Madasu, Manasa; Kini, Radhika; Subramanian, Meenakshi; Goel, Nipun; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5487-5493</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunosuppressive signaling via the A2A adenosine receptor (A2AR) provokes a mechanism that protects inflamed tissues from excessive damage by immune cells.  This mechanism is desirable not only for preventing uncontrolled tissue destruction by overactive immune responses, but also for protecting tumor tissues from antitumor immune responses.  In aforementioned circumstances, T cell priming may occur in an environment contg. high concns. of extracellular adenosine.  To examine qual. changes in T cells activated in the presence of adenosine, the authors asked whether different functional responses of T cells are equally susceptible to A2AR agonists.  In this study, the authors demonstrate that A2AR signaling during T cell activation strongly inhibited development of cytotoxicity and cytokine-producing activity in T cells, whereas the inhibition of T cell proliferation was only marginal.  Both CD8+ and CD4+ T cells proliferated well in the presence of A2AR agonists, but their IFN-γ-producing activities were susceptible to inhibition by cAMP-elevating A2AR.  Importantly, the impaired effector functions were maintained in T cells even after removal of the A2AR agonist, reflecting T cell memory of the immunoregulatory effect of adenosine.  Thus, although the adenosine-rich environment may allow for the expansion of T cells, the functional activation of T cells may be critically impaired.  This physiol. mechanism could explain the inefficiency of antitumor T cells in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHI_3MeHtzmLVg90H21EOLACvtfcHk0li6PzsfQL0S9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ymtb7K&md5=63ebc7c142b13b4c44755e4f848fc7a6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901247%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMadasu%26aufirst%3DM.%26aulast%3DKini%26aufirst%3DR.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DGoel%26aufirst%3DN.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520may%2520allow%2520expansion%2520of%2520T%2520Cells%2520lacking%2520effector%2520functions%2520in%2520extracellular%2520adenosine-rich%2520microenvironments%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D5487%26epage%3D5493%26doi%3D10.4049%2Fjimmunol.0901247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarek, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-03-081646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1182%2Fblood-2007-03-081646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=17909080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=251-259&author=P.+E.+Zarekauthor=C.-T.+Huangauthor=E.+R.+Lutzauthor=J.+Kowalskiauthor=M.+R.+Hortonauthor=J.+Lindenauthor=C.+G.+Drakeauthor=J.+D.+Powell&title=A2A+receptor+signaling+promotes+peripheral+tolerance+by+inducing+T-cell+anergy+and+the+generation+of+adaptive+regulatory+T+cells&doi=10.1182%2Fblood-2007-03-081646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells</span></div><div class="casAuthors">Zarek, Paul E.; Huang, Ching-Tai; Lutz, Eric R.; Kowalski, Jeanne; Horton, Maureen R.; Linden, Joel; Drake, Charles G.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tissue-derived adenosine, acting via the adenosine A2A receptor (A2AR), is emerging as an important neg. regulator of T-cell function.  In this report, we demonstrate that A2AR stimulation not only inhibits the generation of adaptive effector T cells but also promotes the induction of adaptive regulatory T cells.  In vitro, antigen recognition in the setting of A2AR engagement induces T-cell anergy, even in the presence of costimulation.  T cells initially stimulated in the presence of an A2AR agonist fall to proliferate and produce interleukin-2 and interferon (IFN)-γ when rechallenged in the absence of A2AR stimulation.  Likewise, in an in vivo model of autoimmunity, tissue-derived adenosine promotes anergy and abrogates tissue destruction.  Indeed, A2AR stimulation inhibits interleukin-6 expression while enhancing the prodn. of transforming growth factor-β.  Accordingly, treating mice with A2AR agonists not only inhibits Th1 and Th17 effector cell generation but also promotes the generation of Foxp3+ and LAG-3+ regulatory T cells.  In this regard, A2AR agonists fail to prevent autoimmunity by LAG-3-/- clonotypic T cells, implicating an important role for LAG-3 in adenosine-mediated peripheral tolerance.  Overall, our findings demonstrate that extracellular adenosine stimulates the A2AR to promote long-term T-cell anergy and the generation of adaptive regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3fnOF_EePubVg90H21EOLACvtfcHk0li6PzsfQL0S9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVKhsQ%253D%253D&md5=922b3b55acab3235ee77381f08546bc7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-03-081646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-03-081646%26sid%3Dliteratum%253Aachs%26aulast%3DZarek%26aufirst%3DP.%2BE.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DLutz%26aufirst%3DE.%2BR.%26aulast%3DKowalski%26aufirst%3DJ.%26aulast%3DHorton%26aufirst%3DM.%2BR.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DA2A%2520receptor%2520signaling%2520promotes%2520peripheral%2520tolerance%2520by%2520inducing%2520T-cell%2520anergy%2520and%2520the%2520generation%2520of%2520adaptive%2520regulatory%2520T%2520cells%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D251%26epage%3D259%26doi%3D10.1182%2Fblood-2007-03-081646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting immunosuppressive adenosine in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fnrc.2017.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29059149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslehs7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=709-724&author=D.+Vijayanauthor=A.+Youngauthor=M.+W.+L.+Tengauthor=M.+J.+Smyth&title=Targeting+immunosuppressive+adenosine+in+cancer&doi=10.1038%2Fnrc.2017.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting immunosuppressive adenosine in cancer</span></div><div class="casAuthors">Vijayan, Dipti; Young, Arabella; Teng, Michele W. L.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">709-724</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1 (PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a considerable proportion of patients remain unresponsive to these treatments (known as innate resistance).  In addn., one-third of patients relapse after initial response (known as adaptive resistance), which suggests that multiple non-redundant immunosuppressive mechanisms coexist within the tumor microenvironment.  A major immunosuppressive mechanism is the adenosinergic pathway, which now represents an attractive new therapeutic target for cancer therapy.  Activation of this pathway occurs within hypoxic tumors, where extracellular adenosine exerts local suppression through tumor-intrinsic and host-mediated mechanisms.  Preclin. studies in mice with adenosine receptor antagonists and antibodies have reported favorable antitumor immune responses with some definition of the mechanism of action.  Currently, agents targeting the adenosinergic pathway are undergoing first-in-human clin. trials as single agents and in combination with anti-PD1 or anti-PDL1 therapies.  In this Review, we describe the complex interplay of adenosine and adenosine receptors in the development of primary tumors and metastases and discuss the merits of targeting one or more components that compose the adenosinergic pathway.  We also review the early clin. data relating to therapeutic agents inhibiting the adenosinergic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3aiRNPyIwHrVg90H21EOLACvtfcHk0li7nEXXwcEBAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslehs7rO&md5=24d252d351e30154a8f79bc37c2e4b2b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.86%26sid%3Dliteratum%253Aachs%26aulast%3DVijayan%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520immunosuppressive%2520adenosine%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D709%26epage%3D724%26doi%3D10.1038%2Fnrc.2017.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Vilches, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, K.</span></span> <span> </span><span class="NLM_article-title">ATP and its metabolite adenosine as regulators of dendritic cell activity</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">2581</span> <span class="refDoi"> DOI: 10.3389/fimmu.2018.02581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3389%2Ffimmu.2018.02581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30473700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosValsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=C.+Silva-Vilchesauthor=S.+Ringauthor=K.+Mahnke&title=ATP+and+its+metabolite+adenosine+as+regulators+of+dendritic+cell+activity&doi=10.3389%2Ffimmu.2018.02581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ATP and its metabolite adenosine as regulators of dendritic cell activity</span></div><div class="casAuthors">Silva-Vilches, Cinthia; Ring, Sabine; Mahnke, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2581/1-2581/11</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Adenosine (Ado) is a well-studied neurotransmitter, but it also exerts profound immune regulatory functions.  Ado can (i) actively be released by various cells into the tissue environment and can (ii) be produced through the degrdn. of extracellular ATP by the concerted action of CD39 and CD73.  In this sequence of events, the ectoenzyme CD39 degrades ATP into ADP and AMP, resp., and CD73 catalyzes the last step leading to the prodn. of Ado.  Extracellular ATP acts as a "danger" signal and stimulates immune responses, i.e. by inflammasome activation.  Its degrdn. product Ado on the other hand acts rather anti-inflammatory, as it down regulates functions of dendritic cells (DCs) and dampens T cell activation and cytokine secretion.  Thus, the balance of proinflammatory ATP and anti-inflammatory Ado that is regulated by CD39+/CD73+ immune cells, is important for decision making on whether tolerance or immunity ensues.  DCs express both ectoenzymes, enabling them to produce Ado from extracellular ATP by activity of CD73 and CD39 and thus allow dampening of the proinflammatory activity of adjacent leukocytes in the tissue.  On the other hand, as most DCs express at least one out of four so far known Ado receptors (AdoR), DC derived Ado can also act back onto the DCs in an autocrine manner.  This leads to suppression of DC functions that are normally involved in stimulating immune responses.  Moreover, ATP and Ado prodn. thereof acts as "find me" signal that guides cellular interactions of leukocytes during immune responses.  In this review we will state the means by which Ado producing DCs are able to suppress immune responses and how extracellular Ado conditions DCs for their tolerizing properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKT0rwxy8NG7Vg90H21EOLACvtfcHk0li7nEXXwcEBAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosValsLk%253D&md5=6a38d6f457cfe32dda2003c0bb1a7a6b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02581%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Vilches%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DS.%26aulast%3DMahnke%26aufirst%3DK.%26atitle%3DATP%2520and%2520its%2520metabolite%2520adenosine%2520as%2520regulators%2520of%2520dendritic%2520cell%2520activity%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffimmu.2018.02581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span> <span> </span><span class="NLM_article-title">Much ado about adenosine: adenosine synthesis and function in regulatory T Cell biology</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1000108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.4049%2Fjimmunol.1000108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=20686167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslWntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=1993-1998&author=P.+B.+Ernstauthor=J.+C.+Garrisonauthor=L.+F.+Thompson&title=Much+ado+about+adenosine%3A+adenosine+synthesis+and+function+in+regulatory+T+Cell+biology&doi=10.4049%2Fjimmunol.1000108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology</span></div><div class="casAuthors">Ernst, Peter B.; Garrison, James C.; Thompson, Linda F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1993-1998</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Recent studies have reported that adenosine is a significant mediator of regulatory T cell (Treg) function.  Indeed, activation of the adenosine receptor subtypes expressed by a broad range of immune and inflammatory cells attenuates inflammation in several disease models.  This anti-inflammatory response is assocd. with an increase in intracellular cAMP that inhibits cytokine responses of many immune/inflammatory cells, including T cells and APCs.  Thus, adenosine produced by Tregs can provide a paracrine feedback that shapes the host response following an immunol. provocation.  This review discusses the evidence that adenosine is an integral part of Treg biol. and presents some of the mechanisms that may account for its contribution to the resoln. of inflammation and the regulation of the immune/inflammatory cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdf17HA47febVg90H21EOLACvtfcHk0ljuNeORxf8ymw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslWntLo%253D&md5=474c07f3a3b8a879d5605b69da28b817</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1000108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1000108%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DP.%2BB.%26aulast%3DGarrison%26aufirst%3DJ.%2BC.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26atitle%3DMuch%2520ado%2520about%2520adenosine%253A%2520adenosine%2520synthesis%2520and%2520function%2520in%2520regulatory%2520T%2520Cell%2520biology%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D1993%26epage%3D1998%26doi%3D10.4049%2Fjimmunol.1000108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghizadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahsavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amini, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashidpour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azadian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parizadeh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashayekhi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukhtanloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaafari, M. R.</span></span> <span> </span><span class="NLM_article-title">CD73; a key ectonucleotidase in the development of breast cancer: recent advances and perspectives</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">14622</span>– <span class="NLM_lpage">14632</span>, <span class="refDoi"> DOI: 10.1002/jcp.28187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fjcp.28187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=14622-14632&author=A.+Soleimaniauthor=E.+Taghizadehauthor=S.+Shahsavariauthor=Y.+Aminiauthor=H.+Rashidpourauthor=E.+Azadianauthor=A.+Jafariauthor=M.+R.+Parizadehauthor=K.+Mashayekhiauthor=M.+Soukhtanlooauthor=M.+R.+Jaafari&title=CD73%3B+a+key+ectonucleotidase+in+the+development+of+breast+cancer%3A+recent+advances+and+perspectives&doi=10.1002%2Fjcp.28187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives</span></div><div class="casAuthors">Soleimani, Anvar; Taghizadeh, Eskandar; Shahsavari, Shirin; Amini, Yousef; Rashidpour, Hatam; Azadian, Esmaeel; Jafari, Arash; Parizadeh, Mohammad Reza; Mashayekhi, Kazem; Soukhtanloo, Mohammad; Jaafari, Mahmoud Reza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">14622-14632</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tumor cell invasion and metastasis are the definitive cause of mortality in breast cancer (BC).  Hypoxia and pro-inflammatory cytokines upregulate the CD73 gene in the tumor microenvironment.  Subsequently, CD73 triggers mol. and cellular signaling pathways by both enzymic and nonenzymic pathways, which finally leads to breast tumor progression and development.  In this paper, we summarize current advances in the understanding of CD73-driven mechanisms that promote BC development and mortality.  Furthermore, we evaluate the therapeutic potential of CD73 targeting in BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBs3WVqf9ALVg90H21EOLACvtfcHk0ljuNeORxf8ymw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKqurY%253D&md5=4f61a0014a807c20b50e6179706dcb36</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fjcp.28187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.28187%26sid%3Dliteratum%253Aachs%26aulast%3DSoleimani%26aufirst%3DA.%26aulast%3DTaghizadeh%26aufirst%3DE.%26aulast%3DShahsavari%26aufirst%3DS.%26aulast%3DAmini%26aufirst%3DY.%26aulast%3DRashidpour%26aufirst%3DH.%26aulast%3DAzadian%26aufirst%3DE.%26aulast%3DJafari%26aufirst%3DA.%26aulast%3DParizadeh%26aufirst%3DM.%2BR.%26aulast%3DMashayekhi%26aufirst%3DK.%26aulast%3DSoukhtanloo%26aufirst%3DM.%26aulast%3DJaafari%26aufirst%3DM.%2BR.%26atitle%3DCD73%253B%2520a%2520key%2520ectonucleotidase%2520in%2520the%2520development%2520of%2520breast%2520cancer%253A%2520recent%2520advances%2520and%2520perspectives%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D14622%26epage%3D14632%26doi%3D10.1002%2Fjcp.28187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoy, N.</span></span> <span> </span><span class="NLM_article-title">CD73: a new biomarker in triple-negative breast cancer</span>. <i>Transl. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S594</span>– <span class="NLM_lpage">S596</span>, <span class="refDoi"> DOI: 10.21037/tcr.2018.05.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.21037%2Ftcr.2018.05.22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=S594-S596&author=V.+Lafontauthor=H.-A.+Michaudauthor=N.+Bonnefoy&title=CD73%3A+a+new+biomarker+in+triple-negative+breast+cancer&doi=10.21037%2Ftcr.2018.05.22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.21037%2Ftcr.2018.05.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftcr.2018.05.22%26sid%3Dliteratum%253Aachs%26aulast%3DLafont%26aufirst%3DV.%26aulast%3DMichaud%26aufirst%3DH.-A.%26aulast%3DBonnefoy%26aufirst%3DN.%26atitle%3DCD73%253A%2520a%2520new%2520biomarker%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DTransl.%2520Cancer%2520Res.%26date%3D2018%26volume%3D7%26spage%3DS594%26epage%3DS596%26doi%3D10.21037%2Ftcr.2018.05.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1517/14728222.2014.915315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1517%2F14728222.2014.915315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=24798880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFylu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=863-881&author=B.+Allardauthor=M.+Turcotteauthor=J.+Stagg&title=Targeting+CD73+and+downstream+adenosine+receptor+signaling+in+triple-negative+breast+cancer&doi=10.1517%2F14728222.2014.915315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer</span></div><div class="casAuthors">Allard, Bertrand; Turcotte, Martin; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-881</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite significant improvements in diagnosis and therapy over the past 20 years, breast cancer remains a worldwide public health issue.  In particular, triple neg. breast cancer (TNBC), a subset of very aggressive breast tumors, is assocd. with a poor prognosis and has very few efficient therapeutic options.  The ectonucleotidase CD73 has recently emerged as a promising new target for TNBC in preclin. models.  Pharmacol. targeting of CD73 and downstream adenosine A2A/A2B receptor signaling is currently an active field of research that could lead to the development of new cancer therapeutics, including options against TNBC.  Areas covered:This article reviews the basic structural and mol. features of CD73 and its role in the development of cancer, with a particular focus on CD73's role in the biol. of TNBC.  Expert opinion: It was recently demonstrated that CD73 expression in TNBC is assocd. with worse clin. outcomes and increased resistance to anthracycline chemotherapy.  Targeted blockade of the CD73/A2A axis has been shown to impair various aspects of tumorigenesis and displays synergism with other anti-cancer treatments in preclin. studies.  Hence, we strongly argue for the development of CD73 inhibitors and for the repositioning of A2A antagonists in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQhEy8yqpqrVg90H21EOLACvtfcHk0lhhVBOTI59Mag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFylu7bN&md5=2fd1e50c6b84b0f11940d1c6a572aa5a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14728222.2014.915315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2014.915315%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520CD73%2520and%2520downstream%2520adenosine%2520receptor%2520signaling%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D863%26epage%3D881%26doi%3D10.1517%2F14728222.2014.915315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlebois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 expression is an independent prognostic factor in prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1078-0432.CCR-15-1181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26253870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=158-166&author=B.+G.+Leclercauthor=R.+Charleboisauthor=G.+Chouinardauthor=B.+Allardauthor=S.+Pommeyauthor=F.+Saadauthor=J.+Stagg&title=CD73+expression+is+an+independent+prognostic+factor+in+prostate+cancer&doi=10.1158%2F1078-0432.CCR-15-1181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer</span></div><div class="casAuthors">Leclerc, Bruno G.; Charlebois, Roxanne; Chouinard, Guillaume; Allard, Bertrand; Pommey, Sandra; Saad, Fred; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-166</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor immunity in mouse models of cancer, including prostate cancer.  Although high levels of CD73 are assocd. with poor prognosis in various types of cancer, the clin. impact of CD73 in prostate cancer remains unclear.  Exptl. Design: We evaluated the prognostic value of CD73 protein expression and CD8+ cell d. in 285 cases of prostate cancer on tissue microarray (TMA).  Normal adjacent and tumor tissues were evaluated in duplicates.  Results: Univariate and multivariate analyses revealed that high levels of CD73 in normal adjacent prostate epithelium were significantly assocd. with shorter biochem. recurrence (BCR)-free survival.  Notably, CD73 expression in normal epithelium conferred a neg. prognostic value to prostate-infiltrating CD8+ cells.  Surprisingly, high levels of CD73 in the tumor stroma were assocd. with longer BCR-free survival in univariate anal.  In vitro studies revealed that adenosine signaling inhibited NF-κB activity in human prostate cancer cells via A2B adenosine receptors.  Consistent with these results, CD73 expression in the prostate tumor stroma neg. correlated with p65 expression in the nuclei of prostate tumor cells.  Conclusions: Our study revealed that CD73 is an independent prognostic factor in prostate cancer.  Our data support a model in which CD73 expression in the prostate epithelium suppresses immunosurveillance by CD8+ T cells, whereas CD73 expression in the tumor stroma reduces NF-κB signaling in tumor cells via A2B adenosine receptor signaling.  CD73 expression, including in normal adjacent prostate epithelium, can thus effectively discriminate between aggressive and indolent forms of prostate cancer.  Clin Cancer Res; 22(1); 158-66. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9HCI_kLOGLVg90H21EOLACvtfcHk0lhhVBOTI59Mag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D&md5=f775efcc9f67005fcc4d0696399ab79f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1181%26sid%3Dliteratum%253Aachs%26aulast%3DLeclerc%26aufirst%3DB.%2BG.%26aulast%3DCharlebois%26aufirst%3DR.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520expression%2520is%2520an%2520independent%2520prognostic%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D158%26epage%3D166%26doi%3D10.1158%2F1078-0432.CCR-15-1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span> <span> </span><span class="NLM_article-title">Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1756</span>, <span class="refDoi"> DOI: 10.3892/or.2015.4512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3892%2For.2015.4512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26708311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=1750-1756&author=R.+Wuauthor=Y.+Chenauthor=F.+Liauthor=W.+Liauthor=H.+Zhouauthor=Y.+Yangauthor=Z.+Pei&title=Effects+of+CD73+on+human+colorectal+cancer+cell+growth+in+vivo+and+in+vitro&doi=10.3892%2For.2015.4512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro</span></div><div class="casAuthors">Wu, Ruimin; Chen, Yijia; Li, Fuyan; Li, Wei; Zhou, Hong; Yang, Yi; Pei, Zhijun</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1750-1756</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of the present study was to explore the role and mechanism of extracellular ecto-5'-nucleotidase (CD73) in human colorectal cancer growth.  Firstly, CD73 expression was detected in colorectal cancer cell lines both at the mRNA and protein levels.  Secondly, recombinant CD73 interference and overexpression lentiviruses were used, resp.  Colony formation assay, CCK-8 assay and flow cytometry were used to investigate the impact of CD73 on colorectal cancer cell proliferation and cell cycle distribution.  Then, adenosine and CD73 enzyme activity inhibitor (APCP) were used to study the effect of CD73 on Epidermal growth factor receptor (EGFR) and β-catenin/cyclin D1 signaling pathways.  Finally, a human colorectal cancer transplantation nude mouse model was used to observe the effect of CD73 on tumor growth in vivo.  As the results showed, CD73 was highly expressed in the colorectal cancer cell lines.  CD73 promoted colorectal cancer cell proliferation both in vivo and in vitro.  CD73 activated EGFR and the β-catenin/cyclin D1 signaling pathways through its enzyme and non-enzyme activities.  All of the results confirmed that CD73 promotes the growth of human colorectal cancer cells through EGFR and the β-catenin/cyclin D1 signaling pathway.  CD73 may be used as a valuable biomarker of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFQ2Z85cX57Vg90H21EOLACvtfcHk0ljynM1Zhnr20Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFKmtg%253D%253D&md5=bcd1987db105d3b7e822ce587c140807</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3892%2For.2015.4512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4512%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DEffects%2520of%2520CD73%2520on%2520human%2520colorectal%2520cancer%2520cell%2520growth%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D35%26spage%3D1750%26epage%3D1756%26doi%3D10.3892%2For.2015.4512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousineau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendoo, D. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mes-Masson, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 is associated with poor prognosis in high-grade serous ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4494</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-14-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26363007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4494-4503&author=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=G.+Chouinardauthor=I.+Cousineauauthor=J.+Georgeauthor=G.+M.+Chenauthor=D.+M.+A.+Gendooauthor=B.+Haibe-Kainsauthor=T.+Karnauthor=K.+Rahimiauthor=C.+L.+Pageauthor=D.+Provencherauthor=A.-M.+Mes-Massonauthor=J.+Stagg&title=CD73+is+associated+with+poor+prognosis+in+high-grade+serous+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-14-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer</span></div><div class="casAuthors">Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Chouinard, Guillaume; Cousineau, Isabelle; George, Joshy; Chen, Gregory M.; Gendoo, Deena M. A.; Haibe-Kains, Benjamin; Karn, Thomas; Rahimi, Kurosh; Le Page, Cecile; Provencher, Diane; Mes-Masson, Anne-Marie; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4494-4503</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis.  Although preclin. studies suggest that CD73 can be targeted for cancer treatment, the clin. impact of CD73 in ovarian cancer remains unclear.  In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses.  Our results demonstrate that high levels of CD73 are significantly assocd. with shorter disease-free survival and overall survival in patients with HGS ovarian cancer.  Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis assocd. with intraepithelial CD8+ cells.  Notably, CD73 gene expression was highest in the C1/stromal mol. subtype of HGS ovarian cancer and pos. correlated with an epithelial-to-mesenchymal transition gene signature.  Moreover, in vitro studies revealed that CD73 and extracellular adenosine enhance ovarian tumor cell growth as well as expression of antiapoptotic BCL-2 family members.  Finally, in vivo coinjection of ID8 mouse ovarian tumor cells with mouse embryonic fibroblasts showed that CD73 expression in fibroblasts promotes tumor immune escape and thereby tumor growth.  In conclusion, our study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in HGS ovarian cancers.  Cancer Res; 75(21); 4494-503. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0cI-iFGChprVg90H21EOLACvtfcHk0ljynM1Zhnr20Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF&md5=168775cf106084e44de08a6f6a302255</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DGendoo%26aufirst%3DD.%2BM.%2BA.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DRahimi%26aufirst%3DK.%26aulast%3DPage%26aufirst%3DC.%2BL.%26aulast%3DProvencher%26aufirst%3DD.%26aulast%3DMes-Masson%26aufirst%3DA.-M.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4494%26epage%3D4503%26doi%3D10.1158%2F0008-5472.CAN-14-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namburi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span> <span> </span><span class="NLM_article-title">Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">12050</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1200%2FJCO.2018.36.15_suppl.12050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=12050&author=L.+C.+Parkauthor=K.+Rheeauthor=W.+B.+Kimauthor=A.+Choauthor=J.+Songauthor=J.+F.+Ankerauthor=M.+Ohauthor=P.+Baisauthor=S.+Namburiauthor=J.+Chuangauthor=Y.+K.+Chae&title=Immunologic+and+clinical+implications+of+CD73+expression+in+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1200%2FJCO.2018.36.15_suppl.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.12050%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DL.%2BC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DW.%2BB.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DAnker%26aufirst%3DJ.%2BF.%26aulast%3DOh%26aufirst%3DM.%26aulast%3DBais%26aufirst%3DP.%26aulast%3DNamburi%26aufirst%3DS.%26aulast%3DChuang%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DY.%2BK.%26atitle%3DImmunologic%2520and%2520clinical%2520implications%2520of%2520CD73%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D12050%26doi%3D10.1200%2FJCO.2018.36.15_suppl.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span> <span> </span><span class="NLM_article-title">The distinct role of CD73 in the progression of pancreatic cancer</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1007/s00109-018-01742-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1007%2Fs00109-018-01742-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30927045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1yktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=803-815&author=L.+Zhouauthor=S.+Jiaauthor=Y.+Chenauthor=W.+Wangauthor=Z.+Wuauthor=W.+Yuauthor=M.+Zhangauthor=G.+Dingauthor=L.+Cao&title=The+distinct+role+of+CD73+in+the+progression+of+pancreatic+cancer&doi=10.1007%2Fs00109-018-01742-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The distinct role of CD73 in the progression of pancreatic cancer</span></div><div class="casAuthors">Zhou, Liangjing; Jia, Shengnan; Chen, Yan; Wang, Weiming; Wu, Zhengrong; Yu, Weihua; Zhang, Mingjie; Ding, Guoping; Cao, Liping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Recent studies have shown that the non-enzymic function of CD73 plays a key role in tumor progression, but this function of CD73 in pancreatic cancer cells has not been studied.  Furthermore, little is known about the mechanism involved in CD73 regulation in tumors.  Here, we found that CD73 expression was upregulated in pancreatic ductal adenocarcinoma (PDAC) and that its expression correlated with poor prognosis.  CD73 knockdown inhibited cell growth and induced G1 phase arrest via the AKT/ERK/cyclin D signaling pathway.  We also found that tumor necrosis factor receptor (TNFR) 2 was involved in CD73-induced AKT and ERK signaling pathway activation in PDAC.  Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 mRNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.  In summary, this regulatory network of CD73 appears to represent a new mol. mechanism underlying PDAC progression, and the mechanistic interaction between miR-30a-5p, CD73, and TNFR2 may provide new insights into therapeutic strategies for pancreatic cancer.  Key messages: CD73 was upregulated in PDAC and correlated with poor prognosis.  CD73 knockdown inhibited cell growth and induced G1 phase arrest.  TNFR2 was involved in CD73-induced AKT and ERK signaling pathway. miR-30a-5p targeted CD73 and increased the sensitivity to gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxoBGZ-FHv7Vg90H21EOLACvtfcHk0liZwxzUnv4HrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1yktbk%253D&md5=c05b2f98c3e76ddbfa83d87d7b2429af</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00109-018-01742-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-018-01742-0%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DL.%26atitle%3DThe%2520distinct%2520role%2520of%2520CD73%2520in%2520the%2520progression%2520of%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D803%26epage%3D815%26doi%3D10.1007%2Fs00109-018-01742-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertonia, A. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccob, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Campos, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutzc, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assis-Brasild, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza Meyer, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanetto, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span> <span> </span><span class="NLM_article-title">Activity of ecto-5′-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>479</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.mce.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30184475" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=479&publication_year=2019&pages=54-60&author=A.+P.+S.+Bertoniaauthor=P.+A.+Braccobauthor=R.+P.+de+Camposauthor=B.+S.+Lutzcauthor=B.+M.+Assis-Brasildauthor=E.+L.+de+Souza+Meyerauthor=J.+Saffiauthor=E.+Braganholauthor=T.+W.+Furlanettoauthor=M.+R.+Wink&title=Activity+of+ecto-5%E2%80%B2-nucleotidase+%28NT5E%2FCD73%29+is+increased+in+papillary+thyroid+carcinoma+and+its+expression+is+associated+with+metastatic+lymph+nodes&doi=10.1016%2Fj.mce.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DBertonia%26aufirst%3DA.%2BP.%2BS.%26aulast%3DBraccob%26aufirst%3DP.%2BA.%26aulast%3Dde%2BCampos%26aufirst%3DR.%2BP.%26aulast%3DLutzc%26aufirst%3DB.%2BS.%26aulast%3DAssis-Brasild%26aufirst%3DB.%2BM.%26aulast%3Dde%2BSouza%2BMeyer%26aufirst%3DE.%2BL.%26aulast%3DSaffi%26aufirst%3DJ.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DFurlanetto%26aufirst%3DT.%2BW.%26aulast%3DWink%26aufirst%3DM.%2BR.%26atitle%3DActivity%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528NT5E%252FCD73%2529%2520is%2520increased%2520in%2520papillary%2520thyroid%2520carcinoma%2520and%2520its%2520expression%2520is%2520associated%2520with%2520metastatic%2520lymph%2520nodes%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26volume%3D479%26spage%3D54%26epage%3D60%26doi%3D10.1016%2Fj.mce.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.3748/wjg.v19.i12.1912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3748%2Fwjg.v19.i12.1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23569336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlSls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1912-1918&author=X.-X.+Luauthor=Y.-T.+Chenauthor=B.+Fengauthor=X.-B.+Maoauthor=B.+Yuauthor=X.-Y.+Chu&title=Expression+and+clinical+significance+of+CD73+and+hypoxia-inducible+factor-1%CE%B1+in+gastric+carcinoma&doi=10.3748%2Fwjg.v19.i12.1912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma</span></div><div class="casAuthors">Lu, Xiao-Xia; Chen, Yi-Tian; Feng, Bing; Mao, Xiao-Bei; Yu, Bo; Chu, Xiao-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1912-1918</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Aim: To investigate the expression of CD73 and hypoxia-inducible factor-1α (HIF-1α) in human gastric carcinoma and explore their clin. significance and prognostic value.  Methods: CD73 and HIF-1α expressions were detected by immunohistochem. in consecutive sections of tissue samples from 68 gastric carcinoma patients.  The peritumor tissues 2 cm away from the tumor were obtained and served as controls.  The presence of CD73 and HIF-1α was analyzed by immunohistochem. using the Envision technique.  Results: CD73 and HIF-1α expressions in gastric carcinoma were significantly higher than those in gastric mucosal tissues as control (P < 0.001) and showed a close correlation (Spearman r = 0.390, P = 0.001).  Overexpression of CD73 was pos. correlated with differentiation of tumor (P = 0.000), histopathol. (P = 0.041), depth of invasion (P < 0.001), nodal status (P = 0.003), metastasis (P = 0.013) and the American Joint Committee on Cancer (AJCC) stage (P < 0.001).  High expression of HIF-1α was pos. correlated with tumor diam. (P = 0.031), depth of invasion (P = 0.022) and AJCC stage (P = 0.035).  The overall survival rate was low in the patients with high expression of CD73 (P < 0.001).  Moreover, CD73+/HIF-1α+patients had the worst prognosis (P < 0.001).  CD73 expression was proven to be an independent predictor for patients with gastric carcinoma by both multivariate Cox regression anal. (P = 0.021) and receiver operating characteristic curves (P = 0.001).  Conclusion: CD73 expression correlates closely with HIF-1α expression in gastric carcinoma.  CD73 could be an independent prognostic indicator for gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHw5O5j8tl7Vg90H21EOLACvtfcHk0lihXZeb8L73AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlSls7c%253D&md5=ff722e42a09114e5ef9b7fb804ac8b75</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v19.i12.1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v19.i12.1912%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.-X.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DX.-B.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DX.-Y.%26atitle%3DExpression%2520and%2520clinical%2520significance%2520of%2520CD73%2520and%2520hypoxia-inducible%2520factor-1%25CE%25B1%2520in%2520gastric%2520carcinoma%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2013%26volume%3D19%26spage%3D1912%26epage%3D1918%26doi%3D10.3748%2Fwjg.v19.i12.1912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faouzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménétrier-Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leval, L. D.</span></span> <span> </span><span class="NLM_article-title">CD73 expression and clinical significance in human metastatic melanoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">26659</span>– <span class="NLM_lpage">26669</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.18632%2Foncotarget.25426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29928476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26659-26669&author=I.+Monteiroauthor=S.+Viganoauthor=M.+Faouziauthor=I.+Treilleuxauthor=O.+Michielinauthor=C.+M%C3%A9n%C3%A9trier-Cauxauthor=C.+Cauxauthor=P.+Romeroauthor=L.+D.+Leval&title=CD73+expression+and+clinical+significance+in+human+metastatic+melanoma&doi=10.18632%2Foncotarget.25426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 expression and clinical significance in human metastatic melanoma</span></div><div class="casAuthors">Monteiro Ines; de Leval Laurence; Vigano Selena; Romero Pedro; Faouzi Mohamed; Treilleux Isabelle; Michielin Olivier; Menetrier-Caux Christine; Caux Christophe; Menetrier-Caux Christine; Caux Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26659-26669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  CD73 is an ectoenzyme involved in the production of adenosine.  It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.  Results:  CD73 expression was detected in TC in 54% of melanoma metastases, involving < 50% TC in the majority of the cases, with variable intensity.  CD73 expression was significantly associated with a lower Breslow's depth of the primary lesion and was more frequent in patients having received prior non-surgical therapies.  In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) significantly correlated to decreased overall survival (OS) from biopsy.  Of the samples containing TIMC, 35% presented CD73+ TIMC.  Highly infiltrated tumors were more likely to contain CD73+ TIMC.  CD73 expression in TIMC (percentage ≥1%) significantly correlated with improved OS from biopsy.  Conclusions:  Immunohistochemistry detected CD73 expression in more than half of metastatic melanomas.  While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS.  These results encourage the study of anti-CD73 therapies for metastatic melanoma patients.  Methods:  CD73 expression was assessed by immunohistochemistry in metastatic melanomas from 114 patients.  Immunostainings were evaluated in tumor cells (TC) (percentage, intensity (1-3) and H-score) and in tumor-infiltrating mononuclear cells (TIMC) (percentage).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWcmnHKmNelsRAV4D_Ins_fW6udTcc2eYrDkzu7-RgQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFWjsg%253D%253D&md5=016f73cfa655638336b226026b50e053</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25426%26sid%3Dliteratum%253Aachs%26aulast%3DMonteiro%26aufirst%3DI.%26aulast%3DVigano%26aufirst%3DS.%26aulast%3DFaouzi%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DM%25C3%25A9n%25C3%25A9trier-Caux%26aufirst%3DC.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DRomero%26aufirst%3DP.%26aulast%3DLeval%26aufirst%3DL.%2BD.%26atitle%3DCD73%2520expression%2520and%2520clinical%2520significance%2520in%2520human%2520metastatic%2520melanoma%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D26659%26epage%3D26669%26doi%3D10.18632%2Foncotarget.25426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommeyb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kainsc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavisd, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcyd, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">11091</span>– <span class="NLM_lpage">11096</span>, <span class="refDoi"> DOI: 10.1073/pnas.1222251110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1073%2Fpnas.1222251110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23776241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=11091-11096&author=S.+Loiauthor=S.+Pommeybauthor=B.+Haibe-Kainscauthor=P.+A.+Beavisdauthor=P.+K.+Darcydauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+anthracycline+resistance+and+poor+prognosis+in+triple+negative+breast+cancer&doi=10.1073%2Fpnas.1222251110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span></div><div class="casAuthors">Loi, Sherene; Pommey, Sandra; Haibe-Kains, Benjamin; Beavis, Paul A.; Darcy, Phillip K.; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11091-11096,S11091/1-S11091/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is assocd. with a poor prognosis in triple-neg. breast cancers (TNBC).  Because anthracycline-based chemotherapy regimens are std. treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy.  In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly assocd. with a lower rate of pathol. complete response or the disappearance of invasive tumor at surgery.  Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors.  Targeted blockade of CD73 enhanced doxorubicin-mediated antitumor immune responses and significantly prolonged the survival of mice with established metastatic breast cancer.  Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6KtLUgWgbYbVg90H21EOLACvtfcHk0ljB2ATPnvJgrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO&md5=97b58f664273accfcab7096dcbc76db6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222251110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222251110%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DPommeyb%26aufirst%3DS.%26aulast%3DHaibe-Kainsc%26aufirst%3DB.%26aulast%3DBeavisd%26aufirst%3DP.%2BA.%26aulast%3DDarcyd%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520anthracycline%2520resistance%2520and%2520poor%2520prognosis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D11091%26epage%3D11096%26doi%3D10.1073%2Fpnas.1222251110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">The roles of CD73 in cancer</span>. <i>Biomed. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>, <span class="NLM_elocation-id">460654</span> <span class="refDoi"> DOI: 10.1155/2014/460654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1155%2F2014%2F460654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=25126561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC2M7kvVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&author=Z.+Gaoauthor=K.+Dongauthor=H.+Zhang&title=The+roles+of+CD73+in+cancer&doi=10.1155%2F2014%2F460654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of CD73 in cancer</span></div><div class="casAuthors">Gao Zhao-wei; Dong Ke; Zhang Hui-zhong</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">460654</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purinergic signaling has emerged as an important player in cancer progression and is regulated by a series of nucleotidases.  Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer.  Various factors and mechanisms are employed to regulate expression of CD73.  Accumulating studies have shown that CD73 is a key regulatory molecule of cancer cells proliferation, migration and invasion in vitro, tumor angiogenesis, and tumor immune escape in vivo.  With such important roles in cancer, CD73 has become an appealing therapy target.  Recent evidences in mice models demonstrated that targeted blockade of CD73 could be a favorable therapeutic approach for cancer patients in the future.  In this review, we will summarize the multiple roles of CD73 in cancer development, including its clinical significance, its promotive effects on tumor growth, metastasis, and angiogenesis, and its suppressive effects on immune response, regulatory mechanisms of CD73 expression, and current situation of anti-CD73 cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIODqCHThnpYhLSh9fo81bfW6udTcc2eZaHy9LihAmwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7kvVSjtw%253D%253D&md5=3728d88384bc0a82a4cc7f3956dc4f4b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1155%2F2014%2F460654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F460654%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThe%2520roles%2520of%2520CD73%2520in%2520cancer%26jtitle%3DBiomed.%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26doi%3D10.1155%2F2014%2F460654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bareche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisseret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delisle, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellokumpu-Lehtinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes resistance to HER2/ErbB2 antibody therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5652</span>– <span class="NLM_lpage">5663</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-17-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=28855210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5652-5663&author=M.+Turcotteauthor=D.+Allardauthor=D.+Mittalauthor=Y.+Barecheauthor=L.+Buisseretauthor=V.+Joseauthor=S.+Pommeyauthor=V.+Delisleauthor=S.+Loiauthor=H.+Joensuuauthor=P.+Kellokumpu-Lehtinenauthor=C.+Sotiriouauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+resistance+to+HER2%2FErbB2+antibody+therapy&doi=10.1158%2F0008-5472.CAN-17-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy</span></div><div class="casAuthors">Turcotte, Martin; Allard, David; Mittal, Deepak; Bareche, Yacine; Buisseret, Laurence; Jose, Vinu; Pommey, Sandra; Delisle, Vincent; Loi, Sherene; Joensuu, Heikki; Kellokumpu-Lehtinen, Pirkko-Liisa; Sotiriou, Christos; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5652-5663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of the ectonucleotidase CD73 by tumor cells, stromal cells, and immune cells is assocd. in cancer with immune suppression.  In this study, we investigated the role of CD73 on the activity of the anti-HER2/ErbB2 monoclonal antibody (mAb) trastuzumab.  In a prospective, randomized phase III clin. trial evaluating the activity of trastuzumab, high levels of CD73 gene expression were assocd. significantly with poor clin. outcome.  In contrast, high levels of PD-1 and PD-L1 were assocd. with improved clin. outcome.  In immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.  Furthermore, anti-CD73 mAb therapy enhanced the activity of anti-ErbB2 mAb to treat engrafted or spontaneous tumors as well as lung metastases.  Gene ontol. enrichment anal. from gene-expression data revealed a pos. assocn. of CD73 expression with extracellular matrix organization, TGFβ genes, epithelial-to-mesenchymal transition (EMT) transcription factors and hypoxia-inducible-factor (HIF)-1 gene signature.  Human mammary cells treated with TGFβ or undergoing EMT upregulated CD73 cell-surface expression, confirming roles for these pathways.  In conclusion, our findings establish CD73 in mediating resistance to trastuzumab and provide new insights into how CD73 is regulated in breast cancer.  Cancer Res; 77(20); 5652-63. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSI2kxEAJ5cbVg90H21EOLACvtfcHk0lgyBhT_fJSe2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLnM&md5=a71749b68bb6fd0bf6c7fd79410323b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0707%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DBareche%26aufirst%3DY.%26aulast%3DBuisseret%26aufirst%3DL.%26aulast%3DJose%26aufirst%3DV.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDelisle%26aufirst%3DV.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DKellokumpu-Lehtinen%26aufirst%3DP.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520resistance%2520to%2520HER2%252FErbB2%2520antibody%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5652%26epage%3D5663%26doi%3D10.1158%2F0008-5472.CAN-17-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5626</span>– <span class="NLM_lpage">5635</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1078-0432.CCR-13-0545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23983257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5626-5635&author=B.+Allardauthor=S.+Pommeyauthor=M.+J.+Smythauthor=J.+Stagg&title=Targeting+CD73+enhances+the+antitumor+activity+of+anti-PD-1+and+anti-CTLA-4+mAbs&doi=10.1158%2F1078-0432.CCR-13-0545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs</span></div><div class="casAuthors">Allard, Bertrand; Pommey, Sandra; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5626-5635</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been assocd. with durable clin. responses against a variety of cancer types and hold great potential as novel cancer therapeutics.  Recent evidence suggest that targeted blockade of multiple immunosuppressive pathways can induce synergistic antitumor responses.  Exptl. Design: In this study, we investigated whether targeted blockade of CD73, an ectonucleotidase that catabolizes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, can enhance the antitumor activity of anti-CTLA-4 and anti-PD-1 mAbs against transplanted and chem. induced mouse tumors.  Results: Anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against MC38-OVA (colon) and RM-1 (prostate) s.c. tumors, and established metastatic 4T1.2 breast cancer.  Anti-CD73 mAb also significantly enhanced the activity of anti-PD-1 mAb against 3-methylcholanthrene (MCA)-induced fibrosarcomas.  Gene-targeted mice revealed that single-agent therapies and combinatorial treatments were dependent on host IFN-γ and CD8+ T cells, but independent of perforin.  Interestingly, anti-CD73 mAb preferentially synergized with anti-PD-1 mAb.  We investigated the effect of extracellular adenosine on tumor-infiltrating T cells and showed that activation of A2A adenosine receptor enhances PD-1 expression, but not CTLA-4 expression, on tumor-specific CD8+ T cells and CD4+ Foxp3+ T regulatory cells.  Conclusions: Taken together, our study revealed that targeted blockade of CD73 can enhance the therapeutic activity of anti-PD-1 and anti-CTLA-4 mAbs and may thus potentiate therapeutic strategies targeting immune checkpoint inhibitors in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVsy3vL-s1rVg90H21EOLACvtfcHk0lgyBhT_fJSe2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurrP&md5=c7a44398208fbf65f801d9c47935697b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0545%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520CD73%2520enhances%2520the%2520antitumor%2520activity%2520of%2520anti-PD-1%2520and%2520anti-CTLA-4%2520mAbs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5626%26epage%3D5635%26doi%3D10.1158%2F1078-0432.CCR-13-0545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achyut, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbab, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span> <span> </span><span class="NLM_article-title">CD73 on cancer-associated fibroblasts enhanced by the A<sub>2B</sub>-mediated feedforward circuit enforces an immune checkpoint</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">515</span> <span class="refDoi"> DOI: 10.1038/s41467-019-14060-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fs41467-019-14060-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=31980601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFanurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&author=M.+Yuauthor=G.+Guoauthor=L.+Huangauthor=L.+Dengauthor=C.-S.+Changauthor=B.+R.+Achyutauthor=M.+Canningauthor=N.+Xuauthor=A.+S.+Arbabauthor=R.+J.+Bollagauthor=P.+C.+Rodriguezauthor=A.+L.+Mellorauthor=H.+Shiauthor=D.+H.+Munnauthor=Y.+Cui&title=CD73+on+cancer-associated+fibroblasts+enhanced+by+the+A2B-mediated+feedforward+circuit+enforces+an+immune+checkpoint&doi=10.1038%2Fs41467-019-14060-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint</span></div><div class="casAuthors">Yu, Miao; Guo, Gang; Huang, Lei; Deng, Libin; Chang, Chang-Sheng; Achyut, Bhagelu R.; Canning, Madison; Xu, Ningchun; Arbab, Ali S.; Bollag, Roni J.; Rodriguez, Paulo C.; Mellor, Andrew L.; Shi, Huidong; Munn, David H.; Cui, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">515</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.  Elevated CD73 levels in tumor tissues correlate with poor clin. outcomes.  However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified.  Here, we demonstrate that cancer-assocd. fibroblasts (CAFs) constitute the prominent CD73hi population in human colorectal cancers (CRCs) and two CD73- murine tumor models, including a modified CRC.  Clin., high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis.  Mechanistically, CAF-CD73 expression is enhanced via an ADO-A2B receptor-mediated feed forward circuit triggered by tumor cell death, which enforces the CD73-checkpoint.  Simultaneous inhibition of A2A and A2B pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors.  Therefore, the strategic and effective targeting of both the A2B-mediated ADO-CAF-CD73 feed forward circuit and A2A-mediated immune suppression is crucial for improving therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtclNuEzjmsbVg90H21EOLACvtfcHk0liTH4PT7VWECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFanurY%253D&md5=361086e15d0fcc5f5b8bf1bcff90f876</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-14060-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-14060-x%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DC.-S.%26aulast%3DAchyut%26aufirst%3DB.%2BR.%26aulast%3DCanning%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DArbab%26aufirst%3DA.%2BS.%26aulast%3DBollag%26aufirst%3DR.%2BJ.%26aulast%3DRodriguez%26aufirst%3DP.%2BC.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DCui%26aufirst%3DY.%26atitle%3DCD73%2520on%2520cancer-associated%2520fibroblasts%2520enhanced%2520by%2520the%2520A2B-mediated%2520feedforward%2520circuit%2520enforces%2520an%2520immune%2520checkpoint%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26doi%3D10.1038%2Fs41467-019-14060-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngiow, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkauskas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.ccell.2016.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27622332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=391-403&author=A.+Youngauthor=S.+F.+Ngiowauthor=D.+S.+Barkauskasauthor=E.+Sultauthor=C.+Hayauthor=S.+J.+Blakeauthor=Q.+Huangauthor=J.+Liuauthor=K.+Takedaauthor=M.+W.+L.+Tengauthor=K.+Sachsenmeierauthor=M.+J.+Smyth&title=Co-inhibition+of+CD73+and+A2AR+adenosine+signaling+improves+anti-tumor+immune+responses&doi=10.1016%2Fj.ccell.2016.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses</span></div><div class="casAuthors">Young, Arabella; Ngiow, Shin Foong; Barkauskas, Deborah S.; Sult, Erin; Hay, Carl; Blake, Stephen J.; Huang, Qihui; Liu, Jing; Takeda, Kazuyoshi; Teng, Michele W. L.; Sachsenmeier, Kris; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-403</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Preclin. studies targeting the adenosinergic pathway have gained much attention for their clin. potential in overcoming tumor-induced immunosuppression.  Here, we have identified that co-blockade of the ectonucleotidase that generates adenosine CD73 and the A2A adenosine receptor (A2AR) that mediates adenosine signaling in leuokocytes, by using compd. gene-targeted mice or therapeutics that target these mols., limits tumor initiation, growth, and metastasis.  This tumor control requires effector lymphocytes and interferon-γ, while antibodies targeting CD73 promote an optimal therapeutic response in vivo when engaging activating Fc receptors.  In a two-way mixed leukocyte reaction using a fully human anti-CD73, we demonstrated that Fc receptor binding augmented the prodn. of proinflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxhWP1XI1lbVg90H21EOLACvtfcHk0liTH4PT7VWECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrjL&md5=a42578ccc57076490b4d5f7beece849c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DNgiow%26aufirst%3DS.%2BF.%26aulast%3DBarkauskas%26aufirst%3DD.%2BS.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DHay%26aufirst%3DC.%26aulast%3DBlake%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCo-inhibition%2520of%2520CD73%2520and%2520A2AR%2520adenosine%2520signaling%2520improves%2520anti-tumor%2520immune%2520responses%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D391%26epage%3D403%26doi%3D10.1016%2Fj.ccell.2016.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparwasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-10-4246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=21292811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2892-2900&author=J.+Staggauthor=U.+Divisekeraauthor=H.+Duretauthor=T.+Sparwasserauthor=M.+W.+L.+Tengauthor=P.+K.+Darcyauthor=M.+J.+Smyth&title=CD73-deficient+mice+have+increased+antitumor+immunity+and+are+resistant+to+experimental+metastasis&doi=10.1158%2F0008-5472.CAN-10-4246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; Duret, Helene; Sparwasser, Tim; Teng, Michele W. L.; Darcy, Phillip K.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2892-2900</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine.  In this study, we employed CD73 gene-targeted mice to investigate the role of host-derived CD73 on antitumor immunity and tumor cell metastasis.  We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma.  The protective effect of CD73 deficiency on primary tumors was dependent on CD8+ T cells and assocd. with an increased frequency of antigen-specific CD8+ T cells in peripheral blood and tumors and increased antigen-specific IFN-γ prodn.  Replicate studies in bone marrow chimeras established that both hematopoietic and nonhematopoietic expression of CD73 was important to promote tumor immune escape.  Using adoptive reconstitution of T regulatory cell (Treg)-depleted DEREG (depletion of regulatory T cells) mice, we demonstrated that part of the protumorigenic effect of Tregs was dependent on their expression of CD73.  CD73-deficient mice were also protected against pulmonary metastasis of B16F10 melanoma cells after i.v. injection.  Unexpectedly, we found that the prometastatic effect of host-derived CD73 was dependent on CD73 expression on nonhematopoietic cells.  CD73 expression on nonhematopoietic cells, most likely endothelial cells, was crit. for promoting lung metastasis in a manner independent from immunosuppressive effects.  Notably, in vivo blockade of CD73 with a selective inhibitor or anti-CD73 monoclonal antibody significantly reduced tumor growth and metastasis of CD73-neg. tumors.  Taken together, our findings indicate that CD73 may be targeted at multiple levels to induce anticancer effects including at the level of tumor cells, Tregs, and nonhematopoietic cells.  Cancer Res; 71(8); 2892-900.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQxUwCZ8XerVg90H21EOLACvtfcHk0liZiESacwJZAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D&md5=94cc37e9eb84e5e8cce990252cc0e7a2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4246%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DDuret%26aufirst%3DH.%26aulast%3DSparwasser%26aufirst%3DT.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCD73-deficient%2520mice%2520have%2520increased%2520antitumor%2520immunity%2520and%2520are%2520resistant%2520to%2520experimental%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2892%26epage%3D2900%26doi%3D10.1158%2F0008-5472.CAN-10-4246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornish, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anandhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blando, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groot, Jd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepesi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span> <span> </span><span class="NLM_article-title">Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0694-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fs41591-019-0694-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=31873309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=39-46&author=S.+Goswamiauthor=T.+Walleauthor=A.+E.+Cornishauthor=S.+Basuauthor=S.+Anandhanauthor=I.+Fernandezauthor=L.+Venceauthor=J.+Blandoauthor=H.+Zhaoauthor=S.+S.+Yadavauthor=M.+Ottauthor=L.+Y.+Kongauthor=A.+B.+Heimbergerauthor=Jd.+Grootauthor=B.+Sepesiauthor=M.+Overmanauthor=S.+Kopetzauthor=J.+P.+Allisonauthor=D.+Pe%E2%80%99erauthor=P.+Sharma&title=Immune+profiling+of+human+tumors+identifies+CD73+as+a+combinatorial+target+in+glioblastoma&doi=10.1038%2Fs41591-019-0694-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma</span></div><div class="casAuthors">Goswami, Sangeeta; Walle, Thomas; Cornish, Andrew E.; Basu, Sreyashi; Anandhan, Swetha; Fernandez, Irina; Vence, Luis; Blando, Jorge; Zhao, Hao; Yadav, Shalini Singh; Ott, Martina; Kong, Ling Y.; Heimberger, Amy B.; de Groot, John; Sepesi, Boris; Overman, Michael; Kopetz, Scott; Allison, James P.; Pe'er, Dana; Sharma, Padmanee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of many solid tumors.  However, the clin. efficacy of immune checkpoint therapy is limited to a subset of patients with specific tumor types1,2.  Multiple clin. trials with combinatorial immune checkpoint strategies are ongoing; however, the mechanistic rationale for tumor-specific targeting of immune checkpoints is elusive.  To garner an insight into tumor-specific immunomodulatory targets, we analyzed 94 patients representing five different cancer types, including those that respond relatively well to immune checkpoint therapy and those that do not, such as glioblastoma multiforme, prostate cancer and colorectal cancer.  Through mass cytometry and single-cell RNA sequencing, we identified a unique population of CD73hi macrophages in glioblastoma multiforme that persists after anti-PD-1 treatment.  To test if targeting CD73 would be important for a successful combination strategy in glioblastoma multiforme, we performed reverse translational studies using CD73-/- mice.  We found that the absence of CD73 improved survival in a murine model of glioblastoma multiforme treated with anti-CTLA-4 and anti-PD-1.  Our data identified CD73 as a specific immunotherapeutic target to improve antitumor immune responses to immune checkpoint therapy in glioblastoma multiforme and demonstrate that comprehensive human and reverse translational studies can be used for rational design of combinatorial immune checkpoint strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-I-oQEDdirVg90H21EOLACvtfcHk0liZiESacwJZAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFyqsA%253D%253D&md5=f9a50890e5b225436119f4150e53bb60</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0694-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0694-x%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DS.%26aulast%3DWalle%26aufirst%3DT.%26aulast%3DCornish%26aufirst%3DA.%2BE.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DAnandhan%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DI.%26aulast%3DVence%26aufirst%3DL.%26aulast%3DBlando%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYadav%26aufirst%3DS.%2BS.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DL.%2BY.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26aulast%3DGroot%26aufirst%3DJd.%26aulast%3DSepesi%26aufirst%3DB.%26aulast%3DOverman%26aufirst%3DM.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DP.%26atitle%3DImmune%2520profiling%2520of%2520human%2520tumors%2520identifies%2520CD73%2520as%2520a%2520combinatorial%2520target%2520in%2520glioblastoma%26jtitle%3DNat.%2520Med.%26date%3D2020%26volume%3D26%26spage%3D39%26epage%3D46%26doi%3D10.1038%2Fs41591-019-0694-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1073/pnas.0908801107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1073%2Fpnas.0908801107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=20080644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1547-1552&author=J.+Staggauthor=U.+Divisekeraauthor=N.+McLaughlinauthor=J.+Sharkeyauthor=S.+Pommeyauthor=D.+Denoyerauthor=K.+M.+Dwyerauthor=M.+J.+Smyth&title=Anti-CD73+antibody+therapy+inhibits+breast+tumor+growth+and+metastasis&doi=10.1073%2Fpnas.0908801107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; McLaughlin, Nicole; Sharkey, Janelle; Pommey, Sandra; Denoyer, Delphine; Dwyer, Karen M.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1547-1552, S1547/1-S1547/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth.  We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine.  We showed that anti-CD73 mAb therapy significantly delayed primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung metastases.  Notably, anti-CD73 mAb therapy was essentially dependent on the induction of adaptive anti-tumor immune responses.  Knockdown of CD73 in 4T1.2 tumor cells confirmed the tumor-promoting effects of CD73.  In addn. to its immunosuppressive effect, CD73 enhanced tumor cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis.  Accordingly, administration of adenosine-5'-N-ethylcarboxamide to tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung metastasis.  Using selective adenosine-receptor antagonists, we showed that activation of A2B adenosine receptors promoted 4T1.2 tumor cell chemotaxis in vitro and metastasis in vivo.  In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and it also established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2etrhOGG3bVg90H21EOLACvtfcHk0lgktjNZW6x9gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D&md5=7bafdf788526df932910865c2e291959</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0908801107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0908801107%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DMcLaughlin%26aufirst%3DN.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DDwyer%26aufirst%3DK.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-CD73%2520antibody%2520therapy%2520inhibits%2520breast%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D1547%26epage%3D1552%26doi%3D10.1073%2Fpnas.0908801107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulgrew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Doria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holoweckyj, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durham, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leow, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damschroder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 in the tumor microenvironment with MEDI9447</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1208875</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1208875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1080%2F2162402X.2016.1208875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27622077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=C.+M.+Hayauthor=E.+Sultauthor=Q.+Huangauthor=K.+Mulgrewauthor=S.+R.+Fuhrmannauthor=K.+A.+McGlincheyauthor=S.+A.+Hammondauthor=R.+Rothsteinauthor=J.+Rios-Doriaauthor=E.+Poonauthor=N.+Holoweckyjauthor=N.+M.+Durhamauthor=C.+C.+Leowauthor=G.+Diedrichauthor=M.+Damschroderauthor=R.+Herbstauthor=R.+E.+Hollingsworthauthor=K.+F.+Sachsenmeier&title=Targeting+CD73+in+the+tumor+microenvironment+with+MEDI9447&doi=10.1080%2F2162402X.2016.1208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 in the tumor microenvironment with MEDI9447</span></div><div class="casAuthors">Hay, Carl M.; Sult, Erin; Huang, Qihui; Mulgrew, Kathy; Fuhrmann, Stacy R.; McGlinchey, Kelly A.; Hammond, Scott A.; Rothstein, Raymond; Rios-Doria, Jonathan; Poon, Edmund; Holoweckyj, Nick; Durham, Nicholas M.; Leow, Ching Ching; Diedrich, Gundo; Damschroder, Melissa; Herbst, Ronald; Hollingsworth, Robert E.; Sachsenmeier, Kris F.</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1208875/1-e1208875/10</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clin. trials.  Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences.  MEDI9447 results in relief from adenosine monophosphate (AMP)-mediated lymphocyte suppression in vitro and inhibition of mouse syngeneic tumor growth in vivo.  In contrast with other cancer immunotherapy agents such as checkpoint inhibitors or T-cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment of mouse models.  Changes include significant alterations in a no. of tumor micro-environmental subpopulations including increases in CD8+ effector cells and activated macrophages.  Furthermore, these changes correlate directly with responder and non-responder subpopulations within animal studies using syngeneic tumors.  Combination data showing additive activity between MEDI9447 and anti-PD-1 antibodies using human cells in vitro and mouse tumor models further demonstrate the potential value of relieving adenosine-mediated immunosuppression.  Based on these data, a Phase I study to test the safety, tolerability, and clin. activity of MEDI9447 in cancer patients was initiated (NCT02503774).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-rKnwU9Ri1bVg90H21EOLACvtfcHk0lgktjNZW6x9gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsLfE&md5=3ead348a459c3a893e0a3638799dfc7e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1208875%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DC.%2BM.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMulgrew%26aufirst%3DK.%26aulast%3DFuhrmann%26aufirst%3DS.%2BR.%26aulast%3DMcGlinchey%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DS.%2BA.%26aulast%3DRothstein%26aufirst%3DR.%26aulast%3DRios-Doria%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DHoloweckyj%26aufirst%3DN.%26aulast%3DDurham%26aufirst%3DN.%2BM.%26aulast%3DLeow%26aufirst%3DC.%2BC.%26aulast%3DDiedrich%26aufirst%3DG.%26aulast%3DDamschroder%26aufirst%3DM.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHollingsworth%26aufirst%3DR.%2BE.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26atitle%3DTargeting%2520CD73%2520in%2520the%2520tumor%2520microenvironment%2520with%2520MEDI9447%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span>; <span class="NLM_string-name">Burris, H.</span>; <span class="NLM_string-name">Le, D. T.</span>; <span class="NLM_string-name">Hollebecque, A.</span>; <span class="NLM_string-name">Steeghs, N.</span>; <span class="NLM_string-name">Delord, J.-P.</span>; <span class="NLM_string-name">Hilton, J.</span>; <span class="NLM_string-name">Barnhart, B.</span>; <span class="NLM_string-name">Sega, E.</span>; <span class="NLM_string-name">Sanghavi, K.</span>; <span class="NLM_string-name">Klippel, A.</span>; <span class="NLM_string-name">Hedvat, C.</span>; <span class="NLM_string-name">Hilt, E.</span>; <span class="NLM_string-name">Donovan, M.</span>; <span class="NLM_string-name">Gipson, A.</span>; <span class="NLM_string-name">Basciano, P.</span>; <span class="NLM_string-name">Postelnek, J.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Perez, R. P.</span>; <span class="NLM_string-name">Carvajal, R. D.</span></span> <span> </span><span class="NLM_article-title">Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors</span>. In  <i>Cancer Research</i>; <span class="NLM_publisher-name">AACR</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">78</span> (13 Suppl).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1538-7445.AM2018-CT180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+L.+Siu&author=H.+Burris&author=D.+T.+Le&author=A.+Hollebecque&author=N.+Steeghs&author=J.-P.+Delord&author=J.+Hilton&author=B.+Barnhart&author=E.+Sega&author=K.+Sanghavi&author=A.+Klippel&author=C.+Hedvat&author=E.+Hilt&author=M.+Donovan&author=A.+Gipson&author=P.+Basciano&author=J.+Postelnek&author=Y.+Zhao&author=R.+P.+Perez&author=R.+D.+Carvajal&title=Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-CT180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-CT180%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DAbstract%2520CT180%253A%2520Preliminary%2520phase%25201%2520profile%2520of%2520BMS-986179%252C%2520an%2520anti-CD73%2520antibody%252C%2520in%2520combination%2520with%2520nivolumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26btitle%3DCancer%2520Research%26pub%3DAACR%26date%3D2018%26volume%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, R. G. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. W.</span></span> <span> </span><span class="NLM_article-title">An exceptionally potent inhibitor of human CD73</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3331</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=3331-3334&author=C.+E.+Bowmanauthor=R.+G.+d.+Silvaauthor=A.+Phamauthor=S.+W.+Young&title=An+exceptionally+potent+inhibitor+of+human+CD73&doi=10.1021%2Facs.biochem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An Exceptionally Potent Inhibitor of Human CD73</span></div><div class="casAuthors">Bowman, Christine E.; da Silva, Rafael G.; Pham, Amber; Young, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3331-3334</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported the initiation of a Phase I clin. trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973).  We undertook a detailed kinetic anal. of the interaction between human CD73 and AB680 to det. the mode of inhibition.  We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a Ki of 5 pM.  Clin. candidates of this potency are uncommon and deserve special consideration during lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGag3hdjGb7Vg90H21EOLACvtfcHk0lg4vlHsDsN0lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O&md5=ad600cb74b603c4daa3c5f002e1c5f4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DC.%2BE.%26aulast%3DSilva%26aufirst%3DR.%2BG.%2Bd.%26aulast%3DPham%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BW.%26atitle%3DAn%2520exceptionally%2520potent%2520inhibitor%2520of%2520human%2520CD73%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D3331%26epage%3D3334%26doi%3D10.1021%2Facs.biochem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobelmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losenkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irjala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationship of purine and pyrimidine nucleotides as ecto-5′-nucleotidase (CD73) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3677-3695&author=A.+Junkerauthor=C.+Rennauthor=C.+Dobelmannauthor=V.+Namasivayamauthor=S.+Jainauthor=K.+Losenkovaauthor=H.+Irjalaauthor=S.+Ducaauthor=R.+Balasubramanianauthor=S.+Chakrabortyauthor=F.+B%C3%B6rgelauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Structure%E2%80%93activity+relationship+of+purine+and+pyrimidine+nucleotides+as+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+inhibitors&doi=10.1021%2Facs.jmedchem.9b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Junker, Anna; Renn, Christian; Dobelmann, Clemens; Namasivayam, Vigneshwaran; Jain, Shanu; Losenkova, Karolina; Irjala, Heikki; Duca, Sierra; Balasubramanian, Ramachandran; Chakraborty, Saibal; Borgel, Frederik; Zimmermann, Herbert; Yegutkin, Gennady G.; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3677-3695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cluster of differentiation 73 (CD73) converts AMP to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment.  We synthesized 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogs, and compared their CD73 inhibitory potencies.  In the adenine series, most ribose modifications and 1-deaza and 3-deaza were detrimental, but 7-deaza was tolerated.  Uracil substitution with N3-Me, but not larger groups, or 2-thio, was tolerated. 1,2-Diphosphono-Et modifications were not tolerated.  N4-(Aryl)alkyloxy-cytosine derivs., esp. with bulky benzyloxy substituents, showed increased potency.  Among the most potent inhibitors were the 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of 5-fluorouridine, N4-benzoyl-cytidine, N4-[O-(4-benzyloxy)]-cytidine, and N4-[O-(4-naphth-2-ylmethyloxy)]-cytidine (Ki values 5-10 nM at human CD73).  Selected compds. tested at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, esp. those with large nucleobase substituents.  These nucleotide analogs are among the most potent CD73 inhibitors reported and may be considered for development as parenteral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmqsc2IyljbVg90H21EOLACvtfcHk0lhV08HxISnRDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D&md5=374b1862da172f31363dc74a4545661a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00164%26sid%3Dliteratum%253Aachs%26aulast%3DJunker%26aufirst%3DA.%26aulast%3DRenn%26aufirst%3DC.%26aulast%3DDobelmann%26aufirst%3DC.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DLosenkova%26aufirst%3DK.%26aulast%3DIrjala%26aufirst%3DH.%26aulast%3DDuca%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520of%2520purine%2520and%2520pyrimidine%2520nucleotides%2520as%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3677%26epage%3D3695%26doi%3D10.1021%2Facs.jmedchem.9b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">α,β-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5′-nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6248-6263&author=S.+Bhattaraiauthor=M.+Freundliebauthor=J.+Pippelauthor=A.+Meyerauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=N.+Str%C3%A4terauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCller&title=%CE%B1%2C%CE%B2-Methylene-ADP+%28AOPCP%29+derivatives+and+analogues%3A+development+of+potent+and+selective+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Bhattarai, Sanjay; Freundlieb, Marianne; Pippel, Jan; Meyer, Anne; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; Yegutkin, Gennady G.; Straeter, Norbert; El-Tayeb, Ali; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics.  The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivs. modified in various positions were prepd.  Products were tested at rat recombinant eN.  6-(Ar)alkylamino substitution led to the largest improvement in potency.  N6-Monosubstitution was superior to sym. N6,N6-disubstitution.  The most potent inhibitors were N6-(4-chlorobenzyl)- (PSB-12441, Ki 7.23 nM), N6-phenylethyl- (PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] I (PSB-12379, Ki 9.03 nM).  Replacement of the 6-NH group in I by O (PSB-12431) or S (PSB-12553) yielded equally potent inhibitors (9.20 nM and 9.50 nM, resp.).  Selected compds. investigated at the human enzyme did not show species differences; they displayed high selectivity vs. other ecto-nucleotidases and ADP-activated P2Y receptors.  Moreover, high metabolic stability was obsd.  These compds. represent the most potent eN inhibitors described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmxberqVtKLVg90H21EOLACvtfcHk0ljN1Z97QVKRiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF&md5=5f1231a662dd86345b9d3803f1c4e716</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00802%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D%25CE%25B1%252C%25CE%25B2-Methylene-ADP%2520%2528AOPCP%2529%2520derivatives%2520and%2520analogues%253A%2520development%2520of%2520potent%2520and%2520selective%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6248%26epage%3D6263%26doi%3D10.1021%2Facs.jmedchem.5b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strater, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">X-Ray co-crystal structure guides the way to subnanomolar competitive ecto-5′-nucleotidase (CD73) inhibitors for cancer immunotherapy</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">1900075</span> <span class="refDoi"> DOI: 10.1002/adtp.201900075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fadtp.201900075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=S.+Bhattaraiauthor=J.+Pippelauthor=A.+Meyerauthor=M.+Freundliebauthor=C.+Schmiesauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=A.+El-Tayebauthor=G.+G.+Yegutkinauthor=N.+Straterauthor=C.+E.+M%C3%BCller&title=X-Ray+co-crystal+structure+guides+the+way+to+subnanomolar+competitive+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+inhibitors+for+cancer+immunotherapy&doi=10.1002%2Fadtp.201900075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">X-Ray Co-Crystal Structure Guides the Way to Subnanomolar Competitive Ecto-5'-Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Bhattarai, Sanjay; Pippel, Jan; Meyer, Anne; Freundlieb, Marianne; Schmies, Constanze; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; El-Tayeb, Ali; Yegutkin, Gennady G.; Straeter, Norbert; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Therapeutics (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1900075</span>CODEN:
                <span class="NLM_cas:coden">ATWGAP</span>;
        ISSN:<span class="NLM_cas:issn">2366-3987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (CD73, EC 3.1.3.5) catalyzes the extracellular hydrolysis of AMP yielding adenosine, which induces immunosuppression, angiogenesis, metastasis, and proliferation of cancer cells.  CD73 inhibition is therefore proposed as a novel strategy for cancer (immuno)therapy, and CD73 antibodies are currently undergoing clin. trials.  Despite considerable efforts, the development of small mol. CD73 inhibitors has met with limited success.  To develop a suitable drug candidate, a high resoln. (2.05 Å) co-crystal structure of the CD73 inhibitor PSB-12379, a nucleotide analog, in complex with human CD73 is detd.  This allows the rational design and development of a novel inhibitor (PSB-12489) with subnanomolar inhibitory potency toward human and rat CD73, high selectivity, as well as high metabolic stability.  A co-crystal structure of PSB-12489 with CD73 (1.85 Å) reveals the interactions responsible for increased potency.  PSB-12489 is the most potent CD73 inhibitor to date representing a powerful tool compd. and novel lead structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2d7CK7UeK87Vg90H21EOLACvtfcHk0ljN1Z97QVKRiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurnF&md5=dd24eb1f7b34714c513a8f4523b7d3d5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201900075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201900075%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DSchmies%26aufirst%3DC.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStrater%26aufirst%3DN.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DX-Ray%2520co-crystal%2520structure%2520guides%2520the%2520way%2520to%2520subnanomolar%2520competitive%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DAdv.%2520Ther.%26date%3D2019%26volume%3D2%26doi%3D10.1002%2Fadtp.201900075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1021/jm901851t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901851t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2076-2086&author=Y.+Baqiauthor=S.-Y.+Leeauthor=J.+Iqbalauthor=P.+Ripphausenauthor=A.+Lehrauthor=A.+B.+Scheiffauthor=H.+Zimmermannauthor=J.+Bajorathauthor=C.+E.+M%C3%BCller&title=Development+of+potent+and+selective+inhibitors+of+ecto-5%E2%80%B2-nucleotidase+based+on+an+anthraquinone+scaffold&doi=10.1021%2Fjm901851t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Inhibitors of ecto-5'-Nucleotidase Based on an Anthraquinone Scaffold</span></div><div class="casAuthors">Baqi, Younis; Lee, Sang-Yong; Iqbal, Jamshed; Ripphausen, Peter; Lehr, Anne; Scheiff, Anja B.; Zimmermann, Herbert; Bajorath, Jurgen; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2076-2086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels.  EN inhibitors have potential as novel drugs, for example, for the treatment of cancer.  In the present study, we synthesized and investigated a series of 55 anthraquinone derivs. as potential inhibitors of eN, 11 of which are novel compds. and another 11 of which had previously been described but have now been synthesized by an improved method.  We identified several potent inhibitors of rat eN.  The most potent compds. were 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0952, Ki = 260 nM) and 1-amino-4-[2-anthracenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0963, 150 nM), with the latter being the most potent eN inhibitor described to date.  Selected compds. were further characterized and found to exhibit a competitive mechanism of inhibition.  Investigations of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compd. PSB-0952 exhibited the highest degree of selectivity (>150-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJKU5mUcJOrVg90H21EOLACvtfcHk0lgdFYu9C5bwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D&md5=b9e4c62d6423478d5cd4d95f702f689e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901851t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901851t%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DLehr%26aufirst%3DA.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DDevelopment%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%2520based%2520on%2520an%2520anthraquinone%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2076%26epage%3D2086%26doi%3D10.1021%2Fjm901851t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sévigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Identification of sulfonic acids as efficient ecto-5′-nucleotidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.ejmech.2013.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=24215819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=685-691&author=J.+Iqbalauthor=A.+Saeedauthor=R.+Razaauthor=A.+Matinauthor=A.+Hameedauthor=N.+Furtmannauthor=J.+Leckaauthor=J.+S%C3%A9vignyauthor=J.+Bajorath&title=Identification+of+sulfonic+acids+as+efficient+ecto-5%E2%80%B2-nucleotidase+inhibitors&doi=10.1016%2Fj.ejmech.2013.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors</span></div><div class="casAuthors">Iqbal, Jamshed; Saeed, Aamer; Raza, Rabia; Matin, Abdul; Hameed, Abdul; Furtmann, Norbert; Lecka, Joanna; Sevigny, Jean; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (CD73) is well known for its implication in cancer.  Inhibition of ecto-5'-nucleotidases is thought to provide an attractive approach to cancer therapy.  This study identifies sulfonic acid compds. as efficient inhibitors of ecto-5'-nucleotidases.  The compds. were tested against recombinant human and rat ecto-5'-nucleotidases.  The most potent new sulfonic acid inhibitor 6-amino-4-hydroxynaphthalene-2-sulfonic acid (1) of ecto-5'-nucleotidase had an IC50 of 1.32 ± 0.09 μM for the human and 10.4 ± 3.3 μM for the rat enzyme.  Generally, all compds. were more active against the human enzyme.  Plausible binding mode models were developed for this new class of inhibitors.  Furthermore, several sulfonic acid inhibitors were efficient cytotoxic agents when tested on H157 cancer cell lines.  Hence, new ecto-5'-nucleotidases inhibitors displayed significant potential for further development as compds. for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTaWZD3jljR7Vg90H21EOLACvtfcHk0lgdFYu9C5bwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqur3J&md5=60a9a0b81f2acdb7f272ac3cf3a4c872</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DA.%26aulast%3DRaza%26aufirst%3DR.%26aulast%3DMatin%26aufirst%3DA.%26aulast%3DHameed%26aufirst%3DA.%26aulast%3DFurtmann%26aufirst%3DN.%26aulast%3DLecka%26aufirst%3DJ.%26aulast%3DS%25C3%25A9vigny%26aufirst%3DJ.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520sulfonic%2520acids%2520as%2520efficient%2520ecto-5%25E2%2580%25B2-nucleotidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D685%26epage%3D691%26doi%3D10.1016%2Fj.ejmech.2013.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies novel sulfonamide inhibitors of ecto-5′-nucleotidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6576</span>– <span class="NLM_lpage">6581</span>, <span class="refDoi"> DOI: 10.1021/jm300658n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300658n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6576-6581&author=P.+Ripphausenauthor=M.+Freundliebauthor=A.+Brunschweigerauthor=H.+Zimmermannauthor=C.+E.+M%C3%BCllerauthor=J.+Bajorath&title=Virtual+screening+identifies+novel+sulfonamide+inhibitors+of+ecto-5%E2%80%B2-nucleotidase&doi=10.1021%2Fjm300658n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto-5'-Nucleotidase</span></div><div class="casAuthors">Ripphausen, Peter; Freundlieb, Marianne; Brunschweiger, Andreas; Zimmermann, Herbert; Mueller, Christa E.; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6576-6581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metallophosphoesterase that is implicated in the control of purinergic receptor signaling and a no. of assocd. therapeutically relevant effects.  Currently, only very few compds., including ADP, its more stable analog α,β-methylene-ADP, ATP, and anthraquinone derivs. are known to inhibit this enzyme.  In the search for inhibitors with more drug-like properties, we applied a model structure-based virtual screening approach augmented by chem. similarity searching.  On the basis of this anal., 51 candidate compds. were finally selected for exptl. evaluation.  A total of 13 of these mols. were confirmed to have competitive inhibitory activity.  The most potent inhibitor, 6-chloro-2-oxo-N-(4-sulfamoylphenyl)-2H-chromene-3-carboxylic acid amide (17), showed an IC50 value of 1.90 μM.  In contrast to the nucleotide- and anthraquinone-derived antagonists, the newly identified competitive inhibitors are uncharged at physiol. pH values, possess a drug-like structure, and are structurally distinct from known active compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0goFQAkEQe7Vg90H21EOLACvtfcHk0lgflF8_XI15hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D&md5=106abecfd7469af4be3acfb516d237f5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm300658n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300658n%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DVirtual%2520screening%2520identifies%2520novel%2520sulfonamide%2520inhibitors%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6576%26epage%3D6581%26doi%3D10.1021%2Fjm300658n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viviani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccirillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, A. T. T. D.</span></span> <span> </span><span class="NLM_article-title">Virtual screening approach for the identification of hydroxamic acids as novel human ecto-5′-nucleotidase inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=621-630&author=L.+Vivianiauthor=E.+Piccirilloauthor=H.+Ulrichauthor=A.+T.+T.+D.+Amaral&title=Virtual+screening+approach+for+the+identification+of+hydroxamic+acids+as+novel+human+ecto-5%E2%80%B2-nucleotidase+inhibitors&doi=10.1021%2Facs.jcim.9b00884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5'-Nucleotidase Inhibitors</span></div><div class="casAuthors">Viviani, Lucas G.; Piccirillo, Erika; Ulrich, Henning; Amaral, Antonia T.-do</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">621-630</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT, CD73) is a zinc-binding metallophosphatase that plays a key role in extracellular purinergic pathways, being implicated in several physiol. and pathophysiol. processes, such as immune homeostasis, inflammation, and tumor progression.  As such, it has been recognized as a promising biol. target for many diseases, including cancer, infections, and autoimmune diseases.  Despite its importance, so far only a few inhibitors of this target enzyme are known, most of which are not suitable as drug candidates.  Here, we aimed to search for hydroxamic acid-contg. compds. as potential human ecto-5'-NT inhibitors, since this group is known to be a strong zinc chelator.  To this end, we performed a hierarchical virtual screening (VS) search consisting of three consecutive steps (filtering for compds. bearing a hydroxamic acid group, shape-based matching, and docking followed by visual inspection), which were applied to screen the ZINC-14 database ("all purchasable subset").  Out of 25 compds. selected by this VS protocol, 12 were acquired and further submitted to enzymic assays for VS exptl. validation.  Four of them (i.e., 33.3%) were found to inhibit human ecto-5'-NT in the low micromolar range.  The most potent one showed an IC50 value of 6.2 ± 1.0μM.  All identified inhibitors satisfy drug-like criteria and provide novel scaffolds to be explored in further hit-to-lead optimization steps.  Furthermore, to the best of our knowledge, they are the first hydroxamic acid-contg. inhibitors of human ecto-5'-NT described so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4Qiu0YGYKLVg90H21EOLACvtfcHk0lgflF8_XI15hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns7zJ&md5=e27572f72ce511b572a671b2aa4b6448</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00884%26sid%3Dliteratum%253Aachs%26aulast%3DViviani%26aufirst%3DL.%26aulast%3DPiccirillo%26aufirst%3DE.%26aulast%3DUlrich%26aufirst%3DH.%26aulast%3DAmaral%26aufirst%3DA.%2BT.%2BT.%2BD.%26atitle%3DVirtual%2520screening%2520approach%2520for%2520the%2520identification%2520of%2520hydroxamic%2520acids%2520as%2520novel%2520human%2520ecto-5%25E2%2580%25B2-nucleotidase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2020%26volume%3D60%26spage%3D621%26epage%3D630%26doi%3D10.1021%2Facs.jcim.9b00884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahimova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordheim, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrottes5, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaloin, L.</span></span> <span> </span><span class="NLM_article-title">Identification of allosteric inhibitors of the ecto-5′-nucleotidase (CD73) targeting the dimer interface</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1005943</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1371%2Fjournal.pcbi.1005943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29377887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ohs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=R.+Rahimovaauthor=S.+Fontanelauthor=C.+Lionneauthor=L.+P.+Jordheimauthor=S.+Peyrottes5author=L.+Chaloin&title=Identification+of+allosteric+inhibitors+of+the+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+targeting+the+dimer+interface&doi=10.1371%2Fjournal.pcbi.1005943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface</span></div><div class="casAuthors">Rahimova, Rahila; Fontanel, Simon; Lionne, Corinne; Jordheim, Lars Peter; Peyrottes, Suzanne; Chaloin, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005943/1-e1005943/23</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The ecto-5'-nucleotidase CD73 plays an important role in the prodn. of immune-suppressive adenosine in tumor micro-environment, and has become a validated drug target in oncol.  Indeed, the anticancer immune response involves extracellular ATP to block cell proliferation through T-cell activation.  However, in the tumor micro-environment, two extracellular membrane-bound enzymes (CD39 and CD73) are overexpressed and hydrolyze efficiently ATP into AMP then further into immune-suppressive adenosine.  To circumvent the impact of CD73-generated adenosine, we applied an original bioinformatics approach to identify new allosteric inhibitors targeting the dimerization interface of CD73, which should impair the large dynamic motions required for its enzymic function.  Several hit compds. issued from virtual screening campaigns showed a potent inhibition of recombinant CD73 with inhibition consts. in the low micromolar range and exhibited a non-competitive inhibition mode.  The structure-activity relationships studies indicated that several amino acid residues (D366, H456, K471, Y484 and E543 for polar interactions and G453-454, I455, H456, L475, V542 and G544 for hydrophobic contacts) located at the dimerization interface are involved in the tight binding of hit compds. and likely contributed for their inhibitory activity.  Overall, the gathered information will guide the upcoming lead optimization phase that may lead to potent and selective CD73 inhibitors, able to restore the anticancer immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUJI47sJqgLVg90H21EOLACvtfcHk0lj2bL2_JvWV8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ohs7nF&md5=e4374ddf2d0ff143d218fb0cea997238</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005943%26sid%3Dliteratum%253Aachs%26aulast%3DRahimova%26aufirst%3DR.%26aulast%3DFontanel%26aufirst%3DS.%26aulast%3DLionne%26aufirst%3DC.%26aulast%3DJordheim%26aufirst%3DL.%2BP.%26aulast%3DPeyrottes5%26aufirst%3DS.%26aulast%3DChaloin%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520allosteric%2520inhibitors%2520of%2520the%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520targeting%2520the%2520dimer%2520interface%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1005943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="note"><p class="first last">We also made a number of derivatives based on the sulfone phosphonic acid <b>14</b>. However, it was difficult to improve the potency further, and this particular series was not pursued further.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="note"><p class="first last">The stereochemistry of <b>32</b> and <b>35</b> were confirmed by their co-crystal structure with CD73. Data for co-crystal structure with <b>32</b> was not shown. Data for co-crystal structure with <b>35</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Satué, M.</span>; <span class="NLM_string-name">Rodríguez-Martínez, A.</span>; <span class="NLM_string-name">Trapero, C.</span></span> <span> </span><span class="NLM_article-title">In situ identification of ectoenzymes involved in the hydrolysis of extracellular nucleotides</span>. In  <i>Immunohistochemistry</i>; <span class="NLM_publisher-name">IntechOpen</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-13&author=M.+Mart%C3%ADn-Satu%C3%A9&author=A.+Rodr%C3%ADguez-Mart%C3%ADnez&author=C.+Trapero&title=Immunohistochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-Satu%25C3%25A9%26aufirst%3DM.%26atitle%3DIn%2520situ%2520identification%2520of%2520ectoenzymes%2520involved%2520in%2520the%2520hydrolysis%2520of%2520extracellular%2520nucleotides%26btitle%3DImmunohistochemistry%26pub%3DIntechOpen%26date%3D2019%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelsma, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeuwenoord, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D. V.</span></span> <span> </span><span class="NLM_article-title">Combined phosphoramidite-phosphodiester reagents for the synthesis of methylene bisphosphonates</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2955</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1002/anie.201611878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fanie.201611878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1WitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=2955-2959&author=S.+B.+Engelsmaauthor=N.+J.+Meeuwenoordauthor=H.+S.+Overkleeftauthor=G.+A.+van+der+Marelauthor=D.+V.+Filippov&title=Combined+phosphoramidite-phosphodiester+reagents+for+the+synthesis+of+methylene+bisphosphonates&doi=10.1002%2Fanie.201611878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Phosphoramidite-Phosphodiester Reagents for the Synthesis of Methylene Bisphosphonates</span></div><div class="casAuthors">Engelsma, Sander B.; Meeuwenoord, Nico J.; Overkleeft, Hermen S.; van der Marel, Gijsbert A.; Filippov, Dmitri V.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2955-2959</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new class of phosphinylmethylphosphonate reagents has been developed to enable the controlled synthesis of methylene bisphosphonate mono- and diesters.  Condensation of such reagents with an alc. of choice through azole-mediated phosphoramidite chem. followed by in situ oxidn. provides orthogonally protected methylene bisphosphonate tetraesters.  Global deprotection of the tetraester leads to terminal methylene bisphosphonates.  Alternatively, selective deprotection at the terminal phosphonate followed by a condensation between the acquired methylene bisphosphonate triester and a second alc. leads to methylene bisphosphonates diesters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm7pN0PJ86UrVg90H21EOLACvtfcHk0lj2bL2_JvWV8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1WitLw%253D&md5=1d6ac262cb87df558e72c18b4760a551</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201611878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201611878%26sid%3Dliteratum%253Aachs%26aulast%3DEngelsma%26aufirst%3DS.%2BB.%26aulast%3DMeeuwenoord%26aufirst%3DN.%2BJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DFilippov%26aufirst%3DD.%2BV.%26atitle%3DCombined%2520phosphoramidite-phosphodiester%2520reagents%2520for%2520the%2520synthesis%2520of%2520methylene%2520bisphosphonates%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D2955%26epage%3D2959%26doi%3D10.1002%2Fanie.201611878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karschner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of LuxS inhibitors targeting bacterial cell-cell communication</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1021/ol049182i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol049182i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Gmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=3043-3046&author=J.+F.+Alfaroauthor=T.+Zhangauthor=D.+P.+Wynnauthor=E.+L.+Karschnerauthor=Z.+S.+Zhou&title=Synthesis+of+LuxS+inhibitors+targeting+bacterial+cell-cell+communication&doi=10.1021%2Fol049182i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of LuxS Inhibitors Targeting Bacterial Cell-Cell Communication</span></div><div class="casAuthors">Alfaro, Joshua F.; Zhang, Tiao; Wynn, DonRaphael P.; Karschner, Erin L.; Zhou, Zhaohui Sunny</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3043-3046</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quorum sensing is a process by which bacteria sense cell d.  This cell-cell communication process is mediated by autoinducers.  A cross-species messenger, autoinducer-2 (AI-2) is produced from S-ribosyl-L-homocysteine by the LuxS enzyme.  A proposed mechanism for LuxS is an aldose-ketose isomerization of S-ribosylhomocysteine followed by a β-elimination.  The authors report the synthesis of two substrate analogs, S-anhydroribosyl-L-homocysteine and S-homoribosyl-L-cysteine, which prevent the initial and final step of the mechanism, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUGiHRMIlqTbVg90H21EOLACvtfcHk0lg8mRdu9b6FMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Gmt7w%253D&md5=5219e1080cdb42615d662cd6c3c5fb06</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fol049182i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049182i%26sid%3Dliteratum%253Aachs%26aulast%3DAlfaro%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWynn%26aufirst%3DD.%2BP.%26aulast%3DKarschner%26aufirst%3DE.%2BL.%26aulast%3DZhou%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520of%2520LuxS%2520inhibitors%2520targeting%2520bacterial%2520cell-cell%2520communication%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D3043%26epage%3D3046%26doi%3D10.1021%2Fol049182i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':[],'ref44':[],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jenna L. Jeffrey, Kenneth V. Lawson, <span class="NLM_string-name hlFld-ContribAuthor">Jay P. Powers</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13444-13465. <a href="https://doi.org/10.1021/acs.jmedchem.0c01044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01044%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BMetabolism%252Bof%252BExtracellular%252BNucleotides%252Bvia%252BInhibition%252Bof%252BEctonucleotidases%252BCD73%252Band%252BCD39%26aulast%3DJeffrey%26aufirst%3DJenna%2BL.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17062020%26date%3D15092020%26date%3D13082020%26volume%3D63%26issue%3D22%26spage%3D13444%26epage%3D13465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karel P.  Alcedo</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Bowser</span>, <span class="hlFld-ContribAuthor ">Natasha T.  Snider</span>. </span><span class="cited-content_cbyCitation_article-title">The elegant complexity of mammalian ecto-5′-nucleotidase (CD73). </span><span class="cited-content_cbyCitation_journal-name">Trends in Cell Biology</span><span> <strong>2021,</strong> <em>187 </em><a href="https://doi.org/10.1016/j.tcb.2021.05.008" title="DOI URL">https://doi.org/10.1016/j.tcb.2021.05.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tcb.2021.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tcb.2021.05.008%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cell%2520Biology%26atitle%3DThe%252Belegant%252Bcomplexity%252Bof%252Bmammalian%252Becto-5%2525E2%252580%2525B2-nucleotidase%252B%252528CD73%252529%26aulast%3DAlcedo%26aufirst%3DKarel%2BP.%26date%3D2021%26volume%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Nocentini</span>, <span class="hlFld-ContribAuthor ">Clemente  Capasso</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>22 </em>, 1-10. <a href="https://doi.org/10.1080/13543776.2021.1923694" title="DOI URL">https://doi.org/10.1080/13543776.2021.1923694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1923694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1923694%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252BCD73%252Binhibitors%252Bfor%252Bthe%252Bimmunotherapy%252Bof%252Bcancer%25253A%252Ba%252Bpatent%252Band%252Bliterature%252Breview%252B%2525282017%2525E2%252580%252593present%252529%26aulast%3DNocentini%26aufirst%3DAlessio%26date%3D2021%26date%3D2021%26volume%3D22%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana Maria Oliveira  Battastini</span>, <span class="hlFld-ContribAuthor ">Fabricio  Figueiró</span>, <span class="hlFld-ContribAuthor ">Daniela Bitencourt Rosa  Leal</span>, <span class="hlFld-ContribAuthor ">Pedro Henrique  Doleski</span>, <span class="hlFld-ContribAuthor ">Maria Rosa Chitolina  Schetinger</span>. </span><span class="cited-content_cbyCitation_article-title">CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.633603" title="DOI URL">https://doi.org/10.3389/fphar.2021.633603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.633603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.633603%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DCD39%252Band%252BCD73%252Bas%252BPromising%252BTherapeutic%252BTargets%25253A%252BWhat%252BCould%252BBe%252Bthe%252BLimitations%25253F%26aulast%3DBattastini%26aufirst%3DAna%2BMaria%2BOliveira%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Veronica  Salmaso</span>, <span class="hlFld-ContribAuthor ">R. Rama  Suresh</span>, <span class="hlFld-ContribAuthor ">Dilip K.  Tosh</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1039/D1MD00167A" title="DOI URL">https://doi.org/10.1039/D1MD00167A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00167A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00167A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DExpanding%252Bthe%252Brepertoire%252Bof%252Bmethanocarba%252Bnucleosides%252Bfrom%252Bpurinergic%252Bsignaling%252Bto%252Bdiverse%252Btargets%26aulast%3DJacobson%26aufirst%3DKenneth%2BA.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Discovery of OP-5244 (<b>35</b>) from structural modifications of AOPCP. Potency data are reported as the average of at least two independent experiments. <sup><i>a</i></sup>IC<sub>50</sub> value in a biochemical assay; <sup><i>b</i></sup>EC<sub>50</sub> values were generated by directly measuring the inhibition of the production of ADO through inhibition of CD73 activity from AMP in H1568 (NSCLC) cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structures of <b>12</b> with CD73 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9">7JV9</a>). The hydrogen bonds are labeled as dashed lines. Color codes for atoms: O, red; N, dark blue; C, light blue; Cl, green; P, orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of <b>35</b> with CD73 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8">7JV8</a>). The hydrogen bonds are labeled as dashed lines. Color codes for atoms: O, red; N, dark blue; C, light blue; Cl, green; P, orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Functional effects of <b>35</b> on human CD8<sup>+</sup> T cells. <b>35</b> rescued AMP-suppressed T-cell proliferation and cytokine production. Human PBMC-derived CD8<sup>+</sup> T cells were activated for 24 h with tetrameric anti-CD3/CD28/CD2 antibodies in serum-free media, labeled with CellTrace Violet and plated onto 96-well plates. Compounds and AMP were added at indicated concentrations, and cells were incubated for 96 h. Proliferating cells were quantified by flow cytometry. Cytokines in cell supernatants were measured by MSD ELISA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>35</b> inhibited ADO production completely in human and murine cancer cell lines (H1568 and EMT6, respectively) as well as in human CD8<sup>+</sup> T cells. A CD73-targeted antibody (MEDI9447) showed incomplete inhibition in H1568. ADO concentrations were quantitated using mass spectrometry. Here, 100% corresponds to dimethyl sulfoxide (DMSO)-treated cells, 0% corresponds to a very small amount of adenosine produced in the absence of cells. Single data point was collected for each compound concentration in one experiment. Each compound was tested at least 3 times. Shown is a representative experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0007.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative staining images of CD73 enzymatic activities post <b>35</b> treatment in E.G7-OVA consecutive tumor sections. CD73 activity was assessed by incubating tissue cryosections with the indicated concentrations of <b>35</b> in the presence of 1 mM AMP, followed by microscopic detection of the nucleotide-derived Pi as a brown precipitate. The first two boxes are negative and positive controls in which AMP was absent and present in E.G7-OVA tumor sections, respectively, in the absence of the CD73 inhibitor. AOPCP was used for comparison in this experiment. Bar is 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0008.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vivo</i> pharmacodynamics of <b>35</b> in the murine EMT6 model. BALB/c mice were subcutaneously implanted with minipumps with either <b>35</b> at a dose of 15 mg/kg/day or vehicle. (A) Tumor growth inhibition. (B) Significant ADO modulation. (C) Unbound plasma and tumor concentration on Day 9 and Day 13, respectively. *, <i>p</i> < 0.05 vs the vehicle group by Student’s <i>t</i>-test. ****, <i>p</i> < 0.0001 vs the vehicle group by Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0009.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> TIL pharmacodynamics of <b>35</b> in the E.G7-OVA model. C57BL6 mice were treated with <b>35</b> at 150 mg/kg, BID for 16 days, PO. (A) CD8<sup>+</sup>/Treg ratio in the tumor; (B) percentage of CD8<sup>+</sup> T cells in total CD45<sup>+</sup> leukocytes. *, <i>p</i> < 0.05 vs the vehicle group by the Mann–Whitney test. **, <i>p</i> < 0.01 vs the vehicle group by the Mann–Whitney test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>4</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SnCl<sub>4</sub>, 130 °C, 68%; (b) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 50 °C, 58%; (c) SnO(<i>n</i>-Bu)<sub>2</sub>, MeOH, 65 °C, 77%; (d) 2,2-dimethoxypropane, TsOH, <i>N</i>,<i>N</i>-dimethylformamide (DMF), 70 °C, 85%; (e) (i) <b>40</b> for <b>4</b>, <b>41</b> for <b>5</b>, <b>42</b> for <b>6</b>, 1<i>H</i>-imidazole-4,5-dicarbonitrile, <i>t</i>BuOOH, ACN; (ii) HCl in dioxane, water, (CF<sub>3</sub>)<sub>2</sub>CHOH, 56% over two steps for <b>4</b>; 41% over two steps for <b>5</b>; 13% over two steps for <b>6</b>.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of Compounds <b>7</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diethoxyphosphorylacetic acid, <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC), dichloromethane (DCM), 4-dimethylaminopyridine (DMAP), 61–85%; (b) (i) TMSBr, DCM; (ii) (CF<sub>3</sub>)<sub>2</sub>CHOH, 2 N HCl in dioxane, water, 24–35% over 2 steps; (c) (i) DCC, DMSO, trifluoroacetic acid (TFA), pyridine; (ii) NaBH(OAc)<sub>3</sub>, methylamine, HOAc, 1,2-dichloroethane (DCE), 16% over 2 steps; (d) PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), (PhO)<sub>2</sub>P(O)N<sub>3</sub>, THF, 60%; (e) PPh<sub>3</sub>, pyridine, NH<sub>4</sub>OH, 95%; (f) MsCl, Et<sub>3</sub>N, DMAP, DCM, 83%; (g) LDA, −78 °C, 30 min and then diethyl chlorophosphate, 24%.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, diethyl vinylphosphonate, 50 °C, 49%; (b) 80% HOAc, 85 °C; (c) Ac<sub>2</sub>O, DMAP, pyridine, 78% over 2 steps; (d) 4,6-dichloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, TMSOTf, 62%; (e) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 55 °C, 63%; (f) K<sub>2</sub>CO<sub>3</sub>, MeOH; (g) TMSBr, Et<sub>3</sub>N, 26% over 2 steps.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) HOAc, 85 °C; (ii) Ac<sub>2</sub>O, DMAP, pyridine, 57% over 2 steps; (b) SnCl<sub>4</sub>, ACN, room temperature (rt), 72%; (c) 2-chlorobenzylamine, Et<sub>3</sub>N, EtOH, 50 °C, 77%; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH; (e) 2,2-dimethoxypropane, TsOH, 78% over 2 steps; (f) (di<i>-tert</i>-butoxyphosphoryl) methyl trifluoromethanesulfonate, NaH; (g) 50% TFA, 11% over 2 steps.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0014.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Syntheses of Compounds <b>12</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, THF, −78 °C, (<i>t</i>-BuO)<sub>2</sub>P(O)CH<sub>2</sub>OTf, 49%; (b) HCl, (CF<sub>3</sub>)<sub>2</sub>CHOH, 26%; (c) DIAD, PPh<sub>3</sub>, AcSH, THF, 0 °C to rt; (d) DL-dithiothreitol, TEA, MeOH, rt, 98%; (e) NaH, (<i>t</i>-BuO)<sub>2</sub>P(O)CH<sub>2</sub>OTf, DMF, −10 °C to rt, 69%; (f) HCl, water, dioxane, (CF<sub>3</sub>)<sub>2</sub>CHOH, rt, 53%; (g) (i) oxone, MeOH, H<sub>2</sub>O, THF, rt; (ii) HCl, water, dioxane, (CF<sub>3</sub>)<sub>2</sub>CHOH, rt, 65%.</p></p></figure><figure data-id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0015.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Syntheses of Compounds <b>16</b>–<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, DMAP, ACN, 70%; (b) NH<sub>3</sub> in MeOH, 89%; (c) 2,2-dimethoxypropane, TsOH, DMF, 68%; (d) Rh<sub>2</sub>(OAc)<sub>4</sub>, ethyl 2-diazo-2-(diethoxyphosphoryl)acetate, toluene, 100 °C, 76%; (e) LiBH<sub>4</sub>, THF, 0 °C to rt, 62%; (f) (Im)<sub>2</sub>CS, Et<sub>3</sub>N, DCM, rt, 56%; (g) Bu<sub>3</sub>SnH, toluene, reflux, 31%; (h) TMSBr, Et<sub>3</sub>N, ACN, rt, and then 50% TFA, rt, 14–34%; (i) trimethyloxonium tetrafluoroborate, DCM, 1 h, 66%; (j) LiOH, THF.</p></p></figure><figure data-id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0016.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Compounds <b>24</b>–<b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, MeI, THF, 0 °C, 49%; (b) CaCl<sub>2</sub>, NaBH<sub>4</sub>, EtOH, rt, 81%; (c) TMSBr, ACN;, and then H<sub>2</sub>O, overnight, 19–40%; (d) DMP, DCM, rt, 62%; (e) dimethylamine, NaBH(OAc)<sub>3</sub>, DCE, rt, 53%; (f) methylamine, NaBH(OAc)<sub>3</sub>, DCE, rt, 61%; (g) TEA, MsCl, DCM, rt, 26%; (h) DIAD, PPh<sub>3</sub>, HSAc, THF, 0 °C to RT, 73%; (i) DL-dithiothreitol, TEA, MeOH, rt, 23%; (j) K<sub>2</sub>CO<sub>3</sub>, MeI, acetone, rt, 65%; (k) <i>m</i>CPBA, DCM, rt, 68%; (l) LiOH, THF, H<sub>2</sub>O, 93%; (m) (i) oxalyl chloride; (ii) TMSCHN<sub>2</sub>, silver benzoate, 50 °C; (iii) NaBH<sub>4</sub>, CaCl<sub>2</sub>.</p></p></figure><figure data-id="sch8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/medium/jm0c01086_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0017.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Syntheses of Compounds <b>34</b> and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c01086/20200918/images/large/jm0c01086_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01086&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MOMCl, NaHMDS, TBAI, THF, −15 °C, 91%; (b) NaBH<sub>4</sub>, CaCl<sub>2</sub>, EtOH, 0 °C to rt, 80%; (c) CHIRALPAK AD-H, 5% isopropyl alcohol (IPA)/hex isocratic, 41% isolated for <b>55a</b> and 41% for <b>55b</b>; (d) TMSBr, CH<sub>3</sub>CN, rt, H<sub>2</sub>O, ACN, rt, 39%; (e) (i) TMSBr, Et<sub>3</sub>N, ACN, rt; (ii) TFA/H<sub>2</sub>O (1:1), 65%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10184" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10184" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrobak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messaoudi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the CD73-adenosine axis in immuno-oncology</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.imlet.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.imlet.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29758241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2019&pages=31-39&author=D.+Allardauthor=P.+Chrobakauthor=B.+Allardauthor=N.+Messaoudiauthor=J.+Stagg&title=Targeting+the+CD73-adenosine+axis+in+immuno-oncology&doi=10.1016%2Fj.imlet.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the CD73-adenosine axis in immuno-oncology</span></div><div class="casAuthors">Allard, David; Chrobak, Pavel; Allard, Bertrand; Messaoudi, Nouredin; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine.  As such, they constitute crit. components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis.  With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses.  With early-phase clin. trials showing promising results, it is becoming increasingly important to decipher the distinct mechanisms-of-action of adenosine-targeting agents, identify patients that will benefit from these agents and rationally develop novel synergistic combinations.  Given the broad expression of ectonucleotidases and adenosine receptors, a better understanding of cell-specific roles will also be key for successful implementation of this new generation of immuno-oncol. therapeutics.  We here review the latest studies on the roles of CD73 and adenosine in cancer with a focus on cell-specific function.  We also discuss ongoing clin. trials and future avenues for adenosine-targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozzg498nnmnLVg90H21EOLACvtfcHk0liBw8-wnIpW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSku7fJ&md5=31694428ae1cf4c69448bc6ba310f31e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.imlet.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.imlet.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DChrobak%26aufirst%3DP.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DMessaoudi%26aufirst%3DN.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520CD73-adenosine%2520axis%2520in%2520immuno-oncology%26jtitle%3DImmunol.%2520Lett.%26date%3D2019%26volume%3D205%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.imlet.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cancer-derived adenosine: new therapeutic approaches</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F2159-8290.CD-14-0341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=25035124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=879-888&author=A.+Youngauthor=D.+Mittalauthor=J.+Staggauthor=M.+J.+Smyth&title=Targeting+cancer-derived+adenosine%3A+new+therapeutic+approaches&doi=10.1158%2F2159-8290.CD-14-0341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cancer-Derived Adenosine:New Therapeutic Approaches</span></div><div class="casAuthors">Young, Arabella; Mittal, Deepak; Stagg, John; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">879-888</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes.  Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development.  In contrast, A2A adenosine receptor antagonists have progressed to late-stage clin. trials in Parkinson disease, yet evidence of their role in oncol. is limited.  This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic.  Significance: High concns. of immunosuppressive adenosine have been reported in cancers, and adenosine is implicated in the growth of tumors.  This brief review delineates the current treatment strategies and tumor subtypes that will benefit from targeting adenosinergic pathways, alone or in combination with contemporary approaches to cancer treatment.  Cancer Discov; 4(8); 879-88. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfrzk2Na9ZJbVg90H21EOLACvtfcHk0liOpj6KhzvJCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlSrtbzO&md5=3a0c66b7081f996c52c7686034bf5797</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0341%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520cancer-derived%2520adenosine%253A%2520new%2520therapeutic%2520approaches%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D879%26epage%3D888%26doi%3D10.1158%2F2159-8290.CD-14-0341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2161</span>– <span class="NLM_lpage">2173</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.str.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23142347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2161-2173&author=K.+Knappauthor=M.+Zebischauthor=J.+Pippelauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCllerauthor=N.+Str%C3%A4ter&title=Crystal+structure+of+the+human+ecto-5%E2%80%B2-nucleotidase+%28CD73%29%3A+insights+into+the+regulation+of+purinergic+signaling&doi=10.1016%2Fj.str.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling</span></div><div class="casAuthors">Knapp, Karen; Zebisch, Matthias; Pippel, Jan; El-Tayeb, Ali; Mueller, Christa E.; Straeter, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2161-2173</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In vertebrates ecto-5'-nucleotidase (e5NT) catalyzes the hydrolysis of extracellular AMP to adenosine and represents the major control point for extracellular adenosine levels.  Due to its pivotal role for activation of P1 adenosine receptors, e5NT has emerged as an appealing drug target for treatment of inflammation, chronic pain, hypoxia, and cancer.  Crystal structures of the dimeric human e5NT reveal an extensive 114° conformational switch between the open and closed forms of the enzyme.  The dimerization interface is formed by the C-terminal domains and exhibits interchain motions of up to 13°.  Complex structures with adenosine and AMPCP indicate that structural control of the domain movement dets. the selectivity for monophosphate nucleotides.  Binding modes of nucleotide-derived and flavonoid-based compds. complexed to the C-terminal domain in the open form reveal an addnl. binding pocket of ∼210 Å3 that might be explored to design more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MOj4dwx2J7Vg90H21EOLACvtfcHk0lj90zVX3vt00Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gqu7jK&md5=e108171e8079cca4dd11483dfacb909e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnapp%26aufirst%3DK.%26aulast%3DZebisch%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%253A%2520insights%2520into%2520the%2520regulation%2520of%2520purinergic%2520signaling%26jtitle%3DStructure%26date%3D2012%26volume%3D20%26spage%3D2161%26epage%3D2173%26doi%3D10.1016%2Fj.str.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogan, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, C.</span></span> <span> </span><span class="NLM_article-title">5′-Nucleotidases and their new roles in NAD<sup>+</sup> and phosphate metabolism</span>. <i>New J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">845</span>– <span class="NLM_lpage">853</span>, <span class="refDoi"> DOI: 10.1039/b9nj00758j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1039%2Fb9nj00758j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12jtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=845-853&author=K.+L.+Boganauthor=C.+Brenner&title=5%E2%80%B2-Nucleotidases+and+their+new+roles+in+NAD%2B+and+phosphate+metabolism&doi=10.1039%2Fb9nj00758j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">5'-Nucleotidases and their new roles in NAD+ and phosphate metabolism</span></div><div class="casAuthors">Bogan, Katrina L.; Brenner, Charles</div><div class="citationInfo"><span class="NLM_cas:title">New Journal of Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">845-853</span>CODEN:
                <span class="NLM_cas:coden">NJCHE5</span>;
        ISSN:<span class="NLM_cas:issn">1144-0546</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  5'-Nucleotidase (EC 3.1.3.5) designates a set of enzymes, which catalyze the hydrolysis of ribonucleoside and deoxyribonucleoside monophosphates into the corresponding nucleosides plus orthophosphate.  5'-Nucleotidases are classified according to subcellular localization, nucleobase specificity, and their ability to hydrolyze deoxynucleoside monophosphate substrates.  Membrane-bound 5'-nucleotidases are ectoenzymes principally involved in salvage of extracellular nucleosides, and often display a preference toward adenosine monophosphate, thereby modulating signal transduction cascades involving purinergic receptors.  Cytosolic 5'-nucleotidases are members of the haloacid dehalogenase superfamily of enzymes, which are 2-domain proteins contg. a modified Rossman fold as the core and a variable cap structure.  Extracellular and intracellular 5'-nucleotidase activities participate in purine and pyrimidine salvage to support balanced synthesis of nucleotides, which is crit. for maintaining high-fidelity DNA replication.  While the prodn. of ribonucleosides from ribonucleotides by 5'-nucleotidases remains the most well studied function, it appears that the physiol. functions of these activities are more broad.  Indeed, Sdt1, previously termed a pyrimidine-specific 5'-nucleotidase, and Isn1, previously termed an IMP-specific 5'-nucleotidase, have recently been implicated in catabolic processes in NAD metab., and are regulated by the NAD precursor vitamin, nicotinic acid, glucose, and phosphate availability in the medium.  In addn., Usha, Pho5, Sdt1, and Phm8 are phosphate starvation-induced 5'-nucleotidases with diverse substrate specificities that liberate phosphate under phosphate starvation conditions.  Here, the authors review 5'-nucleotidase structure, catalytic mechanism, and substrate specificity, and focus on new biol. roles for these enzymes in nucleotide, NAD, and phosphate metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFsNps9U1JkLVg90H21EOLACvtfcHk0lh5cmGXPIq71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12jtbg%253D&md5=3c1920b322d1a06881f6619b9af2894b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2Fb9nj00758j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb9nj00758j%26sid%3Dliteratum%253Aachs%26aulast%3DBogan%26aufirst%3DK.%2BL.%26aulast%3DBrenner%26aufirst%3DC.%26atitle%3D5%25E2%2580%25B2-Nucleotidases%2520and%2520their%2520new%2520roles%2520in%2520NAD%252B%2520and%2520phosphate%2520metabolism%26jtitle%3DNew%2520J.%2520Chem.%26date%3D2010%26volume%3D34%26spage%3D845%26epage%3D853%26doi%3D10.1039%2Fb9nj00758j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghalamfarsa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazemi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohseni, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojjat-Farsangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadidi-Niaragh, F.</span></span> <span> </span><span class="NLM_article-title">CD73 as a potential opportunity for cancer immunotherapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1080/14728222.2019.1559829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1080%2F14728222.2019.1559829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30556751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=127-142&author=G.+Ghalamfarsaauthor=M.+H.+Kazemiauthor=S.+R.+Mohseniauthor=A.+Masjediauthor=M.+Hojjat-Farsangiauthor=G.+Aziziauthor=M.+Yousefiauthor=F.+Jadidi-Niaragh&title=CD73+as+a+potential+opportunity+for+cancer+immunotherapy&doi=10.1080%2F14728222.2019.1559829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 as a potential opportunity for cancer immunotherapy</span></div><div class="casAuthors">Ghalamfarsa, Ghasem; Kazemi, Mohammad Hossein; Raoofi Mohseni, Sahar; Masjedi, Ali; Hojjat-Farsangi, Mohammad; Azizi, Gholamreza; Yousefi, Mehdi; Jadidi-Niaragh, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-142</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer cells apply various mechanisms to induce and enhance immune escape.  The complex network of immune-response modulating factors in the tumor microenvironment is a reason for the difficulties encountered when attempting to treat many cancers.  Adenosine is a potent immune-modulating factor that can be generated through the degrdn. of ATP by cooperative action of NTPDase1 (CD39) and ecto-5'-nucleotidase (CD73) mols.  Overexpression of CD73 on tumor and immune cells leads to the presence of a high concn. of this factor in the tumor region.  Upregulation of CD73 is assocd. with the overprodn. of adenosine; it suppresses antitumor immune responses and helps proliferation, angiogenesis, and metastasis.: We attempt to clarify the immunobiol. of CD73 in assocn. with its role in cancer development, angiogenesis, and metastasis.  Moreover, we have reviewed CD73-targeting studies and highlighted CD73 as a potent target for cancer immunotherapy.: It seems that blockade of CD73, in combination with immune checkpoint inhibitors such as anti-PD-L1 and anti-CTLA-4, can be a novel promising therapeutic strategy that can be evaluated in the future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vOmOMwkrsbVg90H21EOLACvtfcHk0lh5cmGXPIq71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whsr7P&md5=582913bc842ed86cdec07f5aefa3461b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F14728222.2019.1559829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2019.1559829%26sid%3Dliteratum%253Aachs%26aulast%3DGhalamfarsa%26aufirst%3DG.%26aulast%3DKazemi%26aufirst%3DM.%2BH.%26aulast%3DMohseni%26aufirst%3DS.%2BR.%26aulast%3DMasjedi%26aufirst%3DA.%26aulast%3DHojjat-Farsangi%26aufirst%3DM.%26aulast%3DAzizi%26aufirst%3DG.%26aulast%3DYousefi%26aufirst%3DM.%26aulast%3DJadidi-Niaragh%26aufirst%3DF.%26atitle%3DCD73%2520as%2520a%2520potential%2520opportunity%2520for%2520cancer%2520immunotherapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2019%26volume%3D23%26spage%3D127%26epage%3D142%26doi%3D10.1080%2F14728222.2019.1559829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskó, G.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2016.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.trecan.2016.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27014745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=95-109&author=L.+Antonioliauthor=G.+G.+Yegutkinauthor=P.+Pacherauthor=C.+Blandizziauthor=G.+Hask%C3%B3&title=Anti-CD73+in+cancer+immunotherapy%3A+awakening+new+opportunities&doi=10.1016%2Fj.trecan.2016.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 in cancer immunotherapy: awakening new opportunities</span></div><div class="casAuthors">Antonioli Luca; Yegutkin Gennady G; Pacher Pal; Blandizzi Corrado; Hasko Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">Trends in cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-109</span>
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    </div><div class="casAbstract">In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology.  In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer.  Targeting CD73 results in favorable antitumor effects in pre-clinical models and combined treatments of CD73 blockade with other immune-modulating agents (i.e. anti-CTLA-4 mAb or anti-PD1 mAb) is particularly attractive.  Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 monoclonal antibodies, can potentially constitute a new biologic therapy for cancer patients.  In this review, we discuss the link between CD73 and the onset, development and spread of tumors, highlighting the potential value of this molecule as a target and as a novel biomarker in the context of personalized cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJjr-hcquXE36CEoQgWY10fW6udTcc2eahl-0BW3cLDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srovVKjtA%253D%253D&md5=c67d1d1472d80ac9b0f3f0753dc37196</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2016.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2016.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAntonioli%26aufirst%3DL.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DBlandizzi%26aufirst%3DC.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26atitle%3DAnti-CD73%2520in%2520cancer%2520immunotherapy%253A%2520awakening%2520new%2520opportunities%26jtitle%3DTrends%2520Cancer%26date%3D2016%26volume%3D2%26spage%3D95%26epage%3D109%26doi%3D10.1016%2Fj.trecan.2016.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitkovsky, M.</span></span> <span> </span><span class="NLM_article-title">A2A adenosine receptor may allow expansion of T Cells lacking effector functions in extracellular adenosine-rich microenvironments</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">5487</span>– <span class="NLM_lpage">5493</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0901247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.4049%2Fjimmunol.0901247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=19843934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ymtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=5487-5493&author=A.+Ohtaauthor=A.+Ohtaauthor=M.+Madasuauthor=R.+Kiniauthor=M.+Subramanianauthor=N.+Goelauthor=M.+Sitkovsky&title=A2A+adenosine+receptor+may+allow+expansion+of+T+Cells+lacking+effector+functions+in+extracellular+adenosine-rich+microenvironments&doi=10.4049%2Fjimmunol.0901247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments</span></div><div class="casAuthors">Ohta, Akio; Ohta, Akiko; Madasu, Manasa; Kini, Radhika; Subramanian, Meenakshi; Goel, Nipun; Sitkovsky, Michail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5487-5493</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunosuppressive signaling via the A2A adenosine receptor (A2AR) provokes a mechanism that protects inflamed tissues from excessive damage by immune cells.  This mechanism is desirable not only for preventing uncontrolled tissue destruction by overactive immune responses, but also for protecting tumor tissues from antitumor immune responses.  In aforementioned circumstances, T cell priming may occur in an environment contg. high concns. of extracellular adenosine.  To examine qual. changes in T cells activated in the presence of adenosine, the authors asked whether different functional responses of T cells are equally susceptible to A2AR agonists.  In this study, the authors demonstrate that A2AR signaling during T cell activation strongly inhibited development of cytotoxicity and cytokine-producing activity in T cells, whereas the inhibition of T cell proliferation was only marginal.  Both CD8+ and CD4+ T cells proliferated well in the presence of A2AR agonists, but their IFN-γ-producing activities were susceptible to inhibition by cAMP-elevating A2AR.  Importantly, the impaired effector functions were maintained in T cells even after removal of the A2AR agonist, reflecting T cell memory of the immunoregulatory effect of adenosine.  Thus, although the adenosine-rich environment may allow for the expansion of T cells, the functional activation of T cells may be critically impaired.  This physiol. mechanism could explain the inefficiency of antitumor T cells in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHI_3MeHtzmLVg90H21EOLACvtfcHk0ljlRx0D7EJDSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ymtb7K&md5=63ebc7c142b13b4c44755e4f848fc7a6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0901247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0901247%26sid%3Dliteratum%253Aachs%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMadasu%26aufirst%3DM.%26aulast%3DKini%26aufirst%3DR.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DGoel%26aufirst%3DN.%26aulast%3DSitkovsky%26aufirst%3DM.%26atitle%3DA2A%2520adenosine%2520receptor%2520may%2520allow%2520expansion%2520of%2520T%2520Cells%2520lacking%2520effector%2520functions%2520in%2520extracellular%2520adenosine-rich%2520microenvironments%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D5487%26epage%3D5493%26doi%3D10.4049%2Fjimmunol.0901247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarek, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-03-081646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1182%2Fblood-2007-03-081646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=17909080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=251-259&author=P.+E.+Zarekauthor=C.-T.+Huangauthor=E.+R.+Lutzauthor=J.+Kowalskiauthor=M.+R.+Hortonauthor=J.+Lindenauthor=C.+G.+Drakeauthor=J.+D.+Powell&title=A2A+receptor+signaling+promotes+peripheral+tolerance+by+inducing+T-cell+anergy+and+the+generation+of+adaptive+regulatory+T+cells&doi=10.1182%2Fblood-2007-03-081646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells</span></div><div class="casAuthors">Zarek, Paul E.; Huang, Ching-Tai; Lutz, Eric R.; Kowalski, Jeanne; Horton, Maureen R.; Linden, Joel; Drake, Charles G.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tissue-derived adenosine, acting via the adenosine A2A receptor (A2AR), is emerging as an important neg. regulator of T-cell function.  In this report, we demonstrate that A2AR stimulation not only inhibits the generation of adaptive effector T cells but also promotes the induction of adaptive regulatory T cells.  In vitro, antigen recognition in the setting of A2AR engagement induces T-cell anergy, even in the presence of costimulation.  T cells initially stimulated in the presence of an A2AR agonist fall to proliferate and produce interleukin-2 and interferon (IFN)-γ when rechallenged in the absence of A2AR stimulation.  Likewise, in an in vivo model of autoimmunity, tissue-derived adenosine promotes anergy and abrogates tissue destruction.  Indeed, A2AR stimulation inhibits interleukin-6 expression while enhancing the prodn. of transforming growth factor-β.  Accordingly, treating mice with A2AR agonists not only inhibits Th1 and Th17 effector cell generation but also promotes the generation of Foxp3+ and LAG-3+ regulatory T cells.  In this regard, A2AR agonists fail to prevent autoimmunity by LAG-3-/- clonotypic T cells, implicating an important role for LAG-3 in adenosine-mediated peripheral tolerance.  Overall, our findings demonstrate that extracellular adenosine stimulates the A2AR to promote long-term T-cell anergy and the generation of adaptive regulatory T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3fnOF_EePubVg90H21EOLACvtfcHk0lhbx7B_fUySrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVKhsQ%253D%253D&md5=922b3b55acab3235ee77381f08546bc7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-03-081646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-03-081646%26sid%3Dliteratum%253Aachs%26aulast%3DZarek%26aufirst%3DP.%2BE.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DLutz%26aufirst%3DE.%2BR.%26aulast%3DKowalski%26aufirst%3DJ.%26aulast%3DHorton%26aufirst%3DM.%2BR.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DA2A%2520receptor%2520signaling%2520promotes%2520peripheral%2520tolerance%2520by%2520inducing%2520T-cell%2520anergy%2520and%2520the%2520generation%2520of%2520adaptive%2520regulatory%2520T%2520cells%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D251%26epage%3D259%26doi%3D10.1182%2Fblood-2007-03-081646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Targeting immunosuppressive adenosine in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1038/nrc.2017.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fnrc.2017.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29059149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslehs7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=709-724&author=D.+Vijayanauthor=A.+Youngauthor=M.+W.+L.+Tengauthor=M.+J.+Smyth&title=Targeting+immunosuppressive+adenosine+in+cancer&doi=10.1038%2Fnrc.2017.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting immunosuppressive adenosine in cancer</span></div><div class="casAuthors">Vijayan, Dipti; Young, Arabella; Teng, Michele W. L.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">709-724</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1 (PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a considerable proportion of patients remain unresponsive to these treatments (known as innate resistance).  In addn., one-third of patients relapse after initial response (known as adaptive resistance), which suggests that multiple non-redundant immunosuppressive mechanisms coexist within the tumor microenvironment.  A major immunosuppressive mechanism is the adenosinergic pathway, which now represents an attractive new therapeutic target for cancer therapy.  Activation of this pathway occurs within hypoxic tumors, where extracellular adenosine exerts local suppression through tumor-intrinsic and host-mediated mechanisms.  Preclin. studies in mice with adenosine receptor antagonists and antibodies have reported favorable antitumor immune responses with some definition of the mechanism of action.  Currently, agents targeting the adenosinergic pathway are undergoing first-in-human clin. trials as single agents and in combination with anti-PD1 or anti-PDL1 therapies.  In this Review, we describe the complex interplay of adenosine and adenosine receptors in the development of primary tumors and metastases and discuss the merits of targeting one or more components that compose the adenosinergic pathway.  We also review the early clin. data relating to therapeutic agents inhibiting the adenosinergic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3aiRNPyIwHrVg90H21EOLACvtfcHk0lhbx7B_fUySrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslehs7rO&md5=24d252d351e30154a8f79bc37c2e4b2b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.86%26sid%3Dliteratum%253Aachs%26aulast%3DVijayan%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DTargeting%2520immunosuppressive%2520adenosine%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D709%26epage%3D724%26doi%3D10.1038%2Fnrc.2017.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Vilches, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, K.</span></span> <span> </span><span class="NLM_article-title">ATP and its metabolite adenosine as regulators of dendritic cell activity</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">2581</span> <span class="refDoi"> DOI: 10.3389/fimmu.2018.02581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3389%2Ffimmu.2018.02581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30473700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosValsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=C.+Silva-Vilchesauthor=S.+Ringauthor=K.+Mahnke&title=ATP+and+its+metabolite+adenosine+as+regulators+of+dendritic+cell+activity&doi=10.3389%2Ffimmu.2018.02581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ATP and its metabolite adenosine as regulators of dendritic cell activity</span></div><div class="casAuthors">Silva-Vilches, Cinthia; Ring, Sabine; Mahnke, Karsten</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2581/1-2581/11</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Adenosine (Ado) is a well-studied neurotransmitter, but it also exerts profound immune regulatory functions.  Ado can (i) actively be released by various cells into the tissue environment and can (ii) be produced through the degrdn. of extracellular ATP by the concerted action of CD39 and CD73.  In this sequence of events, the ectoenzyme CD39 degrades ATP into ADP and AMP, resp., and CD73 catalyzes the last step leading to the prodn. of Ado.  Extracellular ATP acts as a "danger" signal and stimulates immune responses, i.e. by inflammasome activation.  Its degrdn. product Ado on the other hand acts rather anti-inflammatory, as it down regulates functions of dendritic cells (DCs) and dampens T cell activation and cytokine secretion.  Thus, the balance of proinflammatory ATP and anti-inflammatory Ado that is regulated by CD39+/CD73+ immune cells, is important for decision making on whether tolerance or immunity ensues.  DCs express both ectoenzymes, enabling them to produce Ado from extracellular ATP by activity of CD73 and CD39 and thus allow dampening of the proinflammatory activity of adjacent leukocytes in the tissue.  On the other hand, as most DCs express at least one out of four so far known Ado receptors (AdoR), DC derived Ado can also act back onto the DCs in an autocrine manner.  This leads to suppression of DC functions that are normally involved in stimulating immune responses.  Moreover, ATP and Ado prodn. thereof acts as "find me" signal that guides cellular interactions of leukocytes during immune responses.  In this review we will state the means by which Ado producing DCs are able to suppress immune responses and how extracellular Ado conditions DCs for their tolerizing properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKT0rwxy8NG7Vg90H21EOLACvtfcHk0lh6pdtqWS8IuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosValsLk%253D&md5=6a38d6f457cfe32dda2003c0bb1a7a6b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02581%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Vilches%26aufirst%3DC.%26aulast%3DRing%26aufirst%3DS.%26aulast%3DMahnke%26aufirst%3DK.%26atitle%3DATP%2520and%2520its%2520metabolite%2520adenosine%2520as%2520regulators%2520of%2520dendritic%2520cell%2520activity%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffimmu.2018.02581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. F.</span></span> <span> </span><span class="NLM_article-title">Much ado about adenosine: adenosine synthesis and function in regulatory T Cell biology</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1000108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.4049%2Fjimmunol.1000108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=20686167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslWntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2010&pages=1993-1998&author=P.+B.+Ernstauthor=J.+C.+Garrisonauthor=L.+F.+Thompson&title=Much+ado+about+adenosine%3A+adenosine+synthesis+and+function+in+regulatory+T+Cell+biology&doi=10.4049%2Fjimmunol.1000108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology</span></div><div class="casAuthors">Ernst, Peter B.; Garrison, James C.; Thompson, Linda F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1993-1998</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Recent studies have reported that adenosine is a significant mediator of regulatory T cell (Treg) function.  Indeed, activation of the adenosine receptor subtypes expressed by a broad range of immune and inflammatory cells attenuates inflammation in several disease models.  This anti-inflammatory response is assocd. with an increase in intracellular cAMP that inhibits cytokine responses of many immune/inflammatory cells, including T cells and APCs.  Thus, adenosine produced by Tregs can provide a paracrine feedback that shapes the host response following an immunol. provocation.  This review discusses the evidence that adenosine is an integral part of Treg biol. and presents some of the mechanisms that may account for its contribution to the resoln. of inflammation and the regulation of the immune/inflammatory cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdf17HA47febVg90H21EOLACvtfcHk0lh6pdtqWS8IuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslWntLo%253D&md5=474c07f3a3b8a879d5605b69da28b817</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1000108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1000108%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DP.%2BB.%26aulast%3DGarrison%26aufirst%3DJ.%2BC.%26aulast%3DThompson%26aufirst%3DL.%2BF.%26atitle%3DMuch%2520ado%2520about%2520adenosine%253A%2520adenosine%2520synthesis%2520and%2520function%2520in%2520regulatory%2520T%2520Cell%2520biology%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D185%26spage%3D1993%26epage%3D1998%26doi%3D10.4049%2Fjimmunol.1000108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghizadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahsavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amini, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashidpour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azadian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parizadeh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashayekhi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukhtanloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaafari, M. R.</span></span> <span> </span><span class="NLM_article-title">CD73; a key ectonucleotidase in the development of breast cancer: recent advances and perspectives</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">14622</span>– <span class="NLM_lpage">14632</span>, <span class="refDoi"> DOI: 10.1002/jcp.28187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fjcp.28187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=14622-14632&author=A.+Soleimaniauthor=E.+Taghizadehauthor=S.+Shahsavariauthor=Y.+Aminiauthor=H.+Rashidpourauthor=E.+Azadianauthor=A.+Jafariauthor=M.+R.+Parizadehauthor=K.+Mashayekhiauthor=M.+Soukhtanlooauthor=M.+R.+Jaafari&title=CD73%3B+a+key+ectonucleotidase+in+the+development+of+breast+cancer%3A+recent+advances+and+perspectives&doi=10.1002%2Fjcp.28187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives</span></div><div class="casAuthors">Soleimani, Anvar; Taghizadeh, Eskandar; Shahsavari, Shirin; Amini, Yousef; Rashidpour, Hatam; Azadian, Esmaeel; Jafari, Arash; Parizadeh, Mohammad Reza; Mashayekhi, Kazem; Soukhtanloo, Mohammad; Jaafari, Mahmoud Reza</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">14622-14632</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tumor cell invasion and metastasis are the definitive cause of mortality in breast cancer (BC).  Hypoxia and pro-inflammatory cytokines upregulate the CD73 gene in the tumor microenvironment.  Subsequently, CD73 triggers mol. and cellular signaling pathways by both enzymic and nonenzymic pathways, which finally leads to breast tumor progression and development.  In this paper, we summarize current advances in the understanding of CD73-driven mechanisms that promote BC development and mortality.  Furthermore, we evaluate the therapeutic potential of CD73 targeting in BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBs3WVqf9ALVg90H21EOLACvtfcHk0lgHwmeKeFeXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKqurY%253D&md5=4f61a0014a807c20b50e6179706dcb36</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fjcp.28187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.28187%26sid%3Dliteratum%253Aachs%26aulast%3DSoleimani%26aufirst%3DA.%26aulast%3DTaghizadeh%26aufirst%3DE.%26aulast%3DShahsavari%26aufirst%3DS.%26aulast%3DAmini%26aufirst%3DY.%26aulast%3DRashidpour%26aufirst%3DH.%26aulast%3DAzadian%26aufirst%3DE.%26aulast%3DJafari%26aufirst%3DA.%26aulast%3DParizadeh%26aufirst%3DM.%2BR.%26aulast%3DMashayekhi%26aufirst%3DK.%26aulast%3DSoukhtanloo%26aufirst%3DM.%26aulast%3DJaafari%26aufirst%3DM.%2BR.%26atitle%3DCD73%253B%2520a%2520key%2520ectonucleotidase%2520in%2520the%2520development%2520of%2520breast%2520cancer%253A%2520recent%2520advances%2520and%2520perspectives%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D14622%26epage%3D14632%26doi%3D10.1002%2Fjcp.28187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoy, N.</span></span> <span> </span><span class="NLM_article-title">CD73: a new biomarker in triple-negative breast cancer</span>. <i>Transl. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S594</span>– <span class="NLM_lpage">S596</span>, <span class="refDoi"> DOI: 10.21037/tcr.2018.05.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.21037%2Ftcr.2018.05.22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=S594-S596&author=V.+Lafontauthor=H.-A.+Michaudauthor=N.+Bonnefoy&title=CD73%3A+a+new+biomarker+in+triple-negative+breast+cancer&doi=10.21037%2Ftcr.2018.05.22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.21037%2Ftcr.2018.05.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftcr.2018.05.22%26sid%3Dliteratum%253Aachs%26aulast%3DLafont%26aufirst%3DV.%26aulast%3DMichaud%26aufirst%3DH.-A.%26aulast%3DBonnefoy%26aufirst%3DN.%26atitle%3DCD73%253A%2520a%2520new%2520biomarker%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DTransl.%2520Cancer%2520Res.%26date%3D2018%26volume%3D7%26spage%3DS594%26epage%3DS596%26doi%3D10.21037%2Ftcr.2018.05.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1517/14728222.2014.915315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1517%2F14728222.2014.915315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=24798880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFylu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=863-881&author=B.+Allardauthor=M.+Turcotteauthor=J.+Stagg&title=Targeting+CD73+and+downstream+adenosine+receptor+signaling+in+triple-negative+breast+cancer&doi=10.1517%2F14728222.2014.915315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer</span></div><div class="casAuthors">Allard, Bertrand; Turcotte, Martin; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-881</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Despite significant improvements in diagnosis and therapy over the past 20 years, breast cancer remains a worldwide public health issue.  In particular, triple neg. breast cancer (TNBC), a subset of very aggressive breast tumors, is assocd. with a poor prognosis and has very few efficient therapeutic options.  The ectonucleotidase CD73 has recently emerged as a promising new target for TNBC in preclin. models.  Pharmacol. targeting of CD73 and downstream adenosine A2A/A2B receptor signaling is currently an active field of research that could lead to the development of new cancer therapeutics, including options against TNBC.  Areas covered:This article reviews the basic structural and mol. features of CD73 and its role in the development of cancer, with a particular focus on CD73's role in the biol. of TNBC.  Expert opinion: It was recently demonstrated that CD73 expression in TNBC is assocd. with worse clin. outcomes and increased resistance to anthracycline chemotherapy.  Targeted blockade of the CD73/A2A axis has been shown to impair various aspects of tumorigenesis and displays synergism with other anti-cancer treatments in preclin. studies.  Hence, we strongly argue for the development of CD73 inhibitors and for the repositioning of A2A antagonists in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQhEy8yqpqrVg90H21EOLACvtfcHk0lgba3tFHyZVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFylu7bN&md5=2fd1e50c6b84b0f11940d1c6a572aa5a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14728222.2014.915315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2014.915315%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520CD73%2520and%2520downstream%2520adenosine%2520receptor%2520signaling%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D863%26epage%3D881%26doi%3D10.1517%2F14728222.2014.915315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leclerc, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlebois, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 expression is an independent prognostic factor in prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1078-0432.CCR-15-1181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26253870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=158-166&author=B.+G.+Leclercauthor=R.+Charleboisauthor=G.+Chouinardauthor=B.+Allardauthor=S.+Pommeyauthor=F.+Saadauthor=J.+Stagg&title=CD73+expression+is+an+independent+prognostic+factor+in+prostate+cancer&doi=10.1158%2F1078-0432.CCR-15-1181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer</span></div><div class="casAuthors">Leclerc, Bruno G.; Charlebois, Roxanne; Chouinard, Guillaume; Allard, Bertrand; Pommey, Sandra; Saad, Fred; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">158-166</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor immunity in mouse models of cancer, including prostate cancer.  Although high levels of CD73 are assocd. with poor prognosis in various types of cancer, the clin. impact of CD73 in prostate cancer remains unclear.  Exptl. Design: We evaluated the prognostic value of CD73 protein expression and CD8+ cell d. in 285 cases of prostate cancer on tissue microarray (TMA).  Normal adjacent and tumor tissues were evaluated in duplicates.  Results: Univariate and multivariate analyses revealed that high levels of CD73 in normal adjacent prostate epithelium were significantly assocd. with shorter biochem. recurrence (BCR)-free survival.  Notably, CD73 expression in normal epithelium conferred a neg. prognostic value to prostate-infiltrating CD8+ cells.  Surprisingly, high levels of CD73 in the tumor stroma were assocd. with longer BCR-free survival in univariate anal.  In vitro studies revealed that adenosine signaling inhibited NF-κB activity in human prostate cancer cells via A2B adenosine receptors.  Consistent with these results, CD73 expression in the prostate tumor stroma neg. correlated with p65 expression in the nuclei of prostate tumor cells.  Conclusions: Our study revealed that CD73 is an independent prognostic factor in prostate cancer.  Our data support a model in which CD73 expression in the prostate epithelium suppresses immunosurveillance by CD8+ T cells, whereas CD73 expression in the tumor stroma reduces NF-κB signaling in tumor cells via A2B adenosine receptor signaling.  CD73 expression, including in normal adjacent prostate epithelium, can thus effectively discriminate between aggressive and indolent forms of prostate cancer.  Clin Cancer Res; 22(1); 158-66. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9HCI_kLOGLVg90H21EOLACvtfcHk0lgba3tFHyZVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVGqsrk%253D&md5=f775efcc9f67005fcc4d0696399ab79f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1181%26sid%3Dliteratum%253Aachs%26aulast%3DLeclerc%26aufirst%3DB.%2BG.%26aulast%3DCharlebois%26aufirst%3DR.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520expression%2520is%2520an%2520independent%2520prognostic%2520factor%2520in%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D158%26epage%3D166%26doi%3D10.1158%2F1078-0432.CCR-15-1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span> <span> </span><span class="NLM_article-title">Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1756</span>, <span class="refDoi"> DOI: 10.3892/or.2015.4512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3892%2For.2015.4512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26708311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=1750-1756&author=R.+Wuauthor=Y.+Chenauthor=F.+Liauthor=W.+Liauthor=H.+Zhouauthor=Y.+Yangauthor=Z.+Pei&title=Effects+of+CD73+on+human+colorectal+cancer+cell+growth+in+vivo+and+in+vitro&doi=10.3892%2For.2015.4512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro</span></div><div class="casAuthors">Wu, Ruimin; Chen, Yijia; Li, Fuyan; Li, Wei; Zhou, Hong; Yang, Yi; Pei, Zhijun</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1750-1756</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of the present study was to explore the role and mechanism of extracellular ecto-5'-nucleotidase (CD73) in human colorectal cancer growth.  Firstly, CD73 expression was detected in colorectal cancer cell lines both at the mRNA and protein levels.  Secondly, recombinant CD73 interference and overexpression lentiviruses were used, resp.  Colony formation assay, CCK-8 assay and flow cytometry were used to investigate the impact of CD73 on colorectal cancer cell proliferation and cell cycle distribution.  Then, adenosine and CD73 enzyme activity inhibitor (APCP) were used to study the effect of CD73 on Epidermal growth factor receptor (EGFR) and β-catenin/cyclin D1 signaling pathways.  Finally, a human colorectal cancer transplantation nude mouse model was used to observe the effect of CD73 on tumor growth in vivo.  As the results showed, CD73 was highly expressed in the colorectal cancer cell lines.  CD73 promoted colorectal cancer cell proliferation both in vivo and in vitro.  CD73 activated EGFR and the β-catenin/cyclin D1 signaling pathways through its enzyme and non-enzyme activities.  All of the results confirmed that CD73 promotes the growth of human colorectal cancer cells through EGFR and the β-catenin/cyclin D1 signaling pathway.  CD73 may be used as a valuable biomarker of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnFQ2Z85cX57Vg90H21EOLACvtfcHk0lgba3tFHyZVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFKmtg%253D%253D&md5=bcd1987db105d3b7e822ce587c140807</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3892%2For.2015.4512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4512%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DEffects%2520of%2520CD73%2520on%2520human%2520colorectal%2520cancer%2520cell%2520growth%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D35%26spage%3D1750%26epage%3D1756%26doi%3D10.3892%2For.2015.4512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chouinard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousineau, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendoo, D. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kains, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mes-Masson, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 is associated with poor prognosis in high-grade serous ovarian cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4494</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-3569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-14-3569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=26363007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4494-4503&author=M.+Turcotteauthor=K.+Springauthor=S.+Pommeyauthor=G.+Chouinardauthor=I.+Cousineauauthor=J.+Georgeauthor=G.+M.+Chenauthor=D.+M.+A.+Gendooauthor=B.+Haibe-Kainsauthor=T.+Karnauthor=K.+Rahimiauthor=C.+L.+Pageauthor=D.+Provencherauthor=A.-M.+Mes-Massonauthor=J.+Stagg&title=CD73+is+associated+with+poor+prognosis+in+high-grade+serous+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-14-3569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer</span></div><div class="casAuthors">Turcotte, Martin; Spring, Kathleen; Pommey, Sandra; Chouinard, Guillaume; Cousineau, Isabelle; George, Joshy; Chen, Gregory M.; Gendoo, Deena M. A.; Haibe-Kains, Benjamin; Karn, Thomas; Rahimi, Kurosh; Le Page, Cecile; Provencher, Diane; Mes-Masson, Anne-Marie; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4494-4503</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis.  Although preclin. studies suggest that CD73 can be targeted for cancer treatment, the clin. impact of CD73 in ovarian cancer remains unclear.  In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses.  Our results demonstrate that high levels of CD73 are significantly assocd. with shorter disease-free survival and overall survival in patients with HGS ovarian cancer.  Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis assocd. with intraepithelial CD8+ cells.  Notably, CD73 gene expression was highest in the C1/stromal mol. subtype of HGS ovarian cancer and pos. correlated with an epithelial-to-mesenchymal transition gene signature.  Moreover, in vitro studies revealed that CD73 and extracellular adenosine enhance ovarian tumor cell growth as well as expression of antiapoptotic BCL-2 family members.  Finally, in vivo coinjection of ID8 mouse ovarian tumor cells with mouse embryonic fibroblasts showed that CD73 expression in fibroblasts promotes tumor immune escape and thereby tumor growth.  In conclusion, our study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in HGS ovarian cancers.  Cancer Res; 75(21); 4494-503. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0cI-iFGChprVg90H21EOLACvtfcHk0li7TI3-conbHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGnu7vF&md5=168775cf106084e44de08a6f6a302255</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3569%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DK.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DChouinard%26aufirst%3DG.%26aulast%3DCousineau%26aufirst%3DI.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%2BM.%26aulast%3DGendoo%26aufirst%3DD.%2BM.%2BA.%26aulast%3DHaibe-Kains%26aufirst%3DB.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DRahimi%26aufirst%3DK.%26aulast%3DPage%26aufirst%3DC.%2BL.%26aulast%3DProvencher%26aufirst%3DD.%26aulast%3DMes-Masson%26aufirst%3DA.-M.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4494%26epage%3D4503%26doi%3D10.1158%2F0008-5472.CAN-14-3569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namburi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span> <span> </span><span class="NLM_article-title">Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">12050</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1200%2FJCO.2018.36.15_suppl.12050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=12050&author=L.+C.+Parkauthor=K.+Rheeauthor=W.+B.+Kimauthor=A.+Choauthor=J.+Songauthor=J.+F.+Ankerauthor=M.+Ohauthor=P.+Baisauthor=S.+Namburiauthor=J.+Chuangauthor=Y.+K.+Chae&title=Immunologic+and+clinical+implications+of+CD73+expression+in+non-small+cell+lung+cancer+%28NSCLC%29&doi=10.1200%2FJCO.2018.36.15_suppl.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.12050%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DL.%2BC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DW.%2BB.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DAnker%26aufirst%3DJ.%2BF.%26aulast%3DOh%26aufirst%3DM.%26aulast%3DBais%26aufirst%3DP.%26aulast%3DNamburi%26aufirst%3DS.%26aulast%3DChuang%26aufirst%3DJ.%26aulast%3DChae%26aufirst%3DY.%2BK.%26atitle%3DImmunologic%2520and%2520clinical%2520implications%2520of%2520CD73%2520expression%2520in%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D12050%26doi%3D10.1200%2FJCO.2018.36.15_suppl.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span> <span> </span><span class="NLM_article-title">The distinct role of CD73 in the progression of pancreatic cancer</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1007/s00109-018-01742-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1007%2Fs00109-018-01742-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30927045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos1yktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=803-815&author=L.+Zhouauthor=S.+Jiaauthor=Y.+Chenauthor=W.+Wangauthor=Z.+Wuauthor=W.+Yuauthor=M.+Zhangauthor=G.+Dingauthor=L.+Cao&title=The+distinct+role+of+CD73+in+the+progression+of+pancreatic+cancer&doi=10.1007%2Fs00109-018-01742-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The distinct role of CD73 in the progression of pancreatic cancer</span></div><div class="casAuthors">Zhou, Liangjing; Jia, Shengnan; Chen, Yan; Wang, Weiming; Wu, Zhengrong; Yu, Weihua; Zhang, Mingjie; Ding, Guoping; Cao, Liping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Recent studies have shown that the non-enzymic function of CD73 plays a key role in tumor progression, but this function of CD73 in pancreatic cancer cells has not been studied.  Furthermore, little is known about the mechanism involved in CD73 regulation in tumors.  Here, we found that CD73 expression was upregulated in pancreatic ductal adenocarcinoma (PDAC) and that its expression correlated with poor prognosis.  CD73 knockdown inhibited cell growth and induced G1 phase arrest via the AKT/ERK/cyclin D signaling pathway.  We also found that tumor necrosis factor receptor (TNFR) 2 was involved in CD73-induced AKT and ERK signaling pathway activation in PDAC.  Further, miR-30a-5p overexpression significantly increased the cytotoxic effect of gemcitabine in pancreatic cancer by directly targeting CD73 mRNA (mRNA), suggesting that regulation of the miR-30a-5p/CD73 axis may play an important role in the development of gemcitabine resistance in pancreatic cancer.  In summary, this regulatory network of CD73 appears to represent a new mol. mechanism underlying PDAC progression, and the mechanistic interaction between miR-30a-5p, CD73, and TNFR2 may provide new insights into therapeutic strategies for pancreatic cancer.  Key messages: CD73 was upregulated in PDAC and correlated with poor prognosis.  CD73 knockdown inhibited cell growth and induced G1 phase arrest.  TNFR2 was involved in CD73-induced AKT and ERK signaling pathway. miR-30a-5p targeted CD73 and increased the sensitivity to gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpxoBGZ-FHv7Vg90H21EOLACvtfcHk0li7TI3-conbHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos1yktbk%253D&md5=c05b2f98c3e76ddbfa83d87d7b2429af</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00109-018-01742-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-018-01742-0%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DL.%26atitle%3DThe%2520distinct%2520role%2520of%2520CD73%2520in%2520the%2520progression%2520of%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D803%26epage%3D815%26doi%3D10.1007%2Fs00109-018-01742-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertonia, A. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccob, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Campos, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutzc, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assis-Brasild, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza Meyer, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braganhol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanetto, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, M. R.</span></span> <span> </span><span class="NLM_article-title">Activity of ecto-5′-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>479</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.mce.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=30184475" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=479&publication_year=2019&pages=54-60&author=A.+P.+S.+Bertoniaauthor=P.+A.+Braccobauthor=R.+P.+de+Camposauthor=B.+S.+Lutzcauthor=B.+M.+Assis-Brasildauthor=E.+L.+de+Souza+Meyerauthor=J.+Saffiauthor=E.+Braganholauthor=T.+W.+Furlanettoauthor=M.+R.+Wink&title=Activity+of+ecto-5%E2%80%B2-nucleotidase+%28NT5E%2FCD73%29+is+increased+in+papillary+thyroid+carcinoma+and+its+expression+is+associated+with+metastatic+lymph+nodes&doi=10.1016%2Fj.mce.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DBertonia%26aufirst%3DA.%2BP.%2BS.%26aulast%3DBraccob%26aufirst%3DP.%2BA.%26aulast%3Dde%2BCampos%26aufirst%3DR.%2BP.%26aulast%3DLutzc%26aufirst%3DB.%2BS.%26aulast%3DAssis-Brasild%26aufirst%3DB.%2BM.%26aulast%3Dde%2BSouza%2BMeyer%26aufirst%3DE.%2BL.%26aulast%3DSaffi%26aufirst%3DJ.%26aulast%3DBraganhol%26aufirst%3DE.%26aulast%3DFurlanetto%26aufirst%3DT.%2BW.%26aulast%3DWink%26aufirst%3DM.%2BR.%26atitle%3DActivity%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528NT5E%252FCD73%2529%2520is%2520increased%2520in%2520papillary%2520thyroid%2520carcinoma%2520and%2520its%2520expression%2520is%2520associated%2520with%2520metastatic%2520lymph%2520nodes%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26volume%3D479%26spage%3D54%26epage%3D60%26doi%3D10.1016%2Fj.mce.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.3748/wjg.v19.i12.1912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.3748%2Fwjg.v19.i12.1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23569336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtlSls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1912-1918&author=X.-X.+Luauthor=Y.-T.+Chenauthor=B.+Fengauthor=X.-B.+Maoauthor=B.+Yuauthor=X.-Y.+Chu&title=Expression+and+clinical+significance+of+CD73+and+hypoxia-inducible+factor-1%CE%B1+in+gastric+carcinoma&doi=10.3748%2Fwjg.v19.i12.1912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma</span></div><div class="casAuthors">Lu, Xiao-Xia; Chen, Yi-Tian; Feng, Bing; Mao, Xiao-Bei; Yu, Bo; Chu, Xiao-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1912-1918</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Co., Ltd.</span>)
        </div><div class="casAbstract">Aim: To investigate the expression of CD73 and hypoxia-inducible factor-1α (HIF-1α) in human gastric carcinoma and explore their clin. significance and prognostic value.  Methods: CD73 and HIF-1α expressions were detected by immunohistochem. in consecutive sections of tissue samples from 68 gastric carcinoma patients.  The peritumor tissues 2 cm away from the tumor were obtained and served as controls.  The presence of CD73 and HIF-1α was analyzed by immunohistochem. using the Envision technique.  Results: CD73 and HIF-1α expressions in gastric carcinoma were significantly higher than those in gastric mucosal tissues as control (P < 0.001) and showed a close correlation (Spearman r = 0.390, P = 0.001).  Overexpression of CD73 was pos. correlated with differentiation of tumor (P = 0.000), histopathol. (P = 0.041), depth of invasion (P < 0.001), nodal status (P = 0.003), metastasis (P = 0.013) and the American Joint Committee on Cancer (AJCC) stage (P < 0.001).  High expression of HIF-1α was pos. correlated with tumor diam. (P = 0.031), depth of invasion (P = 0.022) and AJCC stage (P = 0.035).  The overall survival rate was low in the patients with high expression of CD73 (P < 0.001).  Moreover, CD73+/HIF-1α+patients had the worst prognosis (P < 0.001).  CD73 expression was proven to be an independent predictor for patients with gastric carcinoma by both multivariate Cox regression anal. (P = 0.021) and receiver operating characteristic curves (P = 0.001).  Conclusion: CD73 expression correlates closely with HIF-1α expression in gastric carcinoma.  CD73 could be an independent prognostic indicator for gastric carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHw5O5j8tl7Vg90H21EOLACvtfcHk0liAg8I8-T2-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtlSls7c%253D&md5=ff722e42a09114e5ef9b7fb804ac8b75</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v19.i12.1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v19.i12.1912%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.-X.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DX.-B.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DX.-Y.%26atitle%3DExpression%2520and%2520clinical%2520significance%2520of%2520CD73%2520and%2520hypoxia-inducible%2520factor-1%25CE%25B1%2520in%2520gastric%2520carcinoma%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2013%26volume%3D19%26spage%3D1912%26epage%3D1918%26doi%3D10.3748%2Fwjg.v19.i12.1912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faouzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménétrier-Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leval, L. D.</span></span> <span> </span><span class="NLM_article-title">CD73 expression and clinical significance in human metastatic melanoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">26659</span>– <span class="NLM_lpage">26669</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.25426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.18632%2Foncotarget.25426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29928476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=26659-26669&author=I.+Monteiroauthor=S.+Viganoauthor=M.+Faouziauthor=I.+Treilleuxauthor=O.+Michielinauthor=C.+M%C3%A9n%C3%A9trier-Cauxauthor=C.+Cauxauthor=P.+Romeroauthor=L.+D.+Leval&title=CD73+expression+and+clinical+significance+in+human+metastatic+melanoma&doi=10.18632%2Foncotarget.25426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 expression and clinical significance in human metastatic melanoma</span></div><div class="casAuthors">Monteiro Ines; de Leval Laurence; Vigano Selena; Romero Pedro; Faouzi Mohamed; Treilleux Isabelle; Michielin Olivier; Menetrier-Caux Christine; Caux Christophe; Menetrier-Caux Christine; Caux Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26659-26669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  CD73 is an ectoenzyme involved in the production of adenosine.  It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.  Results:  CD73 expression was detected in TC in 54% of melanoma metastases, involving < 50% TC in the majority of the cases, with variable intensity.  CD73 expression was significantly associated with a lower Breslow's depth of the primary lesion and was more frequent in patients having received prior non-surgical therapies.  In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) significantly correlated to decreased overall survival (OS) from biopsy.  Of the samples containing TIMC, 35% presented CD73+ TIMC.  Highly infiltrated tumors were more likely to contain CD73+ TIMC.  CD73 expression in TIMC (percentage ≥1%) significantly correlated with improved OS from biopsy.  Conclusions:  Immunohistochemistry detected CD73 expression in more than half of metastatic melanomas.  While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS.  These results encourage the study of anti-CD73 therapies for metastatic melanoma patients.  Methods:  CD73 expression was assessed by immunohistochemistry in metastatic melanomas from 114 patients.  Immunostainings were evaluated in tumor cells (TC) (percentage, intensity (1-3) and H-score) and in tumor-infiltrating mononuclear cells (TIMC) (percentage).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWcmnHKmNelsRAV4D_Ins_fW6udTcc2eaWFidYAj7Sz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFWjsg%253D%253D&md5=016f73cfa655638336b226026b50e053</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.25426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.25426%26sid%3Dliteratum%253Aachs%26aulast%3DMonteiro%26aufirst%3DI.%26aulast%3DVigano%26aufirst%3DS.%26aulast%3DFaouzi%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DM%25C3%25A9n%25C3%25A9trier-Caux%26aufirst%3DC.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DRomero%26aufirst%3DP.%26aulast%3DLeval%26aufirst%3DL.%2BD.%26atitle%3DCD73%2520expression%2520and%2520clinical%2520significance%2520in%2520human%2520metastatic%2520melanoma%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D26659%26epage%3D26669%26doi%3D10.18632%2Foncotarget.25426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommeyb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haibe-Kainsc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavisd, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcyd, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">11091</span>– <span class="NLM_lpage">11096</span>, <span class="refDoi"> DOI: 10.1073/pnas.1222251110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1073%2Fpnas.1222251110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23776241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=11091-11096&author=S.+Loiauthor=S.+Pommeybauthor=B.+Haibe-Kainscauthor=P.+A.+Beavisdauthor=P.+K.+Darcydauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+anthracycline+resistance+and+poor+prognosis+in+triple+negative+breast+cancer&doi=10.1073%2Fpnas.1222251110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</span></div><div class="casAuthors">Loi, Sherene; Pommey, Sandra; Haibe-Kains, Benjamin; Beavis, Paul A.; Darcy, Phillip K.; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11091-11096,S11091/1-S11091/21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is assocd. with a poor prognosis in triple-neg. breast cancers (TNBC).  Because anthracycline-based chemotherapy regimens are std. treatment for TNBC, we investigated the relationship between CD73 and anthracycline efficacy.  In TNBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was significantly assocd. with a lower rate of pathol. complete response or the disappearance of invasive tumor at surgery.  Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors.  Targeted blockade of CD73 enhanced doxorubicin-mediated antitumor immune responses and significantly prolonged the survival of mice with established metastatic breast cancer.  Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6KtLUgWgbYbVg90H21EOLACvtfcHk0liAg8I8-T2-pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejsLrO&md5=97b58f664273accfcab7096dcbc76db6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222251110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222251110%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DPommeyb%26aufirst%3DS.%26aulast%3DHaibe-Kainsc%26aufirst%3DB.%26aulast%3DBeavisd%26aufirst%3DP.%2BA.%26aulast%3DDarcyd%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520anthracycline%2520resistance%2520and%2520poor%2520prognosis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D11091%26epage%3D11096%26doi%3D10.1073%2Fpnas.1222251110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">The roles of CD73 in cancer</span>. <i>Biomed. Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>, <span class="NLM_elocation-id">460654</span> <span class="refDoi"> DOI: 10.1155/2014/460654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1155%2F2014%2F460654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=25126561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A280%3ADC%252BC2M7kvVSjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&author=Z.+Gaoauthor=K.+Dongauthor=H.+Zhang&title=The+roles+of+CD73+in+cancer&doi=10.1155%2F2014%2F460654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of CD73 in cancer</span></div><div class="casAuthors">Gao Zhao-wei; Dong Ke; Zhang Hui-zhong</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">460654</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purinergic signaling has emerged as an important player in cancer progression and is regulated by a series of nucleotidases.  Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer.  Various factors and mechanisms are employed to regulate expression of CD73.  Accumulating studies have shown that CD73 is a key regulatory molecule of cancer cells proliferation, migration and invasion in vitro, tumor angiogenesis, and tumor immune escape in vivo.  With such important roles in cancer, CD73 has become an appealing therapy target.  Recent evidences in mice models demonstrated that targeted blockade of CD73 could be a favorable therapeutic approach for cancer patients in the future.  In this review, we will summarize the multiple roles of CD73 in cancer development, including its clinical significance, its promotive effects on tumor growth, metastasis, and angiogenesis, and its suppressive effects on immune response, regulatory mechanisms of CD73 expression, and current situation of anti-CD73 cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIODqCHThnpYhLSh9fo81bfW6udTcc2eY7_A42GElbBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7kvVSjtw%253D%253D&md5=3728d88384bc0a82a4cc7f3956dc4f4b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1155%2F2014%2F460654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F460654%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DThe%2520roles%2520of%2520CD73%2520in%2520cancer%26jtitle%3DBiomed.%2520Res.%2520Int.%26date%3D2014%26volume%3D2014%26doi%3D10.1155%2F2014%2F460654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bareche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisseret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delisle, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellokumpu-Lehtinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">CD73 promotes resistance to HER2/ErbB2 antibody therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5652</span>– <span class="NLM_lpage">5663</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-17-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=28855210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=5652-5663&author=M.+Turcotteauthor=D.+Allardauthor=D.+Mittalauthor=Y.+Barecheauthor=L.+Buisseretauthor=V.+Joseauthor=S.+Pommeyauthor=V.+Delisleauthor=S.+Loiauthor=H.+Joensuuauthor=P.+Kellokumpu-Lehtinenauthor=C.+Sotiriouauthor=M.+J.+Smythauthor=J.+Stagg&title=CD73+promotes+resistance+to+HER2%2FErbB2+antibody+therapy&doi=10.1158%2F0008-5472.CAN-17-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy</span></div><div class="casAuthors">Turcotte, Martin; Allard, David; Mittal, Deepak; Bareche, Yacine; Buisseret, Laurence; Jose, Vinu; Pommey, Sandra; Delisle, Vincent; Loi, Sherene; Joensuu, Heikki; Kellokumpu-Lehtinen, Pirkko-Liisa; Sotiriou, Christos; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5652-5663</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of the ectonucleotidase CD73 by tumor cells, stromal cells, and immune cells is assocd. in cancer with immune suppression.  In this study, we investigated the role of CD73 on the activity of the anti-HER2/ErbB2 monoclonal antibody (mAb) trastuzumab.  In a prospective, randomized phase III clin. trial evaluating the activity of trastuzumab, high levels of CD73 gene expression were assocd. significantly with poor clin. outcome.  In contrast, high levels of PD-1 and PD-L1 were assocd. with improved clin. outcome.  In immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.  Furthermore, anti-CD73 mAb therapy enhanced the activity of anti-ErbB2 mAb to treat engrafted or spontaneous tumors as well as lung metastases.  Gene ontol. enrichment anal. from gene-expression data revealed a pos. assocn. of CD73 expression with extracellular matrix organization, TGFβ genes, epithelial-to-mesenchymal transition (EMT) transcription factors and hypoxia-inducible-factor (HIF)-1 gene signature.  Human mammary cells treated with TGFβ or undergoing EMT upregulated CD73 cell-surface expression, confirming roles for these pathways.  In conclusion, our findings establish CD73 in mediating resistance to trastuzumab and provide new insights into how CD73 is regulated in breast cancer.  Cancer Res; 77(20); 5652-63. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSI2kxEAJ5cbVg90H21EOLACvtfcHk0lgbSUA5tmQBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CqtLnM&md5=a71749b68bb6fd0bf6c7fd79410323b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-0707%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DM.%26aulast%3DAllard%26aufirst%3DD.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DBareche%26aufirst%3DY.%26aulast%3DBuisseret%26aufirst%3DL.%26aulast%3DJose%26aufirst%3DV.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDelisle%26aufirst%3DV.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DKellokumpu-Lehtinen%26aufirst%3DP.%26aulast%3DSotiriou%26aufirst%3DC.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DCD73%2520promotes%2520resistance%2520to%2520HER2%252FErbB2%2520antibody%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D5652%26epage%3D5663%26doi%3D10.1158%2F0008-5472.CAN-17-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5626</span>– <span class="NLM_lpage">5635</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1078-0432.CCR-13-0545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=23983257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5626-5635&author=B.+Allardauthor=S.+Pommeyauthor=M.+J.+Smythauthor=J.+Stagg&title=Targeting+CD73+enhances+the+antitumor+activity+of+anti-PD-1+and+anti-CTLA-4+mAbs&doi=10.1158%2F1078-0432.CCR-13-0545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs</span></div><div class="casAuthors">Allard, Bertrand; Pommey, Sandra; Smyth, Mark J.; Stagg, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5626-5635</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been assocd. with durable clin. responses against a variety of cancer types and hold great potential as novel cancer therapeutics.  Recent evidence suggest that targeted blockade of multiple immunosuppressive pathways can induce synergistic antitumor responses.  Exptl. Design: In this study, we investigated whether targeted blockade of CD73, an ectonucleotidase that catabolizes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, can enhance the antitumor activity of anti-CTLA-4 and anti-PD-1 mAbs against transplanted and chem. induced mouse tumors.  Results: Anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against MC38-OVA (colon) and RM-1 (prostate) s.c. tumors, and established metastatic 4T1.2 breast cancer.  Anti-CD73 mAb also significantly enhanced the activity of anti-PD-1 mAb against 3-methylcholanthrene (MCA)-induced fibrosarcomas.  Gene-targeted mice revealed that single-agent therapies and combinatorial treatments were dependent on host IFN-γ and CD8+ T cells, but independent of perforin.  Interestingly, anti-CD73 mAb preferentially synergized with anti-PD-1 mAb.  We investigated the effect of extracellular adenosine on tumor-infiltrating T cells and showed that activation of A2A adenosine receptor enhances PD-1 expression, but not CTLA-4 expression, on tumor-specific CD8+ T cells and CD4+ Foxp3+ T regulatory cells.  Conclusions: Taken together, our study revealed that targeted blockade of CD73 can enhance the therapeutic activity of anti-PD-1 and anti-CTLA-4 mAbs and may thus potentiate therapeutic strategies targeting immune checkpoint inhibitors in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVsy3vL-s1rVg90H21EOLACvtfcHk0lgbSUA5tmQBDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ahurrP&md5=c7a44398208fbf65f801d9c47935697b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0545%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DStagg%26aufirst%3DJ.%26atitle%3DTargeting%2520CD73%2520enhances%2520the%2520antitumor%2520activity%2520of%2520anti-PD-1%2520and%2520anti-CTLA-4%2520mAbs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5626%26epage%3D5635%26doi%3D10.1158%2F1078-0432.CCR-13-0545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achyut, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbab, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span> <span> </span><span class="NLM_article-title">CD73 on cancer-associated fibroblasts enhanced by the A<sub>2B</sub>-mediated feedforward circuit enforces an immune checkpoint</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">515</span> <span class="refDoi"> DOI: 10.1038/s41467-019-14060-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fs41467-019-14060-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=31980601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFanurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&author=M.+Yuauthor=G.+Guoauthor=L.+Huangauthor=L.+Dengauthor=C.-S.+Changauthor=B.+R.+Achyutauthor=M.+Canningauthor=N.+Xuauthor=A.+S.+Arbabauthor=R.+J.+Bollagauthor=P.+C.+Rodriguezauthor=A.+L.+Mellorauthor=H.+Shiauthor=D.+H.+Munnauthor=Y.+Cui&title=CD73+on+cancer-associated+fibroblasts+enhanced+by+the+A2B-mediated+feedforward+circuit+enforces+an+immune+checkpoint&doi=10.1038%2Fs41467-019-14060-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint</span></div><div class="casAuthors">Yu, Miao; Guo, Gang; Huang, Lei; Deng, Libin; Chang, Chang-Sheng; Achyut, Bhagelu R.; Canning, Madison; Xu, Ningchun; Arbab, Ali S.; Bollag, Roni J.; Rodriguez, Paulo C.; Mellor, Andrew L.; Shi, Huidong; Munn, David H.; Cui, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">515</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A2A receptor.  Elevated CD73 levels in tumor tissues correlate with poor clin. outcomes.  However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified.  Here, we demonstrate that cancer-assocd. fibroblasts (CAFs) constitute the prominent CD73hi population in human colorectal cancers (CRCs) and two CD73- murine tumor models, including a modified CRC.  Clin., high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis.  Mechanistically, CAF-CD73 expression is enhanced via an ADO-A2B receptor-mediated feed forward circuit triggered by tumor cell death, which enforces the CD73-checkpoint.  Simultaneous inhibition of A2A and A2B pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors.  Therefore, the strategic and effective targeting of both the A2B-mediated ADO-CAF-CD73 feed forward circuit and A2A-mediated immune suppression is crucial for improving therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtclNuEzjmsbVg90H21EOLACvtfcHk0lj6Dtitznxr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFanurY%253D&md5=361086e15d0fcc5f5b8bf1bcff90f876</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-14060-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-14060-x%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DC.-S.%26aulast%3DAchyut%26aufirst%3DB.%2BR.%26aulast%3DCanning%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DArbab%26aufirst%3DA.%2BS.%26aulast%3DBollag%26aufirst%3DR.%2BJ.%26aulast%3DRodriguez%26aufirst%3DP.%2BC.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DCui%26aufirst%3DY.%26atitle%3DCD73%2520on%2520cancer-associated%2520fibroblasts%2520enhanced%2520by%2520the%2520A2B-mediated%2520feedforward%2520circuit%2520enforces%2520an%2520immune%2520checkpoint%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26doi%3D10.1038%2Fs41467-019-14060-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngiow, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkauskas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.ccell.2016.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27622332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWitrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=391-403&author=A.+Youngauthor=S.+F.+Ngiowauthor=D.+S.+Barkauskasauthor=E.+Sultauthor=C.+Hayauthor=S.+J.+Blakeauthor=Q.+Huangauthor=J.+Liuauthor=K.+Takedaauthor=M.+W.+L.+Tengauthor=K.+Sachsenmeierauthor=M.+J.+Smyth&title=Co-inhibition+of+CD73+and+A2AR+adenosine+signaling+improves+anti-tumor+immune+responses&doi=10.1016%2Fj.ccell.2016.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses</span></div><div class="casAuthors">Young, Arabella; Ngiow, Shin Foong; Barkauskas, Deborah S.; Sult, Erin; Hay, Carl; Blake, Stephen J.; Huang, Qihui; Liu, Jing; Takeda, Kazuyoshi; Teng, Michele W. L.; Sachsenmeier, Kris; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-403</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Preclin. studies targeting the adenosinergic pathway have gained much attention for their clin. potential in overcoming tumor-induced immunosuppression.  Here, we have identified that co-blockade of the ectonucleotidase that generates adenosine CD73 and the A2A adenosine receptor (A2AR) that mediates adenosine signaling in leuokocytes, by using compd. gene-targeted mice or therapeutics that target these mols., limits tumor initiation, growth, and metastasis.  This tumor control requires effector lymphocytes and interferon-γ, while antibodies targeting CD73 promote an optimal therapeutic response in vivo when engaging activating Fc receptors.  In a two-way mixed leukocyte reaction using a fully human anti-CD73, we demonstrated that Fc receptor binding augmented the prodn. of proinflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxhWP1XI1lbVg90H21EOLACvtfcHk0lj6Dtitznxr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWitrjL&md5=a42578ccc57076490b4d5f7beece849c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DNgiow%26aufirst%3DS.%2BF.%26aulast%3DBarkauskas%26aufirst%3DD.%2BS.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DHay%26aufirst%3DC.%26aulast%3DBlake%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DSachsenmeier%26aufirst%3DK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCo-inhibition%2520of%2520CD73%2520and%2520A2AR%2520adenosine%2520signaling%2520improves%2520anti-tumor%2520immune%2520responses%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D391%26epage%3D403%26doi%3D10.1016%2Fj.ccell.2016.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparwasser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2900</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F0008-5472.CAN-10-4246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=21292811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2892-2900&author=J.+Staggauthor=U.+Divisekeraauthor=H.+Duretauthor=T.+Sparwasserauthor=M.+W.+L.+Tengauthor=P.+K.+Darcyauthor=M.+J.+Smyth&title=CD73-deficient+mice+have+increased+antitumor+immunity+and+are+resistant+to+experimental+metastasis&doi=10.1158%2F0008-5472.CAN-10-4246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; Duret, Helene; Sparwasser, Tim; Teng, Michele W. L.; Darcy, Phillip K.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2892-2900</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine.  In this study, we employed CD73 gene-targeted mice to investigate the role of host-derived CD73 on antitumor immunity and tumor cell metastasis.  We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma.  The protective effect of CD73 deficiency on primary tumors was dependent on CD8+ T cells and assocd. with an increased frequency of antigen-specific CD8+ T cells in peripheral blood and tumors and increased antigen-specific IFN-γ prodn.  Replicate studies in bone marrow chimeras established that both hematopoietic and nonhematopoietic expression of CD73 was important to promote tumor immune escape.  Using adoptive reconstitution of T regulatory cell (Treg)-depleted DEREG (depletion of regulatory T cells) mice, we demonstrated that part of the protumorigenic effect of Tregs was dependent on their expression of CD73.  CD73-deficient mice were also protected against pulmonary metastasis of B16F10 melanoma cells after i.v. injection.  Unexpectedly, we found that the prometastatic effect of host-derived CD73 was dependent on CD73 expression on nonhematopoietic cells.  CD73 expression on nonhematopoietic cells, most likely endothelial cells, was crit. for promoting lung metastasis in a manner independent from immunosuppressive effects.  Notably, in vivo blockade of CD73 with a selective inhibitor or anti-CD73 monoclonal antibody significantly reduced tumor growth and metastasis of CD73-neg. tumors.  Taken together, our findings indicate that CD73 may be targeted at multiple levels to induce anticancer effects including at the level of tumor cells, Tregs, and nonhematopoietic cells.  Cancer Res; 71(8); 2892-900.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQxUwCZ8XerVg90H21EOLACvtfcHk0lj6Dtitznxr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslWjs78%253D&md5=94cc37e9eb84e5e8cce990252cc0e7a2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4246%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DDuret%26aufirst%3DH.%26aulast%3DSparwasser%26aufirst%3DT.%26aulast%3DTeng%26aufirst%3DM.%2BW.%2BL.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DCD73-deficient%2520mice%2520have%2520increased%2520antitumor%2520immunity%2520and%2520are%2520resistant%2520to%2520experimental%2520metastasis%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2892%26epage%3D2900%26doi%3D10.1158%2F0008-5472.CAN-10-4246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornish, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anandhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blando, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groot, Jd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepesi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopetz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pe’er, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span> <span> </span><span class="NLM_article-title">Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0694-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1038%2Fs41591-019-0694-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=31873309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFyqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=39-46&author=S.+Goswamiauthor=T.+Walleauthor=A.+E.+Cornishauthor=S.+Basuauthor=S.+Anandhanauthor=I.+Fernandezauthor=L.+Venceauthor=J.+Blandoauthor=H.+Zhaoauthor=S.+S.+Yadavauthor=M.+Ottauthor=L.+Y.+Kongauthor=A.+B.+Heimbergerauthor=Jd.+Grootauthor=B.+Sepesiauthor=M.+Overmanauthor=S.+Kopetzauthor=J.+P.+Allisonauthor=D.+Pe%E2%80%99erauthor=P.+Sharma&title=Immune+profiling+of+human+tumors+identifies+CD73+as+a+combinatorial+target+in+glioblastoma&doi=10.1038%2Fs41591-019-0694-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma</span></div><div class="casAuthors">Goswami, Sangeeta; Walle, Thomas; Cornish, Andrew E.; Basu, Sreyashi; Anandhan, Swetha; Fernandez, Irina; Vence, Luis; Blando, Jorge; Zhao, Hao; Yadav, Shalini Singh; Ott, Martina; Kong, Ling Y.; Heimberger, Amy B.; de Groot, John; Sepesi, Boris; Overman, Michael; Kopetz, Scott; Allison, James P.; Pe'er, Dana; Sharma, Padmanee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-46</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of many solid tumors.  However, the clin. efficacy of immune checkpoint therapy is limited to a subset of patients with specific tumor types1,2.  Multiple clin. trials with combinatorial immune checkpoint strategies are ongoing; however, the mechanistic rationale for tumor-specific targeting of immune checkpoints is elusive.  To garner an insight into tumor-specific immunomodulatory targets, we analyzed 94 patients representing five different cancer types, including those that respond relatively well to immune checkpoint therapy and those that do not, such as glioblastoma multiforme, prostate cancer and colorectal cancer.  Through mass cytometry and single-cell RNA sequencing, we identified a unique population of CD73hi macrophages in glioblastoma multiforme that persists after anti-PD-1 treatment.  To test if targeting CD73 would be important for a successful combination strategy in glioblastoma multiforme, we performed reverse translational studies using CD73-/- mice.  We found that the absence of CD73 improved survival in a murine model of glioblastoma multiforme treated with anti-CTLA-4 and anti-PD-1.  Our data identified CD73 as a specific immunotherapeutic target to improve antitumor immune responses to immune checkpoint therapy in glioblastoma multiforme and demonstrate that comprehensive human and reverse translational studies can be used for rational design of combinatorial immune checkpoint strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-I-oQEDdirVg90H21EOLACvtfcHk0liB4yi0DI-_Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFyqsA%253D%253D&md5=f9a50890e5b225436119f4150e53bb60</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0694-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0694-x%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DS.%26aulast%3DWalle%26aufirst%3DT.%26aulast%3DCornish%26aufirst%3DA.%2BE.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DAnandhan%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DI.%26aulast%3DVence%26aufirst%3DL.%26aulast%3DBlando%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYadav%26aufirst%3DS.%2BS.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DL.%2BY.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26aulast%3DGroot%26aufirst%3DJd.%26aulast%3DSepesi%26aufirst%3DB.%26aulast%3DOverman%26aufirst%3DM.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DPe%25E2%2580%2599er%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DP.%26atitle%3DImmune%2520profiling%2520of%2520human%2520tumors%2520identifies%2520CD73%2520as%2520a%2520combinatorial%2520target%2520in%2520glioblastoma%26jtitle%3DNat.%2520Med.%26date%3D2020%26volume%3D26%26spage%3D39%26epage%3D46%26doi%3D10.1038%2Fs41591-019-0694-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divisekera, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1073/pnas.0908801107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1073%2Fpnas.0908801107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=20080644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1547-1552&author=J.+Staggauthor=U.+Divisekeraauthor=N.+McLaughlinauthor=J.+Sharkeyauthor=S.+Pommeyauthor=D.+Denoyerauthor=K.+M.+Dwyerauthor=M.+J.+Smyth&title=Anti-CD73+antibody+therapy+inhibits+breast+tumor+growth+and+metastasis&doi=10.1073%2Fpnas.0908801107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis</span></div><div class="casAuthors">Stagg, John; Divisekera, Upulie; McLaughlin, Nicole; Sharkey, Janelle; Pommey, Sandra; Denoyer, Delphine; Dwyer, Karen M.; Smyth, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1547-1552, S1547/1-S1547/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular adenosine is a potent immunosuppressor that accumulates during tumor growth.  We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine.  We showed that anti-CD73 mAb therapy significantly delayed primary 4T1.2 and E0771 tumor growth in immune-competent mice and significantly inhibited the development of spontaneous 4T1.2 lung metastases.  Notably, anti-CD73 mAb therapy was essentially dependent on the induction of adaptive anti-tumor immune responses.  Knockdown of CD73 in 4T1.2 tumor cells confirmed the tumor-promoting effects of CD73.  In addn. to its immunosuppressive effect, CD73 enhanced tumor cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis.  Accordingly, administration of adenosine-5'-N-ethylcarboxamide to tumor-bearing mice significantly enhanced spontaneous 4T1.2 lung metastasis.  Using selective adenosine-receptor antagonists, we showed that activation of A2B adenosine receptors promoted 4T1.2 tumor cell chemotaxis in vitro and metastasis in vivo.  In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and it also established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2etrhOGG3bVg90H21EOLACvtfcHk0liB4yi0DI-_Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOrs7o%253D&md5=7bafdf788526df932910865c2e291959</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0908801107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0908801107%26sid%3Dliteratum%253Aachs%26aulast%3DStagg%26aufirst%3DJ.%26aulast%3DDivisekera%26aufirst%3DU.%26aulast%3DMcLaughlin%26aufirst%3DN.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DPommey%26aufirst%3DS.%26aulast%3DDenoyer%26aufirst%3DD.%26aulast%3DDwyer%26aufirst%3DK.%2BM.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-CD73%2520antibody%2520therapy%2520inhibits%2520breast%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D1547%26epage%3D1552%26doi%3D10.1073%2Fpnas.0908801107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulgrew, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Doria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holoweckyj, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durham, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leow, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damschroder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingsworth, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachsenmeier, K. F.</span></span> <span> </span><span class="NLM_article-title">Targeting CD73 in the tumor microenvironment with MEDI9447</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1208875</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1208875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1080%2F2162402X.2016.1208875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=27622077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=C.+M.+Hayauthor=E.+Sultauthor=Q.+Huangauthor=K.+Mulgrewauthor=S.+R.+Fuhrmannauthor=K.+A.+McGlincheyauthor=S.+A.+Hammondauthor=R.+Rothsteinauthor=J.+Rios-Doriaauthor=E.+Poonauthor=N.+Holoweckyjauthor=N.+M.+Durhamauthor=C.+C.+Leowauthor=G.+Diedrichauthor=M.+Damschroderauthor=R.+Herbstauthor=R.+E.+Hollingsworthauthor=K.+F.+Sachsenmeier&title=Targeting+CD73+in+the+tumor+microenvironment+with+MEDI9447&doi=10.1080%2F2162402X.2016.1208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CD73 in the tumor microenvironment with MEDI9447</span></div><div class="casAuthors">Hay, Carl M.; Sult, Erin; Huang, Qihui; Mulgrew, Kathy; Fuhrmann, Stacy R.; McGlinchey, Kelly A.; Hammond, Scott A.; Rothstein, Raymond; Rios-Doria, Jonathan; Poon, Edmund; Holoweckyj, Nick; Durham, Nicholas M.; Leow, Ching Ching; Diedrich, Gundo; Damschroder, Melissa; Herbst, Ronald; Hollingsworth, Robert E.; Sachsenmeier, Kris F.</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1208875/1-e1208875/10</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clin. trials.  Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences.  MEDI9447 results in relief from adenosine monophosphate (AMP)-mediated lymphocyte suppression in vitro and inhibition of mouse syngeneic tumor growth in vivo.  In contrast with other cancer immunotherapy agents such as checkpoint inhibitors or T-cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment of mouse models.  Changes include significant alterations in a no. of tumor micro-environmental subpopulations including increases in CD8+ effector cells and activated macrophages.  Furthermore, these changes correlate directly with responder and non-responder subpopulations within animal studies using syngeneic tumors.  Combination data showing additive activity between MEDI9447 and anti-PD-1 antibodies using human cells in vitro and mouse tumor models further demonstrate the potential value of relieving adenosine-mediated immunosuppression.  Based on these data, a Phase I study to test the safety, tolerability, and clin. activity of MEDI9447 in cancer patients was initiated (NCT02503774).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-rKnwU9Ri1bVg90H21EOLACvtfcHk0li2fxTj69Cw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsLfE&md5=3ead348a459c3a893e0a3638799dfc7e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1208875%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DC.%2BM.%26aulast%3DSult%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMulgrew%26aufirst%3DK.%26aulast%3DFuhrmann%26aufirst%3DS.%2BR.%26aulast%3DMcGlinchey%26aufirst%3DK.%2BA.%26aulast%3DHammond%26aufirst%3DS.%2BA.%26aulast%3DRothstein%26aufirst%3DR.%26aulast%3DRios-Doria%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DHoloweckyj%26aufirst%3DN.%26aulast%3DDurham%26aufirst%3DN.%2BM.%26aulast%3DLeow%26aufirst%3DC.%2BC.%26aulast%3DDiedrich%26aufirst%3DG.%26aulast%3DDamschroder%26aufirst%3DM.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DHollingsworth%26aufirst%3DR.%2BE.%26aulast%3DSachsenmeier%26aufirst%3DK.%2BF.%26atitle%3DTargeting%2520CD73%2520in%2520the%2520tumor%2520microenvironment%2520with%2520MEDI9447%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span>; <span class="NLM_string-name">Burris, H.</span>; <span class="NLM_string-name">Le, D. T.</span>; <span class="NLM_string-name">Hollebecque, A.</span>; <span class="NLM_string-name">Steeghs, N.</span>; <span class="NLM_string-name">Delord, J.-P.</span>; <span class="NLM_string-name">Hilton, J.</span>; <span class="NLM_string-name">Barnhart, B.</span>; <span class="NLM_string-name">Sega, E.</span>; <span class="NLM_string-name">Sanghavi, K.</span>; <span class="NLM_string-name">Klippel, A.</span>; <span class="NLM_string-name">Hedvat, C.</span>; <span class="NLM_string-name">Hilt, E.</span>; <span class="NLM_string-name">Donovan, M.</span>; <span class="NLM_string-name">Gipson, A.</span>; <span class="NLM_string-name">Basciano, P.</span>; <span class="NLM_string-name">Postelnek, J.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Perez, R. P.</span>; <span class="NLM_string-name">Carvajal, R. D.</span></span> <span> </span><span class="NLM_article-title">Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors</span>. In  <i>Cancer Research</i>; <span class="NLM_publisher-name">AACR</span>, <span class="NLM_year">2018</span>; Vol.  <span class="NLM_volume">78</span> (13 Suppl).</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1158%2F1538-7445.AM2018-CT180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+L.+Siu&author=H.+Burris&author=D.+T.+Le&author=A.+Hollebecque&author=N.+Steeghs&author=J.-P.+Delord&author=J.+Hilton&author=B.+Barnhart&author=E.+Sega&author=K.+Sanghavi&author=A.+Klippel&author=C.+Hedvat&author=E.+Hilt&author=M.+Donovan&author=A.+Gipson&author=P.+Basciano&author=J.+Postelnek&author=Y.+Zhao&author=R.+P.+Perez&author=R.+D.+Carvajal&title=Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-CT180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-CT180%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DAbstract%2520CT180%253A%2520Preliminary%2520phase%25201%2520profile%2520of%2520BMS-986179%252C%2520an%2520anti-CD73%2520antibody%252C%2520in%2520combination%2520with%2520nivolumab%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26btitle%3DCancer%2520Research%26pub%3DAACR%26date%3D2018%26volume%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, R. G. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. W.</span></span> <span> </span><span class="NLM_article-title">An exceptionally potent inhibitor of human CD73</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3331</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=3331-3334&author=C.+E.+Bowmanauthor=R.+G.+d.+Silvaauthor=A.+Phamauthor=S.+W.+Young&title=An+exceptionally+potent+inhibitor+of+human+CD73&doi=10.1021%2Facs.biochem.9b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An Exceptionally Potent Inhibitor of Human CD73</span></div><div class="casAuthors">Bowman, Christine E.; da Silva, Rafael G.; Pham, Amber; Young, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3331-3334</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported the initiation of a Phase I clin. trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973).  We undertook a detailed kinetic anal. of the interaction between human CD73 and AB680 to det. the mode of inhibition.  We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a Ki of 5 pM.  Clin. candidates of this potency are uncommon and deserve special consideration during lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYGag3hdjGb7Vg90H21EOLACvtfcHk0li2fxTj69Cw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWjur3O&md5=ad600cb74b603c4daa3c5f002e1c5f4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00448%26sid%3Dliteratum%253Aachs%26aulast%3DBowman%26aufirst%3DC.%2BE.%26aulast%3DSilva%26aufirst%3DR.%2BG.%2Bd.%26aulast%3DPham%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BW.%26atitle%3DAn%2520exceptionally%2520potent%2520inhibitor%2520of%2520human%2520CD73%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D3331%26epage%3D3334%26doi%3D10.1021%2Facs.biochem.9b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Junker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobelmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losenkova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irjala, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationship of purine and pyrimidine nucleotides as ecto-5′-nucleotidase (CD73) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3677</span>– <span class="NLM_lpage">3695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3677-3695&author=A.+Junkerauthor=C.+Rennauthor=C.+Dobelmannauthor=V.+Namasivayamauthor=S.+Jainauthor=K.+Losenkovaauthor=H.+Irjalaauthor=S.+Ducaauthor=R.+Balasubramanianauthor=S.+Chakrabortyauthor=F.+B%C3%B6rgelauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Structure%E2%80%93activity+relationship+of+purine+and+pyrimidine+nucleotides+as+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+inhibitors&doi=10.1021%2Facs.jmedchem.9b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Junker, Anna; Renn, Christian; Dobelmann, Clemens; Namasivayam, Vigneshwaran; Jain, Shanu; Losenkova, Karolina; Irjala, Heikki; Duca, Sierra; Balasubramanian, Ramachandran; Chakraborty, Saibal; Borgel, Frederik; Zimmermann, Herbert; Yegutkin, Gennady G.; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3677-3695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cluster of differentiation 73 (CD73) converts AMP to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment.  We synthesized 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogs, and compared their CD73 inhibitory potencies.  In the adenine series, most ribose modifications and 1-deaza and 3-deaza were detrimental, but 7-deaza was tolerated.  Uracil substitution with N3-Me, but not larger groups, or 2-thio, was tolerated. 1,2-Diphosphono-Et modifications were not tolerated.  N4-(Aryl)alkyloxy-cytosine derivs., esp. with bulky benzyloxy substituents, showed increased potency.  Among the most potent inhibitors were the 5'-O-[(phosphonomethyl)phosphonic acid] derivs. of 5-fluorouridine, N4-benzoyl-cytidine, N4-[O-(4-benzyloxy)]-cytidine, and N4-[O-(4-naphth-2-ylmethyloxy)]-cytidine (Ki values 5-10 nM at human CD73).  Selected compds. tested at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, esp. those with large nucleobase substituents.  These nucleotide analogs are among the most potent CD73 inhibitors reported and may be considered for development as parenteral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmqsc2IyljbVg90H21EOLACvtfcHk0li2fxTj69Cw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltlSmsb8%253D&md5=374b1862da172f31363dc74a4545661a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00164%26sid%3Dliteratum%253Aachs%26aulast%3DJunker%26aufirst%3DA.%26aulast%3DRenn%26aufirst%3DC.%26aulast%3DDobelmann%26aufirst%3DC.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DLosenkova%26aufirst%3DK.%26aulast%3DIrjala%26aufirst%3DH.%26aulast%3DDuca%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520of%2520purine%2520and%2520pyrimidine%2520nucleotides%2520as%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3677%26epage%3D3695%26doi%3D10.1021%2Facs.jmedchem.9b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sträter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">α,β-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5′-nucleotidase (CD73) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6248-6263&author=S.+Bhattaraiauthor=M.+Freundliebauthor=J.+Pippelauthor=A.+Meyerauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=G.+G.+Yegutkinauthor=N.+Str%C3%A4terauthor=A.+El-Tayebauthor=C.+E.+M%C3%BCller&title=%CE%B1%2C%CE%B2-Methylene-ADP+%28AOPCP%29+derivatives+and+analogues%3A+development+of+potent+and+selective+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors</span></div><div class="casAuthors">Bhattarai, Sanjay; Freundlieb, Marianne; Pippel, Jan; Meyer, Anne; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; Yegutkin, Gennady G.; Straeter, Norbert; El-Tayeb, Ali; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6248-6263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics.  The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivs. modified in various positions were prepd.  Products were tested at rat recombinant eN.  6-(Ar)alkylamino substitution led to the largest improvement in potency.  N6-Monosubstitution was superior to sym. N6,N6-disubstitution.  The most potent inhibitors were N6-(4-chlorobenzyl)- (PSB-12441, Ki 7.23 nM), N6-phenylethyl- (PSB-12425, Ki 8.04 nM), and N6-benzyl-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] I (PSB-12379, Ki 9.03 nM).  Replacement of the 6-NH group in I by O (PSB-12431) or S (PSB-12553) yielded equally potent inhibitors (9.20 nM and 9.50 nM, resp.).  Selected compds. investigated at the human enzyme did not show species differences; they displayed high selectivity vs. other ecto-nucleotidases and ADP-activated P2Y receptors.  Moreover, high metabolic stability was obsd.  These compds. represent the most potent eN inhibitors described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmxberqVtKLVg90H21EOLACvtfcHk0liZRdJoPjVWbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fF&md5=5f1231a662dd86345b9d3803f1c4e716</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00802%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStr%25C3%25A4ter%26aufirst%3DN.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D%25CE%25B1%252C%25CE%25B2-Methylene-ADP%2520%2528AOPCP%2529%2520derivatives%2520and%2520analogues%253A%2520development%2520of%2520potent%2520and%2520selective%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6248%26epage%3D6263%26doi%3D10.1021%2Facs.jmedchem.5b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Tayeb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yegutkin, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strater, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">X-Ray co-crystal structure guides the way to subnanomolar competitive ecto-5′-nucleotidase (CD73) inhibitors for cancer immunotherapy</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">1900075</span> <span class="refDoi"> DOI: 10.1002/adtp.201900075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fadtp.201900075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=S.+Bhattaraiauthor=J.+Pippelauthor=A.+Meyerauthor=M.+Freundliebauthor=C.+Schmiesauthor=A.+Abdelrahmanauthor=A.+Fieneauthor=S.-Y.+Leeauthor=H.+Zimmermannauthor=A.+El-Tayebauthor=G.+G.+Yegutkinauthor=N.+Straterauthor=C.+E.+M%C3%BCller&title=X-Ray+co-crystal+structure+guides+the+way+to+subnanomolar+competitive+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+inhibitors+for+cancer+immunotherapy&doi=10.1002%2Fadtp.201900075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">X-Ray Co-Crystal Structure Guides the Way to Subnanomolar Competitive Ecto-5'-Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Bhattarai, Sanjay; Pippel, Jan; Meyer, Anne; Freundlieb, Marianne; Schmies, Constanze; Abdelrahman, Aliaa; Fiene, Amelie; Lee, Sang-Yong; Zimmermann, Herbert; El-Tayeb, Ali; Yegutkin, Gennady G.; Straeter, Norbert; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Therapeutics (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1900075</span>CODEN:
                <span class="NLM_cas:coden">ATWGAP</span>;
        ISSN:<span class="NLM_cas:issn">2366-3987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (CD73, EC 3.1.3.5) catalyzes the extracellular hydrolysis of AMP yielding adenosine, which induces immunosuppression, angiogenesis, metastasis, and proliferation of cancer cells.  CD73 inhibition is therefore proposed as a novel strategy for cancer (immuno)therapy, and CD73 antibodies are currently undergoing clin. trials.  Despite considerable efforts, the development of small mol. CD73 inhibitors has met with limited success.  To develop a suitable drug candidate, a high resoln. (2.05 Å) co-crystal structure of the CD73 inhibitor PSB-12379, a nucleotide analog, in complex with human CD73 is detd.  This allows the rational design and development of a novel inhibitor (PSB-12489) with subnanomolar inhibitory potency toward human and rat CD73, high selectivity, as well as high metabolic stability.  A co-crystal structure of PSB-12489 with CD73 (1.85 Å) reveals the interactions responsible for increased potency.  PSB-12489 is the most potent CD73 inhibitor to date representing a powerful tool compd. and novel lead structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2d7CK7UeK87Vg90H21EOLACvtfcHk0liZRdJoPjVWbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurnF&md5=dd24eb1f7b34714c513a8f4523b7d3d5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201900075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201900075%26sid%3Dliteratum%253Aachs%26aulast%3DBhattarai%26aufirst%3DS.%26aulast%3DPippel%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DSchmies%26aufirst%3DC.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DFiene%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DYegutkin%26aufirst%3DG.%2BG.%26aulast%3DStrater%26aufirst%3DN.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DX-Ray%2520co-crystal%2520structure%2520guides%2520the%2520way%2520to%2520subnanomolar%2520competitive%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520inhibitors%2520for%2520cancer%2520immunotherapy%26jtitle%3DAdv.%2520Ther.%26date%3D2019%26volume%3D2%26doi%3D10.1002%2Fadtp.201900075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiff, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1021/jm901851t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901851t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2076-2086&author=Y.+Baqiauthor=S.-Y.+Leeauthor=J.+Iqbalauthor=P.+Ripphausenauthor=A.+Lehrauthor=A.+B.+Scheiffauthor=H.+Zimmermannauthor=J.+Bajorathauthor=C.+E.+M%C3%BCller&title=Development+of+potent+and+selective+inhibitors+of+ecto-5%E2%80%B2-nucleotidase+based+on+an+anthraquinone+scaffold&doi=10.1021%2Fjm901851t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Potent and Selective Inhibitors of ecto-5'-Nucleotidase Based on an Anthraquinone Scaffold</span></div><div class="casAuthors">Baqi, Younis; Lee, Sang-Yong; Iqbal, Jamshed; Ripphausen, Peter; Lehr, Anne; Scheiff, Anja B.; Zimmermann, Herbert; Bajorath, Jurgen; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2076-2086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-Nucleotidase (eN, CD73) plays a major role in controlling extracellular adenosine levels.  EN inhibitors have potential as novel drugs, for example, for the treatment of cancer.  In the present study, we synthesized and investigated a series of 55 anthraquinone derivs. as potential inhibitors of eN, 11 of which are novel compds. and another 11 of which had previously been described but have now been synthesized by an improved method.  We identified several potent inhibitors of rat eN.  The most potent compds. were 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0952, Ki = 260 nM) and 1-amino-4-[2-anthracenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0963, 150 nM), with the latter being the most potent eN inhibitor described to date.  Selected compds. were further characterized and found to exhibit a competitive mechanism of inhibition.  Investigations of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y2, P2Y4, P2Y6, and P2Y12 showed that compd. PSB-0952 exhibited the highest degree of selectivity (>150-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJKU5mUcJOrVg90H21EOLACvtfcHk0liZRdJoPjVWbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslKnurw%253D&md5=b9e4c62d6423478d5cd4d95f702f689e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901851t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901851t%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DLehr%26aufirst%3DA.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DDevelopment%2520of%2520potent%2520and%2520selective%2520inhibitors%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%2520based%2520on%2520an%2520anthraquinone%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2076%26epage%3D2086%26doi%3D10.1021%2Fjm901851t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sévigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Identification of sulfonic acids as efficient ecto-5′-nucleotidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1016%2Fj.ejmech.2013.10.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=24215819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOqur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=685-691&author=J.+Iqbalauthor=A.+Saeedauthor=R.+Razaauthor=A.+Matinauthor=A.+Hameedauthor=N.+Furtmannauthor=J.+Leckaauthor=J.+S%C3%A9vignyauthor=J.+Bajorath&title=Identification+of+sulfonic+acids+as+efficient+ecto-5%E2%80%B2-nucleotidase+inhibitors&doi=10.1016%2Fj.ejmech.2013.10.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors</span></div><div class="casAuthors">Iqbal, Jamshed; Saeed, Aamer; Raza, Rabia; Matin, Abdul; Hameed, Abdul; Furtmann, Norbert; Lecka, Joanna; Sevigny, Jean; Bajorath, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (CD73) is well known for its implication in cancer.  Inhibition of ecto-5'-nucleotidases is thought to provide an attractive approach to cancer therapy.  This study identifies sulfonic acid compds. as efficient inhibitors of ecto-5'-nucleotidases.  The compds. were tested against recombinant human and rat ecto-5'-nucleotidases.  The most potent new sulfonic acid inhibitor 6-amino-4-hydroxynaphthalene-2-sulfonic acid (1) of ecto-5'-nucleotidase had an IC50 of 1.32 ± 0.09 μM for the human and 10.4 ± 3.3 μM for the rat enzyme.  Generally, all compds. were more active against the human enzyme.  Plausible binding mode models were developed for this new class of inhibitors.  Furthermore, several sulfonic acid inhibitors were efficient cytotoxic agents when tested on H157 cancer cell lines.  Hence, new ecto-5'-nucleotidases inhibitors displayed significant potential for further development as compds. for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTaWZD3jljR7Vg90H21EOLACvtfcHk0lieWDfdTEqB6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOqur3J&md5=60a9a0b81f2acdb7f272ac3cf3a4c872</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.053%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DSaeed%26aufirst%3DA.%26aulast%3DRaza%26aufirst%3DR.%26aulast%3DMatin%26aufirst%3DA.%26aulast%3DHameed%26aufirst%3DA.%26aulast%3DFurtmann%26aufirst%3DN.%26aulast%3DLecka%26aufirst%3DJ.%26aulast%3DS%25C3%25A9vigny%26aufirst%3DJ.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520sulfonic%2520acids%2520as%2520efficient%2520ecto-5%25E2%2580%25B2-nucleotidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D70%26spage%3D685%26epage%3D691%26doi%3D10.1016%2Fj.ejmech.2013.10.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripphausen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freundlieb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identifies novel sulfonamide inhibitors of ecto-5′-nucleotidase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6576</span>– <span class="NLM_lpage">6581</span>, <span class="refDoi"> DOI: 10.1021/jm300658n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300658n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6576-6581&author=P.+Ripphausenauthor=M.+Freundliebauthor=A.+Brunschweigerauthor=H.+Zimmermannauthor=C.+E.+M%C3%BCllerauthor=J.+Bajorath&title=Virtual+screening+identifies+novel+sulfonamide+inhibitors+of+ecto-5%E2%80%B2-nucleotidase&doi=10.1021%2Fjm300658n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto-5'-Nucleotidase</span></div><div class="casAuthors">Ripphausen, Peter; Freundlieb, Marianne; Brunschweiger, Andreas; Zimmermann, Herbert; Mueller, Christa E.; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6576-6581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound metallophosphoesterase that is implicated in the control of purinergic receptor signaling and a no. of assocd. therapeutically relevant effects.  Currently, only very few compds., including ADP, its more stable analog α,β-methylene-ADP, ATP, and anthraquinone derivs. are known to inhibit this enzyme.  In the search for inhibitors with more drug-like properties, we applied a model structure-based virtual screening approach augmented by chem. similarity searching.  On the basis of this anal., 51 candidate compds. were finally selected for exptl. evaluation.  A total of 13 of these mols. were confirmed to have competitive inhibitory activity.  The most potent inhibitor, 6-chloro-2-oxo-N-(4-sulfamoylphenyl)-2H-chromene-3-carboxylic acid amide (17), showed an IC50 value of 1.90 μM.  In contrast to the nucleotide- and anthraquinone-derived antagonists, the newly identified competitive inhibitors are uncharged at physiol. pH values, possess a drug-like structure, and are structurally distinct from known active compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0goFQAkEQe7Vg90H21EOLACvtfcHk0lieWDfdTEqB6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2gtL4%253D&md5=106abecfd7469af4be3acfb516d237f5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm300658n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300658n%26sid%3Dliteratum%253Aachs%26aulast%3DRipphausen%26aufirst%3DP.%26aulast%3DFreundlieb%26aufirst%3DM.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DVirtual%2520screening%2520identifies%2520novel%2520sulfonamide%2520inhibitors%2520of%2520ecto-5%25E2%2580%25B2-nucleotidase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6576%26epage%3D6581%26doi%3D10.1021%2Fjm300658n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viviani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccirillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, A. T. T. D.</span></span> <span> </span><span class="NLM_article-title">Virtual screening approach for the identification of hydroxamic acids as novel human ecto-5′-nucleotidase inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00884</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00884" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCns7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2020&pages=621-630&author=L.+Vivianiauthor=E.+Piccirilloauthor=H.+Ulrichauthor=A.+T.+T.+D.+Amaral&title=Virtual+screening+approach+for+the+identification+of+hydroxamic+acids+as+novel+human+ecto-5%E2%80%B2-nucleotidase+inhibitors&doi=10.1021%2Facs.jcim.9b00884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5'-Nucleotidase Inhibitors</span></div><div class="casAuthors">Viviani, Lucas G.; Piccirillo, Erika; Ulrich, Henning; Amaral, Antonia T.-do</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">621-630</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ecto-5'-nucleotidase (ecto-5'-NT, CD73) is a zinc-binding metallophosphatase that plays a key role in extracellular purinergic pathways, being implicated in several physiol. and pathophysiol. processes, such as immune homeostasis, inflammation, and tumor progression.  As such, it has been recognized as a promising biol. target for many diseases, including cancer, infections, and autoimmune diseases.  Despite its importance, so far only a few inhibitors of this target enzyme are known, most of which are not suitable as drug candidates.  Here, we aimed to search for hydroxamic acid-contg. compds. as potential human ecto-5'-NT inhibitors, since this group is known to be a strong zinc chelator.  To this end, we performed a hierarchical virtual screening (VS) search consisting of three consecutive steps (filtering for compds. bearing a hydroxamic acid group, shape-based matching, and docking followed by visual inspection), which were applied to screen the ZINC-14 database ("all purchasable subset").  Out of 25 compds. selected by this VS protocol, 12 were acquired and further submitted to enzymic assays for VS exptl. validation.  Four of them (i.e., 33.3%) were found to inhibit human ecto-5'-NT in the low micromolar range.  The most potent one showed an IC50 value of 6.2 ± 1.0μM.  All identified inhibitors satisfy drug-like criteria and provide novel scaffolds to be explored in further hit-to-lead optimization steps.  Furthermore, to the best of our knowledge, they are the first hydroxamic acid-contg. inhibitors of human ecto-5'-NT described so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4Qiu0YGYKLVg90H21EOLACvtfcHk0lieWDfdTEqB6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCns7zJ&md5=e27572f72ce511b572a671b2aa4b6448</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00884%26sid%3Dliteratum%253Aachs%26aulast%3DViviani%26aufirst%3DL.%26aulast%3DPiccirillo%26aufirst%3DE.%26aulast%3DUlrich%26aufirst%3DH.%26aulast%3DAmaral%26aufirst%3DA.%2BT.%2BT.%2BD.%26atitle%3DVirtual%2520screening%2520approach%2520for%2520the%2520identification%2520of%2520hydroxamic%2520acids%2520as%2520novel%2520human%2520ecto-5%25E2%2580%25B2-nucleotidase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2020%26volume%3D60%26spage%3D621%26epage%3D630%26doi%3D10.1021%2Facs.jcim.9b00884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahimova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordheim, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrottes5, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaloin, L.</span></span> <span> </span><span class="NLM_article-title">Identification of allosteric inhibitors of the ecto-5′-nucleotidase (CD73) targeting the dimer interface</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1005943</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1371%2Fjournal.pcbi.1005943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=29377887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Ohs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=R.+Rahimovaauthor=S.+Fontanelauthor=C.+Lionneauthor=L.+P.+Jordheimauthor=S.+Peyrottes5author=L.+Chaloin&title=Identification+of+allosteric+inhibitors+of+the+ecto-5%E2%80%B2-nucleotidase+%28CD73%29+targeting+the+dimer+interface&doi=10.1371%2Fjournal.pcbi.1005943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface</span></div><div class="casAuthors">Rahimova, Rahila; Fontanel, Simon; Lionne, Corinne; Jordheim, Lars Peter; Peyrottes, Suzanne; Chaloin, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1005943/1-e1005943/23</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The ecto-5'-nucleotidase CD73 plays an important role in the prodn. of immune-suppressive adenosine in tumor micro-environment, and has become a validated drug target in oncol.  Indeed, the anticancer immune response involves extracellular ATP to block cell proliferation through T-cell activation.  However, in the tumor micro-environment, two extracellular membrane-bound enzymes (CD39 and CD73) are overexpressed and hydrolyze efficiently ATP into AMP then further into immune-suppressive adenosine.  To circumvent the impact of CD73-generated adenosine, we applied an original bioinformatics approach to identify new allosteric inhibitors targeting the dimerization interface of CD73, which should impair the large dynamic motions required for its enzymic function.  Several hit compds. issued from virtual screening campaigns showed a potent inhibition of recombinant CD73 with inhibition consts. in the low micromolar range and exhibited a non-competitive inhibition mode.  The structure-activity relationships studies indicated that several amino acid residues (D366, H456, K471, Y484 and E543 for polar interactions and G453-454, I455, H456, L475, V542 and G544 for hydrophobic contacts) located at the dimerization interface are involved in the tight binding of hit compds. and likely contributed for their inhibitory activity.  Overall, the gathered information will guide the upcoming lead optimization phase that may lead to potent and selective CD73 inhibitors, able to restore the anticancer immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUJI47sJqgLVg90H21EOLACvtfcHk0lhCS_jZP9NnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Ohs7nF&md5=e4374ddf2d0ff143d218fb0cea997238</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005943%26sid%3Dliteratum%253Aachs%26aulast%3DRahimova%26aufirst%3DR.%26aulast%3DFontanel%26aufirst%3DS.%26aulast%3DLionne%26aufirst%3DC.%26aulast%3DJordheim%26aufirst%3DL.%2BP.%26aulast%3DPeyrottes5%26aufirst%3DS.%26aulast%3DChaloin%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520allosteric%2520inhibitors%2520of%2520the%2520ecto-5%25E2%2580%25B2-nucleotidase%2520%2528CD73%2529%2520targeting%2520the%2520dimer%2520interface%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1005943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="note"><p class="first last">We also made a number of derivatives based on the sulfone phosphonic acid <b>14</b>. However, it was difficult to improve the potency further, and this particular series was not pursued further.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="note"><p class="first last">The stereochemistry of <b>32</b> and <b>35</b> were confirmed by their co-crystal structure with CD73. Data for co-crystal structure with <b>32</b> was not shown. Data for co-crystal structure with <b>35</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Satué, M.</span>; <span class="NLM_string-name">Rodríguez-Martínez, A.</span>; <span class="NLM_string-name">Trapero, C.</span></span> <span> </span><span class="NLM_article-title">In situ identification of ectoenzymes involved in the hydrolysis of extracellular nucleotides</span>. In  <i>Immunohistochemistry</i>; <span class="NLM_publisher-name">IntechOpen</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-13&author=M.+Mart%C3%ADn-Satu%C3%A9&author=A.+Rodr%C3%ADguez-Mart%C3%ADnez&author=C.+Trapero&title=Immunohistochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-Satu%25C3%25A9%26aufirst%3DM.%26atitle%3DIn%2520situ%2520identification%2520of%2520ectoenzymes%2520involved%2520in%2520the%2520hydrolysis%2520of%2520extracellular%2520nucleotides%26btitle%3DImmunohistochemistry%26pub%3DIntechOpen%26date%3D2019%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelsma, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeuwenoord, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D. V.</span></span> <span> </span><span class="NLM_article-title">Combined phosphoramidite-phosphodiester reagents for the synthesis of methylene bisphosphonates</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2955</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1002/anie.201611878</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=10.1002%2Fanie.201611878" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1WitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=2955-2959&author=S.+B.+Engelsmaauthor=N.+J.+Meeuwenoordauthor=H.+S.+Overkleeftauthor=G.+A.+van+der+Marelauthor=D.+V.+Filippov&title=Combined+phosphoramidite-phosphodiester+reagents+for+the+synthesis+of+methylene+bisphosphonates&doi=10.1002%2Fanie.201611878"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Phosphoramidite-Phosphodiester Reagents for the Synthesis of Methylene Bisphosphonates</span></div><div class="casAuthors">Engelsma, Sander B.; Meeuwenoord, Nico J.; Overkleeft, Hermen S.; van der Marel, Gijsbert A.; Filippov, Dmitri V.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2955-2959</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new class of phosphinylmethylphosphonate reagents has been developed to enable the controlled synthesis of methylene bisphosphonate mono- and diesters.  Condensation of such reagents with an alc. of choice through azole-mediated phosphoramidite chem. followed by in situ oxidn. provides orthogonally protected methylene bisphosphonate tetraesters.  Global deprotection of the tetraester leads to terminal methylene bisphosphonates.  Alternatively, selective deprotection at the terminal phosphonate followed by a condensation between the acquired methylene bisphosphonate triester and a second alc. leads to methylene bisphosphonates diesters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm7pN0PJ86UrVg90H21EOLACvtfcHk0lhCS_jZP9NnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1WitLw%253D&md5=1d6ac262cb87df558e72c18b4760a551</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201611878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201611878%26sid%3Dliteratum%253Aachs%26aulast%3DEngelsma%26aufirst%3DS.%2BB.%26aulast%3DMeeuwenoord%26aufirst%3DN.%2BJ.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DFilippov%26aufirst%3DD.%2BV.%26atitle%3DCombined%2520phosphoramidite-phosphodiester%2520reagents%2520for%2520the%2520synthesis%2520of%2520methylene%2520bisphosphonates%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D2955%26epage%3D2959%26doi%3D10.1002%2Fanie.201611878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karschner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of LuxS inhibitors targeting bacterial cell-cell communication</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1021/ol049182i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol049182i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Gmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=3043-3046&author=J.+F.+Alfaroauthor=T.+Zhangauthor=D.+P.+Wynnauthor=E.+L.+Karschnerauthor=Z.+S.+Zhou&title=Synthesis+of+LuxS+inhibitors+targeting+bacterial+cell-cell+communication&doi=10.1021%2Fol049182i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of LuxS Inhibitors Targeting Bacterial Cell-Cell Communication</span></div><div class="casAuthors">Alfaro, Joshua F.; Zhang, Tiao; Wynn, DonRaphael P.; Karschner, Erin L.; Zhou, Zhaohui Sunny</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3043-3046</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quorum sensing is a process by which bacteria sense cell d.  This cell-cell communication process is mediated by autoinducers.  A cross-species messenger, autoinducer-2 (AI-2) is produced from S-ribosyl-L-homocysteine by the LuxS enzyme.  A proposed mechanism for LuxS is an aldose-ketose isomerization of S-ribosylhomocysteine followed by a β-elimination.  The authors report the synthesis of two substrate analogs, S-anhydroribosyl-L-homocysteine and S-homoribosyl-L-cysteine, which prevent the initial and final step of the mechanism, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUGiHRMIlqTbVg90H21EOLACvtfcHk0lhCS_jZP9NnUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Gmt7w%253D&md5=5219e1080cdb42615d662cd6c3c5fb06</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fol049182i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049182i%26sid%3Dliteratum%253Aachs%26aulast%3DAlfaro%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWynn%26aufirst%3DD.%2BP.%26aulast%3DKarschner%26aufirst%3DE.%2BL.%26aulast%3DZhou%26aufirst%3DZ.%2BS.%26atitle%3DSynthesis%2520of%2520LuxS%2520inhibitors%2520targeting%2520bacterial%2520cell-cell%2520communication%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D3043%26epage%3D3046%26doi%3D10.1021%2Fol049182i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9','PDB','7JV9'); return false;">PDB: 7JV9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8','PDB','7JV8'); return false;">PDB: 7JV8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i122"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01086">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60326"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01086?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01086</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><i>In vivo</i> and <i>ex vivo</i> study protocols; HPLC profiles of compounds <b>12</b>, <b>30</b>, <b>32</b>, and <b>35</b>; determination of the cocrystal structures of <b>12</b> and <b>35</b> CD73 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_001.pdf">jm0c01086_si_001.pdf (1.23 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01086/suppl_file/jm0c01086_si_002.csv">jm0c01086_si_002.csv (2.9 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB files of the cocrystal structures of <b>12</b> and <b>35</b> with CD73 have been deposited with the PDB data bank (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV9">7JV9</a> for <b>12</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JV8">7JV8</a> for <b>35</b>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01086&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-18%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01086%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01086" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679995b01a983d7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
